Initiation of Antiretroviral Therapy in Early Asymptom

New England Journal of Medicine 373, 795-807

DOI: 10.1056/nejmoa1506816

Citation Report

#	ARTICLE	IF	CITATIONS
1	Enhancing efforts to address infections. Lancet HIV, the, 2015, 2, e406-e407.	2.1	0
2	Towards test and treat strategy for HIV in sub-Saharan Africa. BMJ, The, 2015, 351, h6839.	3.0	10
3	HIV infection. Nature Reviews Disease Primers, 2015, 1, 15035.	18.1	340
4	Graying of the HIV epidemic: a challenge for inpatient medicine providers. Journal of Community Hospital Internal Medicine Perspectives, 2015, 5, 29428.	0.4	12
5	HIV testing in Europe: how can primary care contribute?. Sexually Transmitted Infections, 2015, 91, 464-465.	0.8	4
6	Rationale and design of FORTH: a randomised controlled trial assessing the effectiveness of HIV self-testing in increasing HIV testing frequency among gay and bisexual men. BMC Infectious Diseases, 2015, 15, 561.	1.3	9
7	Restricted access to antiretroviral treatment for undocumented migrants: a bottle neck to control the HIV epidemic in the EU/EEA. BMC Public Health, 2015, 15, 1228.	1.2	49
8	IAPAC Guidelines for Optimizing the HIV Care Continuum for Adults and Adolescents. Journal of the International Association of Providers of AIDS Care, 2015, 14, S3-S34.	0.6	95
9	Good continuum of HIV care in Belgium despite weaknesses in retention and linkage to care among migrants. BMC Infectious Diseases, 2015, 15, 496.	1.3	26
10	The impact of nurse-driven targeted HIV screening in 8 emergency departments: study protocol for the DICI-VIH cluster-randomized two-period crossover trial. BMC Infectious Diseases, 2015, 16, 51.	1.3	4
11	Factors associated with unprotected anal sex with multiple non-steady partners in the past 12Âmonths: results from the European Men-Who-Have-Sex-With-Men Internet Survey (EMIS 2010). BMC Public Health, 2015, 16, 47.	1.2	37
12	The HIV care cascade: a systematic review of data sources, methodology and comparability. Journal of the International AIDS Society, 2015, 18, 20634.	1.2	92
13	Targeted screening of at-risk adults for acute HIV-1 infection in sub-Saharan Africa. Aids, 2015, 29, S221-S230.	1.0	48
14	Accounting for and responding to HIV-associated mortality. Aids, 2015, 30, 1.	1.0	5
15	The impact of scalingâ€up combination antiretroviral therapy on patterns of mortality among HIVâ€positive persons in British Columbia, Canada. Journal of the International AIDS Society, 2015, 18, 20261.	1,2	29
16	Getting to 90-90-90 in paediatric HIV: What is needed?. Journal of the International AIDS Society, 2015, 18, 20770.	1,2	13
17	90â€90â€90 â€" Charting a steady course to end the paediatric HIV epidemic. Journal of the International AIDS Society, 2015, 18, 20296.	1.2	28
18	Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care. Journal of the International AIDS Society, 2015, 18, 20024.	1.2	22

#	Article	IF	CITATIONS
19	What Triggers a Diagnosis of HIV Infection in the Tokyo Metropolitan Area? Implications for Preventing the Spread of HIV Infection in Japan. PLoS ONE, 2015, 10, e0143874.	1.1	9
20	Elevated Biomarkers of Inflammation and Coagulation in Patients with HIV Are Associated with Higher Framingham and VACS Risk Index Scores. PLoS ONE, 2015, 10, e0144312.	1.1	49
21	HIV-Associated TB Syndemic: A Growing Clinical Challenge Worldwide. Frontiers in Public Health, 2015, 3, 281.	1.3	50
22	World Health Organization to recommend early treatment for everyone with HIV. Nature, 2015, , .	13.7	3
23	2015 – a seminal year for HIV biomedical prevention. Journal of the International AIDS Society, 2015, 18, 20814.	1.2	3
24	The Art of HIV Elimination: Past and Present Science. Journal of AIDS & Clinical Research, 2015, 6, .	0.5	10
25	Higher risks of mother-to-child HIV transmission in countries with lower HIV prevalence: UNAIDS 2013 results for 32 countries with generalised epidemics. Journal of Virus Eradication, 2015, 1, 257-263.	0.3	9
26	Brief Report. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 323-328.	0.9	8
27	A stepwise advance out of the shadows: leading HIV to its clearance. Future Virology, 2015, 10, 1263-1266.	0.9	0
28	Applying Public Health Principles to the HIV Epidemic — How Are We Doing?. New England Journal of Medicine, 2015, 373, 2281-2287.	13.9	84
29	Ending the HIV–AIDS Pandemic — Follow the Science. New England Journal of Medicine, 2015, 373, 2197-2199.	13.9	76
30	Scaling Up Antiretroviral Therapy in Africa: Are We There Yet?: Table 1 Clinical Infectious Diseases, 2015, 62, civ931.	2.9	1
31	Antiretroviral therapy for HIV should be started at diagnosis regardless of CD4+ count, study concludes:. BMJ, The, 2015, 351, h3943.	3.0	0
32	Overcoming Impediments to Global Implementation of Early Antiretroviral Therapy. New England Journal of Medicine, 2015, 373, 875-876.	13.9	26
33	No one with HIV should die from tuberculosis. Lancet, The, 2015, 386, e48-e50.	6.3	8
34	The Impact of Alcohol Use and Related Disorders on the HIV Continuum of Care: a Systematic Review. Current HIV/AIDS Reports, 2015, 12, 421-436.	1.1	155
35	Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?. Current HIV/AIDS Reports, 2015, 12, 375-387.	1.1	56
36	Integrating Antiretroviral Strategies for Human Immunodeficiency Virus Prevention: Post- and Pre-Exposure Prophylaxis and Early Treatment. Open Forum Infectious Diseases, 2015, 2, ofv126.	0.4	9

#	Article	IF	CITATIONS
37	Post-treatment control: a functional cure for HIV. Future Virology, 2015, 10, 1245-1256.	0.9	0
38	Does early ART in sub-Saharan Africa decrease mortality?. Lancet HIV, the, 2015, 2, e354-e355.	2.1	1
39	Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia. Journal of Virus Eradication, 2016, 2, 32-35.	0.3	1
40	Alemtuzumab-induced elimination of HIV-1-infected immune cells. Journal of Virus Eradication, 2016, 2, 12-18.	0.3	7
41	HIV/AIDS in the South-East Asia region: progress and challenges. Journal of Virus Eradication, 2016, 2, 1-6.	0.3	40
42	South Africa's adoption of the World Health Organization's  test and treat' guidelines: Are we too ambitious?. South African Medical Journal, 2016, 106, 952.	0.2	1
44	Retention and mortality outcomes from a communityâ€supported public–private HIV treatment programme in Myanmar. Journal of the International AIDS Society, 2016, 19, 20926.	1.2	7
45	TB as a cause of hospitalization and inâ€hospital mortality among people living with HIV worldwide: a systematic review and metaâ€analysis. Journal of the International AIDS Society, 2016, 19, 20714.	1.2	108
46	HIV Infection and AIDS in Sub-Saharan Africa: Current Status, Challenges and Opportunities. Open AIDS Journal, 2016, 10, 34-48.	0.1	595
47	Virological efficacy of PI monotherapy for HIV-1 in clinical practice. Journal of Antimicrobial Chemotherapy, 2016, 71, 3228-3234.	1.3	12
48	Evidence-based perspectives on the implementation of screening for neurocognitive impairment in HIV. Neurobehavioral HIV Medicine, 2016, Volume 7, 31-41.	2.0	1
49	Sustaining the future of HIV counselling to reach $90\hat{a} \in 90\hat{a} \in 90\hat{a}$: a regional country analysis. Journal of the International AIDS Society, 2016, 19, 20751.	1.2	39
50	Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date. HIV/AIDS - Research and Palliative Care, 2016, Volume 8, 157-164.	0.4	29
51	Perspectives for immunotherapy: which applications might achieve an HIV functional cure?. Oncotarget, 2016, 7, 38946-38958.	0.8	12
52	Five-year risk of HIV diagnosis subsequent to 147 hospital-based indicator diseases: a Danish nationwide population-based cohort study. Clinical Epidemiology, 2016, Volume 8, 333-340.	1.5	9
53	Trinta anos de enfrentamento à epidemia da Aids no Brasil, 1985-2015. Ciencia E Saude Coletiva, 2016, 21, 1553-1564.	0.1	31
54	Access to HIV care in the context of universal test and treat: challenges within the ANRS 12249 TasP clusterâ€randomized trial in rural South Africa. Journal of the International AIDS Society, 2016, 19, 20913.	1.2	62
55	Early Antiretroviral Therapy at High CD4 Counts Does Not Improve Arterial Elasticity: A Substudy of the Strategic Timing of AntiRetroviral Treatment (START) Trial. Open Forum Infectious Diseases, 2016, 3, ofw213.	0.4	15

#	Article	IF	CITATIONS
56	Timing of antiretroviral therapy and TB treatment outcomes in patients with TB-HIV in Myanmar. Public Health Action, 2016, 6, 111-117.	0.4	3
57	Treatment failure and drug resistance in HIVâ€positive patients on tenofovirâ€based firstâ€line antiretroviral therapy in western Kenya. Journal of the International AIDS Society, 2016, 19, 20798.	1.2	29
58	A Review of Management of Inflammation in the HIV Population. BioMed Research International, 2016, 2016, 1-12.	0.9	24
59	Therapeutic Drug Monitoring of Antiretrovirals. , 2016, , 135-163.		0
60	CD4 Variability in Malawi: Implications for Use of a CD4 Threshold of 500 Cells/mm3 Versus Universal Eligibility for Antiretroviral Therapy. Open Forum Infectious Diseases, 2016, 3, ofw180.	0.4	2
62	Interruptions of antiretroviral therapy in children and adolescents with HIV infection in clinical practice: a retrospective cohort study in the USA. Journal of the International AIDS Society, 2016, 19, 20936.	1.2	6
63	Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes, 2016, 7, 119.	1.0	10
64	The incidence of tuberculosis among hiv-positive individuals with high CD4 counts: implications for policy. BMC Infectious Diseases, 2016, 16, 266.	1.3	8
65	Acceptability and feasibility of point-of-care CD4 testing on HIV continuum of care in low and middle income countries: a systematic review. BMC Health Services Research, 2016, 16, 343.	0.9	28
66	The Shifting Paradigm of Care for Adults Living With HIV: Smoking Cessation for Longer Life. Journal of Infectious Diseases, 2016, 214, 1618-1620.	1.9	8
67	Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Medicine, 2016, 13, e1002015.	3.9	232
68	Relevance of Interleukin-6 and D-Dimer for Serious Non-AIDS Morbidity and Death among HIV-Positive Adults on Suppressive Antiretroviral Therapy. PLoS ONE, 2016, 11, e0155100.	1.1	150
69	The Men Who Have Sex with Men HIV Care Cascade in Rio de Janeiro, Brazil. PLoS ONE, 2016, 11, e0157309.	1.1	16
70	The HIV Care Continuum among Female Sex Workers: A Key Population in Lilongwe, Malawi. PLoS ONE, 2016, 11, e0147662.	1.1	41
71	Progress in Reversing the HIV Epidemic through Intensified Access to Antiretroviral Therapy: Results from a Nationally Representative Population-Based Survey in Kenya, 2012. PLoS ONE, 2016, 11, e0148068.	1.1	5
72	Liver Toxicity of Current Antiretroviral Regimens in HIV-Infected Patients with Chronic Viral Hepatitis in a Real-Life Setting: The HEPAVIR SEG-HEP Cohort. PLoS ONE, 2016, 11, e0148104.	1.1	12
73	Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study. PLoS ONE, 2016, 11, e0154221.	1.1	13
74	Discordant Immune Response with Antiretroviral Therapy in HIV-1: A Systematic Review of Clinical Outcomes. PLoS ONE, 2016, 11, e0156099.	1.1	44

#	Article	IF	Citations
75	Retention of HIV-Infected Children in the First 12 Months of Anti-Retroviral Therapy and Predictors of Attrition in Resource Limited Settings: A Systematic Review. PLoS ONE, 2016, 11, e0156506.	1.1	44
76	Evaluation of the FACSPresto, a New Point of Care Device for the Enumeration of CD4% and Absolute CD4+ T Cell Counts in HIV Infection. PLoS ONE, 2016, 11, e0157546.	1.1	12
77	Plasma CXCL10, sCD163 and sCD14 Levels Have Distinct Associations with Antiretroviral Treatment and Cardiovascular Disease Risk Factors. PLoS ONE, 2016, 11, e0158169.	1.1	28
78	Impact and Cost-Effectiveness of Point-Of-Care CD4 Testing on the HIV Epidemic in South Africa. PLoS ONE, 2016, 11, e0158303.	1.1	16
79	DNA/MVA Vaccination of HIV-1 Infected Participants with Viral Suppression on Antiretroviral Therapy, followed by Treatment Interruption: Elicitation of Immune Responses without Control of Re-Emergent Virus. PLoS ONE, 2016, 11, e0163164.	1.1	26
80	Elevated Basal Pre-infection CXCL10 in Plasma and in the Small Intestine after Infection Are Associated with More Rapid HIV/SIV Disease Onset. PLoS Pathogens, 2016, 12, e1005774.	2.1	50
81	Choice of antiretroviral drugs for continued treatment scaleâ€up in a public health approach: what more do we need to know?. Journal of the International AIDS Society, 2016, 19, 20504.	1.2	33
82	What is the role of CD4 count in a large public health antiretroviral programme?. Southern African Journal of HIV Medicine, 2016, 17, 446.	0.3	12
83	HIV Infection and Infertility., 0,,.		6
84	Ending the HIV/AIDS epidemic in low- and middle-income countries by 2030: is it possible?. F1000Research, 2016, 5, 2328.	0.8	20
85	The impact of transient combination antiretroviral treatment in early HIV infection on viral suppression and immunologic response in later treatment. Aids, 2016, 30, 879-888.	1.0	9
86	Increased antiretroviral therapy prescription and HIV viral suppression among persons receiving clinical care for HIV infection. Aids, 2016, 30, 2117-2124.	1.0	46
87	Hormonal Contraception, Pregnancy, Breastfeeding, and Risk of HIV Disease Progression Among Zambian Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 345-352.	0.9	7
88	Is Genotype Testing Really Cost-Effective for Primary Resistance in Brazil?. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, e54-e56.	0.9	0
89	Critical Review. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 153-161.	0.9	16
90	Impact of Peer Support on Behavior Change Among Newly Diagnosed Australian Gay Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 565-571.	0.9	15
91	Timing of Antiretroviral Treatment, Immunovirologic Status, and TB Risk: Implications for Testing and Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 572-578.	0.9	6
92	Immune activation and cardiovascular disease in chronic HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 216-225.	1.5	72

#	Article	IF	Citations
93	Do people with HIV infection have a higher risk of fracture compared with those without HIV infection?. Current Opinion in HIV and AIDS, 2016, 11, 301-305.	1.5	24
94	Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults. JAMA - Journal of the American Medical Association, 2016, 316, 191.	3.8	533
95	Comparing results from multiple imputation and dynamic marginal structural models for estimating when to start antiretroviral therapy. Statistics in Medicine, 2016, 35, 4335-4351.	0.8	2
96	Immune activation and paediatric HIV-1 disease outcome. Current Opinion in HIV and AIDS, 2016, 11 , $146-155$.	1.5	39
97	Immune activation in HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 201-208.	1.5	19
98	Immune activation and immune aging in HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 242-249.	1.5	66
99	Rate and predictors of progression in elite and viremic HIV-1 controllers. Aids, 2016, 30, 1209-1220.	1.0	69
100	Early antiretroviral therapy initiation in west Africa has no adverse social consequences. Aids, 2016, 30, 1677-1682.	1.0	2
101	Inflammation, immune activation, and cardiovascular disease in HIV. Aids, 2016, 30, 1495-1509.	1.0	152
102	The protease inhibitors and HIV-associated bone loss. Current Opinion in HIV and AIDS, 2016, 11, 333-342.	1.5	36
104	Brief Report: Enhanced Normalization of CD4/CD8 Ratio With Earlier Antiretroviral Therapy at Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 69-73.	0.9	38
105	The Latent Reservoir for HIV-1: How Immunologic Memory and Clonal Expansion Contribute to HIV-1 Persistence. Journal of Immunology, 2016, 197, 407-417.	0.4	121
106	HIV infection and immune activation. Current Opinion in HIV and AIDS, 2016, 11, 191-200.	1.5	75
107	Once vs twice-daily abacavir and lamivudine in African children. Aids, 2016, 30, 1761-1770.	1.0	8
108	Chronic Morbidity Among Older Children and Adolescents at Diagnosis of HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 275-281.	0.9	39
109	Frequency and impact of suboptimal immune recovery on first-line antiretroviral therapy within the International Epidemiologic Databases to Evaluate AIDS in East Africa. Aids, 2016, 30, 1913-1922.	1.0	38
110	Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe. International Journal of Epidemiology, 2017, 46, dyw097.	0.9	30
111	Sexual behaviour among people with HIV according to self-reported antiretroviral treatment and viral load status. Aids, 2016, 30, 1745-1759.	1.0	15

#	Article	IF	CITATIONS
112	Changing Antiretroviral Eligibility Criteria. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 338-344.	0.9	2
113	Ethical Implications of Social Stigma Associated with the Promotion and Use of Pre-Exposure Prophylaxis for HIV Prevention. LGBT Health, 2016, 3, 103-108.	1.8	16
114	Expansion of the Adherence Club model for stable antiretroviral therapy patients in the Cape Metro, South Africa 2011–2015. Tropical Medicine and International Health, 2016, 21, 743-749.	1.0	51
115	The complex relationship between CD4 count, HIV viral load, trimethoprim-sulfamethoxazole prophylaxis, and skin-and-soft-tissue infection risk in patients with HIV: insights from a causal diagram and simulation study. Epidemiology and Infection, 2016, 144, 2889-2898.	1.0	1
116	Healthcare resources are inadequate to address the burden of illness among HIV-infected male prisoners in Malaysia. International Journal of Prisoner Health, 2016, 12, 253-269.	0.5	19
117	Lower coronary plaque burden in patients with HIV presenting with acute coronary syndrome. Open Heart, 2016, 3, e000511.	0.9	10
118	Scale-up of ART in Malawi has reduced case notification rates in HIV-positive and HIV-negative tuberculosis. Public Health Action, 2016, 6, 247-251.	0.4	11
119	Biased smallâ€molecule ligands for selective inhibition of HIVâ€1 cell entry via CCR5. Pharmacology Research and Perspectives, 2016, 4, e00262.	1.1	4
120	Protecting the confidentiality and security of personal health information in low- and middle-income countries in the era of SDGs and Big Data. Global Health Action, 2016, 9, 32089.	0.7	35
121	The Anticipated Clinical and Economic Effects of 90–90–90 in South Africa. Annals of Internal Medicine, 2016, 165, 325.	2.0	36
122	Copenhagen comorbidity in HIV infection (COCOMO) study: a study protocol for a longitudinal, non-interventional assessment of non-AIDS comorbidity in HIV infection in Denmark. BMC Infectious Diseases, 2016, 16, 713.	1.3	61
123	Building Capacity for Data-Driven Decision Making in African HIV Testing Programs: Field Perspectives on Data Use Workshops. AIDS Education and Prevention, 2016, 28, 472-484.	0.6	7
124	Pulmonary effects of timing of antiretroviral therapy initiation. Lancet Respiratory Medicine, the, 2016, 4, 929-930.	5.2	0
125	A network intervention that locates and intervenes with recently HIV-infected persons: The Transmission Reduction Intervention Project (TRIP). Scientific Reports, 2016, 6, 38100.	1.6	60
126	Universal Antiretroviral Treatment Eligibility for Children and Adolescents Living With HIV. Pediatric Infectious Disease Journal, 2016, 35, 1225-1228.	1.1	3
127	Evolution of HIV virulence in response to widespread scale up of antiretroviral therapy: a modeling study. Virus Evolution, 2016, 2, vew028.	2.2	21
128	Systematic review and meta-analysis of the adolescent HIV continuum of care in South Africa: the Cresting Wave. BMJ Global Health, 2016, 1, e000004.	2.0	115
129	Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Global Health, 2016, 1, e000010.	2.0	240

#	ARTICLE	IF	CITATIONS
130	Sustained 10-year gain in adult life expectancy following antiretroviral therapy roll-out in rural Malawi: July 2005 to June 2014. International Journal of Epidemiology, 2017, 46, dyw208.	0.9	23
131	Initiating antiretroviral therapy in HIV-infected patients with >500 CD4 cells/µL provides more benefit than delaying treatment. Evidence-Based Medicine, 2016, 21, 26-26.	0.6	2
132	The per-protocol effect of immediate versus deferred antiretroviral therapy initiation. Aids, 2016, 30, 2659-2663.	1.0	21
133	Baseline CD4 Count and Adherence to Antiretroviral Therapy: A Systematic Review and Meta-Analysis. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 514-521.	0.9	22
134	Beyond Undetectable Viral Load: Effect of Nucleotides on Inflammation. EBioMedicine, 2016, 13, 31-32.	2.7	2
135	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. The Lancet Gastroenterology and Hepatology, 2016, 1, 317-327.	3.7	80
136	HIV care and treatment experiences among female sex workers living with HIV in sub-Saharan Africa: A systematic review. African Journal of AIDS Research, 2016, 15, 377-386.	0.3	90
137	CardiopatÃa isquémica en el VIH: profundizando en el conocimiento del riesgo cardiovascular. Revista Espanola De Cardiologia, 2016, 69, 1204-1213.	0.6	10
138	Botswana's progress toward achieving the 2020 UNAIDS 90-90-90 antiretroviral therapy and virological suppression goals: a population-based survey. Lancet HIV, the, 2016, 3, e221-e230.	2.1	197
139	Effects of Antiretroviral Therapy on Immune Function and Arterial Inflammation in Treatment-Naive Patients With Human Immunodeficiency Virus Infection. JAMA Cardiology, 2016, 1, 474.	3.0	66
140	Inflammation and Arterial Injury in Individuals With Human Immunodeficiency Virus Infection. JAMA Cardiology, 2016, 1, 481.	3.0	6
141	Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection. Medical Clinics of North America, 2016, 100, 927-950.	1.1	11
142	Protecting bone in long-term HIV positive patients receiving antiretrovirals. Expert Review of Anti-Infective Therapy, 2016, 14, 587-599.	2.0	4
143	Cost Effectiveness of Protease Inhibitor Monotherapy Versus Standard Triple Therapy in the Long-Term Management of HIV Patients: Analysis Using Evidence from the PIVOT Trial. Pharmacoeconomics, 2016, 34, 795-804.	1.7	9
144	Home testing and counselling with linkage to care. Lancet HIV,the, 2016, 3, e244-e246.	2.1	1
145	Improving the Quality of and Access to HIV Rapid Testing in the Caribbean Region: Program Implementation, Outcomes, and Recommendations. AIDS Research and Human Retroviruses, 2016, 32, 879-884.	0.5	6
146	Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV,the, 2016, 3, e247-e258.	2.1	63
147	LEDGIN-mediated Inhibition of Integrase–LEDGF/p75 Interaction Reduces Reactivation of Residual Latent HIV. EBioMedicine, 2016, 8, 248-264.	2.7	90

#	ARTICLE	IF	CITATIONS
148	Narrowing the Gap in Life Expectancy Between HIV-Infected and HIV-Uninfected Individuals With Access to Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 39-46.	0.9	316
149	Reactivation tuberculosis: role of surveillance. Expert Review of Anti-Infective Therapy, 2016, 14, 501-509.	2.0	2
150	Recent Insights Into Cardiovascular Disease (CVD) Risk Among HIV-Infected Adults. Current HIV/AIDS Reports, 2016, 13, 44-52.	1.1	47
151	Non-Nucleoside Reverse Transcriptase Inhibitor–Based Antiretroviral Therapy in Perinatally HIV-Infected, Treatment-NaÃ⁻ve Adolescents in Asia. Journal of Adolescent Health, 2016, 58, 451-459.	1.2	10
152	Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection. Journal of Infectious Diseases, 2016, 213, 1523-1531.	1.9	39
153	Promoting male partner HIV testing and safer sexual decision making through secondary distribution of self-tests by HIV-negative female sex workers and women receiving antenatal and post-partum care in Kenya: a cohort study. Lancet HIV,the, 2016, 3, e266-e274.	2.1	232
154	Immune activation and HIV. Current Opinion in HIV and AIDS, 2016, 11, 129-130.	1.5	35
155	Testing the hypothesis that treatment can eliminate HIV: a nationwide, population-based study of the Danish HIV epidemic in men who have sex with men. Lancet Infectious Diseases, The, 2016, 16, 789-796.	4.6	42
156	Choice of first-line antiretroviral therapy regimen and treatment outcomes for HIV in a middle income compared to a high income country: a cohort study. BMC Infectious Diseases, 2016, 16, 106.	1.3	10
157	Interleukin 6 Is a Stronger Predictor of Clinical Events Than High-Sensitivity C-Reactive Protein or D-Dimer During HIV Infection. Journal of Infectious Diseases, 2016, 214, 408-416.	1.9	94
158	Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV. Current Hypertension Reports, 2016, 18, 46.	1.5	36
159	A shot at AIDS. Current Opinion in Biotechnology, 2016, 42, 147-151.	3.3	9
160	Sharp increase in rates of HIV transmitted drug resistance at antenatal clinics in Botswana demonstrates the need for routine surveillance. Journal of Antimicrobial Chemotherapy, 2016, 71, 1361-1366.	1.3	30
161	Development and Evaluation of a Modified Fourth-Generation Human Immunodeficiency Virus Enzyme Immunoassay for Cross-Sectional Incidence Estimation in Clade B Populations. AIDS Research and Human Retroviruses, 2016, 32, 756-762.	0.5	7
162	B-cell development and pneumococcal immunity in vertically acquired HIV infection. Aids, 2016, 30, 1867-1876.	1.0	5
163	Metabolic and Cardiovascular Complications in HIV/HCV-Co-infected Patients. Current HIV/AIDS Reports, 2016, 13, 328-339.	1.1	15
164	Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis. Lancet HIV, the, 2016, 3, e510-e520.	2.1	151
165	Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. Clinical Infectious Diseases, 2016, 63, 1668-1676.	2.9	76

#	Article	IF	CITATIONS
166	Development of peptide inhibitors of HIV transmission. Bioactive Materials, 2016, 1, 109-121.	8.6	22
167	Methadone maintenance therapy and viral suppression among HIV-infected opioid users: The impacts of crack and injection cocaine use. Drug and Alcohol Dependence, 2016, 168, 211-218.	1.6	17
168	Early initiation of antiretroviral therapy: debate over? – Authors' reply. Lancet Infectious Diseases, The, 2016, 16, 769-770.	4.6	0
169	Fracture management in HIV positive individuals: a systematic review. International Orthopaedics, 2016, 40, 2429-2445.	0.9	17
170	Trends in Cardiovascular Disease Mortality Among Persons With HIV in New York City, 2001–2012. Clinical Infectious Diseases, 2016, 63, 1122-1129.	2.9	61
171	Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. AIDS Research and Therapy, 2016, 13, 27.	0.7	62
172	HIV testing in the acute medical unit. British Journal of Hospital Medicine (London, England: 2005), 2016, 77, C138-C143.	0.2	0
173	Test and treat: the early experiences in a clinic serving women at high risk of HIV infection in Kampala. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 33-38.	0.6	27
174	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	6.3	4,934
175	Current trends and intricacies in the management of HIV-associated pulmonary tuberculosis. AIDS Research and Therapy, 2016, 13, 34.	0.7	26
176	The HIV prevention cascade: more smoke than thunder?. Lancet HIV, the, 2016, 3, e286-e288.	2.1	18
177	Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen. Expert Review of Clinical Pharmacology, 2016, 9, 1493-1503.	1.3	26
178	HCVâ€HIV coâ€infected patients: no longer a â€~special' population?. Liver International, 2016, 36, 43-46.	1.9	26
179	Update on Pediatric Human Immunodeficiency Virus Infection. Advances in Pediatrics, 2016, 63, 147-171.	0.5	1
180	Lost opportunities to identify and treat <scp>HIV</scp> â€positive patients: results from a baseline assessment of providerâ€initiated <scp>HIV</scp> testing and counselling (PITC) in <scp>M</scp> alawi. Tropical Medicine and International Health, 2016, 21, 479-485.	1.0	35
181	Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000–2010. Journal of Infectious Diseases, 2016, 214, 862-872.	1.9	116
182	The risk of late or advanced presentation of HIV infected patients is still high, associated factors evolve but impact on overall mortality is vanishing over calendar years: results from the Italian MASTER Cohort. BMC Public Health, 2016, 16, 878.	1.2	37
183	Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies. Clinical Infectious Diseases, 2016, 63, 1373-1379.	2.9	25

#	Article	IF	Citations
184	<i>Editorial Commentary</i> : Can We Afford to Control the HIV Epidemic With Antiretrovirals? Can We Afford Not to Do So?. Clinical Infectious Diseases, 2016, 63, 1505-1507.	2.9	1
185	British HIV Association guidelines for the treatment of <scp>HIV</scp> â€1â€positive adults with antiretroviral therapy 2015. HIV Medicine, 2016, 17, s2-s104.	1.0	78
186	HIV-related stigma and universal testing and treatment for HIV prevention and care: design of an implementation science evaluation nested in the HPTN 071 (PopART) cluster-randomized trial in Zambia and South Africa. Health Policy and Planning, 2016, 31, 1342-1354.	1.0	41
187	Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence. Current HIV/AIDS Reports, 2016, 13, 289-296.	1.1	103
188	Differences Between Men Who Have Sex with Men (MSM) with Low CD4 Cell Counts at Their First HIV Test and MSM with Higher CD4 Counts in Bangkok, Thailand. AIDS and Behavior, 2016, 20, 398-407.	1.4	10
189	From Durban to Durban: end of AIDS further than hoped. Lancet HIV, the, 2016, 3, e403-e405.	2.1	4
190	Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy. Current HIV/AIDS Reports, 2016, 13, 297-308.	1.1	16
191	New Antiretroviral Treatment for HIV. Infectious Diseases and Therapy, 2016, 5, 329-352.	1.8	16
192	Maraviroc in addition to cART during primary HIV infection: Results from MAIN randomized clinical trial and 96-weeks follow-up. Journal of Clinical Virology, 2016, 85, 86-89.	1.6	2
193	Immunologic Biomarkers, Morbidity, and Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2016, 214, S44-S50.	1.9	195
194	Global challenges in human immunodeficiency virus and syphilis coinfection among men who have sex with men. Expert Review of Anti-Infective Therapy, 2016, 14, 1037-1046.	2.0	19
195	Cardiovascular Disease, Statins, and HIV. Journal of Infectious Diseases, 2016, 214, S83-S92.	1.9	25
196	Significant Improvements Are Needed in HIV Care Continuum to Meet 90-90-90 Targets in Georgia. Journal of the International Association of Providers of AIDS Care, 2016, 15, 451-454.	0.6	3
197	Factors associated with antiretroviral treatment initiation amongst HIV-positive individuals linked to care within a universal test and treat programme: early findings of the ANRS 12249 TasP trial in rural South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 39-51.	0.6	47
198	Evaluation of the Aptima HIV-1 Quant Dx Assay Using Plasma and Dried Blood Spots. Journal of Clinical Microbiology, 2016, 54, 2597-2601.	1.8	16
199	Health facility challenges to the provision of Option B+ in western Kenya: a qualitative study. Health Policy and Planning, 2017, 32, czw122.	1.0	38
200	Xpert MTB/RIF ― why the lack of morbidity and mortality impact in intervention trials?. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016, 110, 432-444.	0.7	50
201	Antiretrovirals for HIV Treatment and Prevention. JAMA - Journal of the American Medical Association, 2016, 316, 151.	3.8	7

#	Article	IF	CITATIONS
202	Can the Heterosexual HIV Epidemic be Eliminated in South Africa Using Combination Prevention? A Modeling Analysis. American Journal of Epidemiology, 2016, 184, 239-248.	1.6	13
203	Exploring critical questions for the implementation of "universal test and treat―approaches to HIV prevention and care. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1-6.	0.6	15
204	Update in Tuberculosis/Pulmonary Infections 2015. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 142-146.	2.5	10
205	Contribution of antiretroviral therapy to cardiovascular disease risk in HIV-infected patients. Future Virology, 2016, 11, 509-527.	0.9	2
206	HIV Screening. JAMA - Journal of the American Medical Association, 2016, 316, 213.	3.8	5
207	Visions for an AIDS-Free Generation. JAMA - Journal of the American Medical Association, 2016, 316, 154.	3.8	0
208	Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in prisoners. Lancet, The, 2016, 388, 1115-1126.	6.3	157
209	Antiretroviral Therapy for the Prevention of HIV-1 Transmission. New England Journal of Medicine, 2016, 375, 830-839.	13.9	1,282
210	Centers for Disease Control and Prevention-Funded Human Immunodeficiency Virus Testing, Positivity, and Service Delivery among Newly Diagnosed Women in 61 Health Department Jurisdictions, United States, 2014. Women's Health Issues, 2016, 26, 496-503.	0.9	3
211	HIV Treatment as Prevention: Implications for Health Promotion. Health Promotion International, 2018, 33, daw080.	0.9	1
212	Increase in CD4 + T-Cell Count at the Time of HIV Diagnosis and Antiretroviral Treatment Initiation Among Persons With HIV in New York City. Journal of Infectious Diseases, 2016, 214, 1682-1686.	1.9	10
213	An overview of the Human Immunodeficiency Virus (HIV). Journal of Paramedic Practice: the Clinical Monthly for Emergency Care Professionals, 2016, 8, 507-514.	0.0	1
214	Ischemic Heart Disease in HIV: An In-depth Look at Cardiovascular Risk. Revista Espanola De Cardiologia (English Ed), 2016, 69, 1204-1213.	0.4	7
215	Early Height and Weight Changes in Children Using Cotrimoxazole Prophylaxis With Antiretroviral Therapy. Clinical Infectious Diseases, 2016, 63, ciw514.	2.9	8
216	Immune perturbations in HIV-1–infected individuals who make broadly neutralizing antibodies. Science Immunology, 2016, 1, aag0851.	5.6	120
217	China's national plan to combat antimicrobial resistance. Lancet Infectious Diseases, The, 2016, 16, 1216-1218.	4.6	58
218	Achieving the 90–90–90 target: incentives for HIV testing. Lancet Infectious Diseases, The, 2016, 16, 1215-1216.	4.6	11
219	Pulmonary effects of immediate versus deferred antiretroviral therapy in HIV-positive individuals: a nested substudy within the multicentre, international, randomised, controlled Strategic Timing of Antiretroviral Treatment (START) trial. Lancet Respiratory Medicine, the, 2016, 4, 980-989.	5.2	38

#	Article	IF	CITATIONS
220	Primate immunodeficiency virus classification and nomenclature: Review. Infection, Genetics and Evolution, 2016, 46, 150-158.	1.0	47
221	Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention. New England Journal of Medicine, 2016, 375, 1726-1737.	13.9	268
222	Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients. Expert Review of Anti-Infective Therapy, 2016, 14, 1113-1126.	2.0	6
223	An observational study on the incidence of tuberculosis among a cohort of HIV infected adults in a setting with low prevalence of tuberculosis. HIV Clinical Trials, 2016, 17, 181-188.	2.0	4
224	Improved Survival in HIV Treatment Programmes in Asia. Antiviral Therapy, 2016, 21, 517-527.	0.6	18
225	Effect of coinfection with hepatitis C virus on survival of individuals with HIV-1 infection. Current Opinion in HIV and AIDS, 2016, 11, 521-526.	1.5	24
226	HIV testing among men who have sex with men in Tijuana, Mexico: a cross-sectional study. BMJ Open, 2016, 6, e010388.	0.8	21
227	Epidemiological impact of achieving UNAIDS 90-90-90 targets for HIV care in India: a modelling study. BMJ Open, 2016, 6, e011914.	0.8	10
228	Challenges in initiating antiretroviral therapy for all HIV-infected people regardless of CD4 cell count. Infectious Diseases of Poverty, 2016, 5, 85.	1.5	46
229	Changing HIV treatment eligibility under health system constraints in sub-Saharan Africa. Aids, 2016, 30, 2341-2350.	1.0	39
230	Hospitalization for Anxiety and Mood Disorders in HIV-Infected and -Uninfected Gay and Bisexual Men. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 589-597.	0.9	10
231	Combined models for pre- and post-treatment longitudinal biomarker data: an application to CD4 counts in HIV-patients. BMC Medical Research Methodology, 2016, 16, 121.	1.4	5
232	The need to scale up HIV indicator condition-guided testing for early case-finding: a case-control study in primary care. BMC Family Practice, 2016, 17, 161.	2.9	20
233	Evaluation of a demand-creation intervention for couples' HIV testing services among married or cohabiting individuals in Rakai, Uganda: a cluster-randomized intervention trial. BMC Infectious Diseases, 2016, 16, 379.	1.3	11
234	Does directly observed therapy improve tuberculosis treatment? More evidence is needed to guide tuberculosis policy. BMC Infectious Diseases, 2016, 16, 537.	1.3	35
235	Predictors of viral suppression and rebound among HIV-positive men who have sex with men in a large multi-site Canadian cohort. BMC Infectious Diseases, 2016, 16, 590.	1.3	36
236	Performance of point-of-care CD4 testing technologies in resource-constrained settings: a systematic review and meta-analysis. BMC Infectious Diseases, 2016, 16, 592.	1.3	15
237	CD4-cell counts and presence of AIDS in HIV-positive patients entering specialized care—a comparison of migrant groups in the German ClinSurv HIV Cohort Study, 1999–2013. BMC Infectious Diseases, 2016, 16, 739.	1.3	3

#	ARTICLE	IF	CITATIONS
238	Progesterone supplementation for HIV-positive pregnant women on protease inhibitor-based antiretroviral regimens (the ProSPAR study): a study protocol for a pilot randomized controlled trial. Pilot and Feasibility Studies, 2016, 2, 49.	0.5	11
239	How have guidelines on when to start antiretroviral therapy affected survival of people living with HIV infection?. Current Opinion in HIV and AIDS, 2016, 11, 487-491.	1.5	14
240	Outcomes of Acutely HIV-1-Infected Individuals following Rapid Antiretroviral Therapy Initiation. Antiviral Therapy, 2017, 22, 77-80.	0.6	21
241	HIV and ageing. Current Opinion in HIV and AIDS, 2016, 11, 527-536.	1.5	112
242	Looking Beyond the Cascade of HIV Care to End the AIDS Epidemic: Estimation of the Time Interval From HIV Infection to Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 348-355.	0.9	39
243	Effect of sociodemographic factors on survival of people living with HIV. Current Opinion in HIV and AIDS, 2016, 11, 501-506.	1.5	18
244	Lessons from acute HIV infection. Current Opinion in HIV and AIDS, 2016, 11, 555-560.	1.5	47
245	Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe. Current Opinion in HIV and AIDS, 2016, 11, 492-500.	1.5	274
246	Dysfunctional phenotypes of CD4+ and CD8+ T cells are comparable in patients initiating ART during early or chronic HIV-1 infection. Medicine (United States), 2016, 95, e3738.	0.4	18
247	Pneumococcal vaccination of HIV-infected young adults is an important global priority. Aids, 2016, 30, 1991-1993.	1.0	1
248	A longitudinal, HIV care continuum. Aids, 2016, 30, 2227-2234.	1.0	49
249	Influence of geographic origin, sex, and HIV transmission group on the outcome of first-line combined antiretroviral therapy in France. Aids, 2016, 30, 2235-2246.	1.0	8
250	Chronic lung disease in HIV-infected children established on antiretroviral therapy. Aids, 2016, 30, 2795-2803.	1.0	49
251	High levels of retention in care with streamlined care and universal test and treat in East Africa. Aids, 2016, 30, 2855-2864.	1.0	61
252	Initiation of antiretroviral therapy based on the 2015 WHO guidelines. Aids, 2016, 30, 2865-2873.	1.0	13
253	Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability. Aids, 2016, 30, 2815-2822.	1.0	4
254	Reducing HIV infection in people who inject drugs is impossible without targeting recently-infected subjects. Aids, 2016, 30, 2885-2890.	1.0	18
255	Heavy Alcohol Use Is Associated With Worse Retention in HIV Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 419-425.	0.9	80

#	Article	IF	CITATIONS
256	The role of healthcare providers in the roll out of preexposure prophylaxis. Current Opinion in HIV and AIDS, 2016, 11, 41-48.	1.5	116
257	Determinants of residual viraemia during combination <scp>HIV</scp> treatment: Impacts of baseline <scp>HIV RNA</scp> levels and treatment choice. HIV Medicine, 2016, 17, 495-504.	1.0	9
258	Systematic Review of Prevalence and Predictors of Frailty in Individuals with Human Immunodeficiency Virus. Journal of the American Geriatrics Society, 2016, 64, 1006-1014.	1.3	67
259	Retention in care of HIVâ€infected pregnant and lactating women starting ART under Option B+ in rural Mozambique. Tropical Medicine and International Health, 2016, 21, 1003-1012.	1.0	43
260	Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome in Older Adults. Clinics in Geriatric Medicine, 2016, 32, 571-583.	1.0	6
261	Cognitive Impairment Among Older Individuals with HIV Infection. Current Geriatrics Reports, 2016, 5, 63-70.	1.1	7
262	Current and (Potential) Future Effects of the Affordable Care Act on HIV Prevention. Current HIV/AIDS Reports, 2016, 13, 95-106.	1.1	12
263	Cascade of Refusal—What Does It Mean for the Future of Treatment as Prevention in Sub-Saharan Africa?. Current HIV/AIDS Reports, 2016, 13, 125-130.	1.1	18
264	Critical considerations for adopting the HIV †treat all†approach in Zimbabwe: is the nation poised?. Public Health Action, 2016, 6, 3-7.	0.4	10
265	Collaborative activities and treatment outcomes in patients with HIV-associated tuberculosis in Viet Nam. Public Health Action, 2016, 6, 8-14.	0.4	4
266	Reasons for not starting antiretroviral therapy in HIV-1-infected individuals: a changing landscape. Infection, 2016, 44, 521-529.	2.3	7
268	Incidence and Prevalence of Opportunistic and Other Infections and the Impact of Antiretroviral Therapy Among HIV-infected Children in Low- and Middle-income Countries: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2016, 62, 1586-1594.	2.9	59
269	Long-Acting Injectable Preexposure Prophylaxis for HIV Prevention in South Africa: Is There a Will and a Way?. Journal of Infectious Diseases, 2016, 213, 1519-1520.	1.9	7
270	Initiation of Antiretroviral Therapy During Acute HIV-1 Infection Leads to a High Rate of Nonreactive HIV Serology. Clinical Infectious Diseases, 2016, 63, 555-561.	2.9	104
271	Immune recovery in HIV-infected patients after Candida esophagitis is impaired despite long-term antiretroviral therapy. Aids, 2016, 30, 1923-1933.	1.0	6
272	CD4 cell count at initiation of ART, long-term likelihood of achieving CD4 >750 cells/mm3 and mortality risk. Journal of Antimicrobial Chemotherapy, 2016, 71, 2654-2662.	1.3	27
273	Early initiation of antiretroviral therapy: debate over?. Lancet Infectious Diseases, The, 2016, 16, 769.	4.6	0
274	Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents, and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial. Lancet HIV,the, 2016, 3, e421-e430.	2.1	51

#	ARTICLE	IF	CITATIONS
275	Brief Report: HIV Drug Resistance in Adults Failing Early Antiretroviral Treatment: Results From the HIV Prevention Trials Network 052 Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 304-309.	0.9	14
276	Peru's HIV care continuum among men who have sex with men and transgender women: opportunities to optimize treatment and prevention. International Journal of STD and AIDS, 2016, 27, 1039-1048.	0.5	42
277	Medium-grade tubular proteinuria is common in HIV-positive patients and specifically associated with exposure to tenofovir disoproxil Fumarate. Infection, 2016, 44, 641-649.	2.3	11
278	Substance use and HIV infection awareness among HIV-infected female sex workers in Lilongwe, Malawi. International Journal of Drug Policy, 2016, 30, 124-131.	1.6	22
279	An unusual case of underlying rilpivirine resistance in an antiretroviral-na \tilde{A} -ve man with AIDS. International Journal of STD and AIDS, 2016, 27, 1346-1349.	0.5	1
280	The role of antiretroviral therapy in reducing TB incidence and mortality in high HIV-TB burden countries. Asian Pacific Journal of Tropical Disease, 2016, 6, 243-247.	0.5	1
281	Pattern, Determinants, and Impact of HIV Spending on Care and Treatment in 38 High-Burden Low- and Middle-Income Countries. Journal of the International Association of Providers of AIDS Care, 2016, 15, 91-100.	0.6	24
282	Predictors of opportunistic illnesses incidence in post combination antiretroviral therapy era in an urban cohort from Rio de Janeiro, Brazil. BMC Infectious Diseases, 2016, 16, 134.	1.3	12
283	Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study. BMC Infectious Diseases, 2016, 16, 189.	1.3	21
284	Same day ART initiation versus clinic-based pre-ART assessment and counselling for individuals newly tested HIV-positive during community-based HIV testing in rural Lesotho $\hat{a} \in \hat{a}$ a randomized controlled trial (CASCADE trial). BMC Public Health, 2016, 16, 329.	1.2	35
285	Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy. BMC Medicine, 2016, 14, 50.	2.3	35
286	Evolution of changes in cognitive function after the initiation of antiretroviral therapy. AIDS Research and Therapy, 2016, 13, 20.	0.7	8
287	Human Immunodeficiency Virus as a Chronic Disease: Evaluation and Management of Nonacquired Immune Deficiency Syndrome-Defining Conditions. Open Forum Infectious Diseases, 2016, 3, ofw097.	0.4	37
288	The good, the bad and the ugly: determinants of antiretroviral-associated toxicities. Future Virology, 2016, 11, 239-243.	0.9	0
289	Guidelines for Evaluation and Management of Cognitive Disorders in HIV-Positive Individuals. Current HIV/AIDS Reports, 2016, 13, 235-240.	1.1	32
290	One in 4 HIV-Positive South Africans Awaiting ART Initiation Report Condomless Sex With a Serodiscordant Partner. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e77-e79.	0.9	7
291	Acute Infections, Cost per Infection and Turnaround Time in Three United States Hospital Laboratories Using Fourth-Generation Antigen-Antibody Human Immunodeficiency Virus Immunoassays. Open Forum Infectious Diseases, 2016, 3, ofv188.	0.4	1
292	The transmission of Mycobacterium tuberculosis in high burden settings. Lancet Infectious Diseases, The, 2016, 16, 227-238.	4.6	149

#	Article	IF	Citations
293	Current treatment options for hepatitis C patients co-infected with HIV. Expert Review of Gastroenterology and Hepatology, 2016, 10, 689-695.	1.4	12
294	Early HIV treatment to forestall drug resistance. Lancet Infectious Diseases, The, 2016, 16, 512-513.	4.6	5
295	Antiretroviral Therapy in Early HIV Infection. New England Journal of Medicine, 2016, 374, 393-394.	13.9	6
296	HIV, Viral Suppression and New Technologies of Surveillance and Control. Body and Society, 2016, 22, 82-107.	0.3	24
297	High mortality and prevalence of HIV and tuberculosis in adults with chronic cough in Malawi: a cohort study. International Journal of Tuberculosis and Lung Disease, 2016, 20, 202-210.	0.6	11
298	HIV treatment: time to lean forward. Lancet, The, 2016, 387, 27.	6.3	7
299	Timing of antiretroviral therapy initiation after diagnosis of recent human immunodeficiency virus infection and CD4+ T-cell recovery. Clinical Microbiology and Infection, 2016, 22, 290.e5-290.e8.	2.8	9
300	Global Considerations in Human Immunodeficiency Virus-Associated Respiratory Disease. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 166-180.	0.8	3
301	Role of immune activation in progression to AIDS. Current Opinion in HIV and AIDS, 2016, 11, 131-137.	1.5	58
302	Diagnosing and treating HIV-associated sensory neuropathy: a global perspective. Pain Management, 2016, 6, 191-199.	0.7	14
303	Evaluation and Diagnosis of HIV-Associated Lung Disease. Seminars in Respiratory and Critical Care Medicine, 2016, 37, 199-213.	0.8	9
304	START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases, 2016, 3, ofw032.	0.4	27
305	Let's treat everyone with HIV now: what happens next?. Lancet HIV, the, 2016, 3, e109-e110.	2.1	0
306	Scale-up of Routine Viral Load Testing in Resource-Poor Settings: Current and Future Implementation Challenges: Table 1 Clinical Infectious Diseases, 2016, 62, 1043-1048.	2.9	177
307	The Chronicity of HIV Infection Should Drive the Research Strategy of NeuroHIV Treatment Studies: A Critical Review. CNS Drugs, 2016, 30, 53-69.	2.7	42
308	Effect of Advanced HIV Infection on the Respiratory Microbiome. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 226-235.	2.5	83
309	Pathophysiology and management of cardiovascular disease in patients with HIV. Lancet Diabetes and Endocrinology, the, 2016, 4, 598-610.	5 . 5	66
310	CD4 Cell Count: Declining Value for Antiretroviral Therapy Eligibility. Clinical Infectious Diseases, 2016, 62, 1022-1028.	2.9	21

#	Article	IF	CITATIONS
311	Challenges in the Elimination of Pediatric HIV-1 Infection. New England Journal of Medicine, 2016, 374, 761-770.	13.9	112
312	Antiretroviral therapy: Shifting sands. Medical Journal Armed Forces India, 2016, 72, 54-60.	0.3	6
313	Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection. Drugs, 2016, 76, 533-549.	4.9	59
314	Global challenges keynote address <i>in memoriam</i> to colleagues lost in the Malaysia airlines 17 crash. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 3-7.	0.6	1
315	Retention in care during the first 3 years of antiretroviral therapy for women in Malawi's option B+ programme: an observational cohort study. Lancet HIV,the, 2016, 3, e175-e182.	2.1	154
316	Bloodstream infections in HIV-infected patients. Virulence, 2016, 7, 320-328.	1.8	38
317	Modeling and Cost-Effectiveness in HIV Prevention. Current HIV/AIDS Reports, 2016, 13, 64-75.	1.1	25
318	History of AIDS in HIV-Infected Patients Is Associated With Higher In-Hospital Mortality Following Admission for Acute Myocardial Infarction and Stroke. Journal of Infectious Diseases, 2016, 213, 1955-1961.	1.9	17
319	HIV-1–Related Cardiovascular Disease Is Associated With Chronic Inflammation, Frequent Pericardial Effusions, and Probable Myocardial Edema. Circulation: Cardiovascular Imaging, 2016, 9, e004430.	1.3	88
320	HIV-associated neurocognitive disorder â€" pathogenesis and prospects for treatment. Nature Reviews Neurology, 2016, 12, 234-248.	4.9	690
321	Laboratory Monitoring of Antiretroviral Therapy for HIV Infection: Cost-Effectiveness and Budget Impact of Current and Novel Strategies. Clinical Infectious Diseases, 2016, 62, 1454-1462.	2.9	14
322	Incidence of Opportunistic Infections and the Impact of Antiretroviral Therapy Among HIV-Infected Adults in Low- and Middle-Income Countries: A Systematic Review and Meta-analysis. Clinical Infectious Diseases, 2016, 62, 1595-1603.	2.9	113
323	Linkage to care: a step on the path, but not the destination. Lancet HIV, the, 2016, 3, e193-e194.	2.1	3
324	Factors associated with presenting late or with advanced HIV disease in the Netherlands, 1996–2014: results from a national observational cohort. BMJ Open, 2016, 6, e009688.	0.8	66
325	Sources of HIV infection among men having sex with men and implications for prevention. Science Translational Medicine, 2016, 8, 320ra2.	5.8	106
326	From START to finish: implications of the START study. Lancet Infectious Diseases, The, 2016, 16, 13-14.	4.6	10
327	Retention in Early Care at an HIV Outpatient Clinic in Rio de Janeiro, Brazil, 2000–2013. AIDS and Behavior, 2016, 20, 1039-1048.	1.4	10
328	Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding. Clinical Microbiology Reviews, 2016, 29, 149-161.	5.7	132

#	ARTICLE	IF	CITATIONS
329	Diffusion of Newer HIV Prevention Innovations: Variable Practices of Frontline Infectious Diseases Physicians. Clinical Infectious Diseases, 2016, 62, 99-105.	2.9	33
330	The Influence of Medication Attitudes on Utilization of Antiretroviral Therapy (ART) in Indonesian Prisons. AIDS and Behavior, 2016, 20, 1026-1038.	1.4	21
331	Embodied, clinical and pharmaceutical uncertainty: people with HIV anticipate the feasibility of HIV treatment as prevention (TasP). Critical Public Health, 2017, 27, 63-74.	1.4	9
332	Men from Sub-Saharan Africa Living in Worker Hostels in France: A Hidden Population with Poor Access to HIV Testing. Journal of Immigrant and Minority Health, 2017, 19, 991-994.	0.8	5
333	Getting the balance right: Scaling-up treatment and prevention. Global Public Health, 2017, 12, 483-497.	1.0	4
334	General practitioners' barriers and facilitators towards new provider-initiated HIV testing strategies: a qualitative study. International Journal of STD and AIDS, 2017, 28, 459-466.	0.5	26
335	HIV-infected presumptive tuberculosis patients without tuberculosis: How many are eligible for antiretroviral therapy in Karnataka, India?. Journal of Epidemiology and Global Health, 2017, 7, 11.	1.1	7
336	Public Knowledge and Attitudes to HIV: Research From Three Decades in Sweden. International Journal of Sexual Health, 2017, 29, 22-31.	1.2	3
337	Reply to Meijide et al. Clinical Infectious Diseases, 2017, 64, 389-390.	2.9	0
338	High prevalence and low cure rate of tuberculosis among patients with HIV in Xinjiang, China. BMC Infectious Diseases, 2017, 17, 15.	1.3	18
339	Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per $\hat{l}^1/4L$: secondary outcome results from a randomised controlled trial. Lancet HIV,the, 2017, 4, e105-e112.	2.1	44
340	Swaziland HIV Incidence Measurement Survey (SHIMS): a prospective national cohort study. Lancet HIV,the, 2017, 4, e83-e92.	2.1	78
341	Assisted partner services for HIV in Kenya: a cluster randomised controlled trial. Lancet HIV,the, 2017, 4, e74-e82.	2.1	98
342	Better to know: the importance of early HIV diagnosis. Lancet Public Health, The, 2017, 2, e6-e7.	4.7	24
343	Severe bacterial infections: overlooked opportunistic diseases. Lancet HIV, the, 2017, 4, e94-e95.	2.1	2
344	Progress Toward Achieving the UNAIDS 90-90-90 Goals in HIV Care From Diagnosis to Durable Viral Suppression in the Country of Georgia. AIDS Research and Human Retroviruses, 2017, 33, 999-1003.	0.5	3
345	Patient engagement in HIV care and treatment in Zambia, 2004–2014. Tropical Medicine and International Health, 2017, 22, 332-339.	1.0	4
346	Barriers to access and uptake of antiretroviral therapy among HIV-positive men who have sex with men in Hanoi, Vietnam: from HIV testing to treatment. Culture, Health and Sexuality, 2017, 19, 859-872.	1.0	10

#	Article	IF	CITATIONS
347	Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV. Expert Review of Anti-Infective Therapy, 2017, 15, 195-209.	2.0	22
348	The HIV Care Continuumâ€"Is the Whole Greater Than the Sum of Its Parts? Implications for Interventions in a Test and Treat World. EBioMedicine, 2017, 17, 18-19.	2.7	0
349	HIV-related pneumococcal disease prevention in adults. Expert Review of Respiratory Medicine, 2017, 11, 181-199.	1.0	12
351	The impact of changes in <scp>HIV</scp> management guidelines on time to treatment initiation in Australia. HIV Medicine, 2017, 18, 701-703.	1.0	3
352	Tuberculosis Associated with HIV Infection. Microbiology Spectrum, 2017, 5, .	1.2	51
353	Assessing cervical intraepithelial neoplasia as an indicator disease for <scp>HIV</scp> in a low endemic setting: a populationâ€based register study. BJOG: an International Journal of Obstetrics and Gynaecology, 2017, 124, 1680-1687.	1.1	2
354	Engagement in the HIV care cascade and barriers to antiretroviral therapy uptake among female sex workers in Port Elizabeth, South Africa: findings from a respondent-driven sampling study. Sexually Transmitted Infections, 2017, 93, 290-296.	0.8	57
355	Community-Acquired Pneumonia in HIV-Positive Patients: an Update on Etiologies, Epidemiology and Management. Current Infectious Disease Reports, 2017, 19, 2.	1.3	9
356	The importance of registration of sexual orientation and recognition of indicator conditions for an adequate HIV risk-assessment. BMC Infectious Diseases, 2017, 17, 178.	1.3	19
357	Impact of rectal gonorrhoea and chlamydia on HIV viral load in the rectum: potential significance for onward transmission. International Journal of STD and AIDS, 2017, 28, 1034-1037.	0.5	6
358	Diagnostic and vaccine strategies to prevent infections in patients with inflammatory bowel disease. Journal of Infection, 2017, 74, 433-441.	1.7	28
359	Significant publications on infectious diseases pharmacotherapy in 2015. American Journal of Health-System Pharmacy, 2017, 74, 238-252.	0.5	12
360	Determinants of virological outcome and adverse events in African children treated with paediatric nevirapine fixed-dose-combination tablets. Aids, 2017, 31, 905-915.	1.0	7
361	Aging with HIV in the ART era. Seminars in Diagnostic Pathology, 2017, 34, 384-397.	1.0	56
362	The Roles of Behavioral and Social Science Research in the Fight Against HIV/AIDS: A Functional Framework. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 371-381.	0.9	21
363	Linkage to Care After HIV Diagnosis in New York City: Better Than We Thought. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e18-e21.	0.9	4
364	Sexualverhalten, STIs und HIVâ€Ãœbertragungsrisiken bei HIVâ€positiven MSM – AnsÃŒe für die ÃÆtliche PrÃŒntionsarbeit. JDDG - Journal of the German Society of Dermatology, 2017, 15, 421-429.	0.4	2
365	International Sexual Partnerships May Be Shaped by Sexual Histories and Socioeconomic Status. Sexually Transmitted Diseases, 2017, 44, 306-309.	0.8	0

#	Article	IF	CITATIONS
366	Using a network-based approach and targeted maximum likelihood estimation to evaluate the effect of adding pre-exposure prophylaxis to an ongoing test-and-treat trial. Clinical Trials, 2017, 14, 201-210.	0.7	4
367	Barriers to Universal Prescribing of Antiretroviral Therapy by HIV Care Providers in the United States, 2013–2014. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 479-487.	0.9	16
368	The Impact of Preexposure Prophylaxis Among Men Who Have Sex With Men: An Individual-Based Model. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 175-183.	0.9	48
369	Using the multiphase optimization strategy (MOST) to optimize an HIV care continuum intervention for vulnerable populations: a study protocol. BMC Public Health, 2017, 17, 383.	1.2	46
370	Improved life expectancy of people living with HIV: who is left behind?. Lancet HIV, the, 2017, 4, e324-e326.	2.1	67
371	U.S. HIV Incidence and Transmission Goals, 2020 and 2025. American Journal of Preventive Medicine, 2017, 53, 275-281.	1.6	14
372	HIV-Associated Malignant Lymphoma. Oncology Research and Treatment, 2017, 40, 82-87.	0.8	27
373	Individualized antiretroviral therapeutic approaches. Aids, 2017, 31, 1065-1071.	1.0	22
374	HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton/small clusters. Journal of Antimicrobial Chemotherapy, 2017, 72, 2171-2183.	1.3	8
375	Measuring and managing cognitive impairment in HIV. Aids, 2017, 31, S165-S172.	1.0	11
376	Brief Report: Impact of Early Antiretroviral Therapy on the Performance of HIV Rapid Tests and HIV Incidence Assays. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 426-430.	0.9	20
377	Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV, the, 2017, 4, e349-e356.	2.1	805
378	Improved quality of life with immediate versus deferred initiation of antiretroviral therapy in early asymptomatic HIV infection. Aids, 2017, 31, 953-963.	1.0	72
379	Large cluster outbreaks sustain the HIV epidemic among MSM in Quebec. Aids, 2017, 31, 707-717.	1.0	31
380	Viral Infections in Children, Volume I., 2017, , .		2
381	The HIV Care Cascade and sub-analysis of those linked to but not retained in care: the experience from a tertiary HIV referral service in Dublin Ireland. HIV Clinical Trials, 2017, 18, 93-99.	2.0	14
382	Immunosenescence and hurdles in the clinical management of older HIV-patients. Virulence, 2017, 8, 508-528.	1.8	9
383	Multiple viral infections in primary effusion lymphoma: a model of viral cooperation in lymphomagenesis. Expert Review of Hematology, 2017, 10, 505-514.	1.0	23

#	Article	IF	CITATIONS
384	Toward a universal antiretroviral regimen. Current Opinion in HIV and AIDS, 2017, 12, 359-368.	1.5	10
385	Effect of Legal Status on the Early Treatment Outcomes of Migrants Beginning Combined Antiretroviral Therapy at an Outpatient Clinic in Milan, Italy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 315-321.	0.9	13
386	A tale of two countries: allâ€cause mortality among people living with <scp>HIV</scp> and receiving combination antiretroviral therapy in the <scp>UK</scp> and Canada. HIV Medicine, 2017, 18, 655-666.	1.0	4
387	Early initiation of antiretroviral therapy prevents HIV transmission to seronegative sexual partners. Evidence-Based Medicine, 2017, 22, 29-29.	0.6	1
388	Monitoring HIV Treatment and the Health Sector Cascade: From Treatment Numbers to Impact. AIDS and Behavior, 2017, 21, 15-22.	1.4	7
389	Atazanavir sulfate + cobicistat for the treatment of HIV infection. Expert Review of Anti-Infective Therapy, 2017, 15, 569-576.	2.0	9
390	Medical table: A major tool for antimicrobial stewardship policy. MÃ@decine Et Maladies Infectieuses, 2017, 47, 311-318.	5.1	11
391	HIV viral load scale-up. Current Opinion in HIV and AIDS, 2017, 12, 157-164.	1.5	30
392	Cash vs. food assistance to improve adherence to antiretroviral therapy among HIV-infected adults in Tanzania. Aids, 2017, 31, 815-825.	1.0	62
393	Financial Incentives for Linkage to Care and Viral Suppression Among HIV-Positive Patients. JAMA Internal Medicine, 2017, 177, 1083.	2.6	105
394	Prevalence of and risk factors for depressive symptoms among people living with HIV/AIDS receiving antiretroviral treatment in Wuhan, China: a short report. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 1524-1528.	0.6	13
396	Trends in baseline CD4 cell counts and risk factors for late antiretroviral therapy initiation among HIV-positive patients in Shanghai, a retrospective cross-sectional study. BMC Infectious Diseases, 2017, 17, 285.	1.3	14
397	HIV-1–Associated Atherosclerosis. Journal of the American College of Cardiology, 2017, 69, 3084-3098.	1.2	119
398	The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 44-51.	0.9	179
399	Increased Persistence of Initial Treatment for HIV Infection With Modern Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 111-115.	0.9	16
400	Progress Toward Achieving UNAIDS 90-90-90 in Rural Communities in East Africa. JAMA - Journal of the American Medical Association, 2017, 317, 2172.	3.8	2
401	Association of Implementation of a Universal Testing and Treatment Intervention With HIV Diagnosis, Receipt of Antiretroviral Therapy, and Viral Suppression in East Africa. JAMA - Journal of the American Medical Association, 2017, 317, 2196.	3.8	116
402	Incidence, presentation and outcome ofÂtoxoplasmosis in HIV infected in the combination antiretroviral therapy era. Journal of Infection, 2017, 75, 263-273.	1.7	22

#	Article	IF	CITATIONS
403	Moving toward test and start. Aids, 2017, 31, 1489-1493.	1.0	7
404	Association of CD4+ T-cell Count, HIV-1 RNA Viral Load, and Antiretroviral Therapy With Kaposi Sarcoma Risk Among HIV-infected Persons in the United States and Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 382-390.	0.9	37
405	Changes in Cardiovascular Disease Risk Factors With Immediate Versus Deferred Antiretroviral Therapy Initiation Among HIVâ€Positive Participants in the START (Strategic Timing of Antiretroviral) Tj ETQq0 0	0 ng B T /Ov	verboock 10 Tf !
406	Moving from Public Health Failure to Opportunity. Journal of the International Association of Providers of AIDS Care, 2017, 16, 107-109.	0.6	1
407	The role of activists in access to HIV and tuberculosis treatment and prevention. Current Opinion in HIV and AIDS, 2017, 12, 398-402.	1.5	5
408	Prevalence of Anal HPV and Anal Dysplasia in HIV-Infected Women From Johannesburg, South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, e59-e64.	0.9	13
409	Determining the factors associated with bloodâ€borne virus testing of substance misusers presenting to hospital. Internal Medicine Journal, 2017, 47, 907-914.	0.5	1
410	Antiretroviral Therapy Containing HIV Protease Inhibitors Enhances Fracture Risk by Impairing Osteoblast Differentiation and Bone Quality. Journal of Infectious Diseases, 2017, 215, 1893-1897.	1.9	15
412	Relationship Between Time to Initiation of Antiretroviral Therapy and Treatment Outcomes: A Cohort Analysis of ART Eligible Adolescents in Zimbabwe. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 390-398.	0.9	11
413	Preventing acquisition of HIV is the only path to an AIDS-free generation. Proceedings of the National Academy of Sciences of the United States of America, 2017, 114, 3798-3800.	3.3	14
414	Management of Tuberculosis in Special Populations. , 2017, , 141-190.		1
416	Not just PrEP: other reasons for London's HIV decline. Lancet HIV, the, 2017, 4, e153.	2.1	29
417	Effect of Korean Red Ginseng intake on the survival duration of human immunodeficiency virus type 1 patients. Journal of Ginseng Research, 2017, 41, 222-226.	3.0	18
418	Diagnosis and Treatment of Kaposi Sarcoma. American Journal of Clinical Dermatology, 2017, 18, 529-539.	3.3	98
419	Combination antiretroviral therapy and cancer risk. Current Opinion in HIV and AIDS, 2017, 12, 12-19.	1.5	31
420	Virologic outcomes in early antiretroviral treatment: HPTN 052. HIV Clinical Trials, 2017, 18, 100-109.	2.0	20
421	Evaluation of the Predictive Potential of the Short Acute Retroviral Syndrome Severity Score for HIV-1 Disease Progression in Individuals With Acute HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, e114-e117.	0.9	5
422	National HIV Care Continua for Key Populations. Journal of the International Association of Providers of AIDS Care, 2017, 16, 125-132.	0.6	30

#	Article	IF	CITATIONS
423	HIV Prevention and Treatment: The Evolving Role of the Emergency Department. Annals of Emergency Medicine, 2017, 70, 562-572.e3.	0.3	25
424	Handbook of Tuberculosis. , 2017, , .		3
425	Using geospatial mapping to design HIV elimination strategies for sub-Saharan Africa. Science Translational Medicine, 2017, 9, .	5.8	41
427	Coronary Artery Disease in HIV-Infected Patients: Downside of Living Longer. Current Atherosclerosis Reports, 2017, 19, 18.	2.0	31
428	Sexual risk behavior, sexually transmitted infections, and HIV transmission risks in HIV \hat{a} epositive men who have sex with men (MSM) \hat{a} e" approaches for medical prevention. JDDG - Journal of the German Society of Dermatology, 2017, 15, 421-428.	0.4	11
429	Association Between Human Immunodeficiency Virus Infection and Cardiovascular Diseases. JAMA Cardiology, 2017, 2, 123.	3.0	6
430	Presentation for care and antenatal management of HIV in the UK, 2009â^2014. HIV Medicine, 2017, 18, 161-170.	1.0	23
431	Cancer Incidence in Persons Living With HIV. Clinical Infectious Diseases, 2017, 64, 388-389.	2.9	2
432	HIV and Nonischemic Heart Disease. Journal of the American College of Cardiology, 2017, 69, 83-91.	1.2	50
433	HIV and Ischemic Heart Disease. Journal of the American College of Cardiology, 2017, 69, 73-82.	1.2	98
434	Population levels and geographical distribution of HIV RNA in rural Ugandan and Kenyan communities, including serodiscordant couples: a cross-sectional analysis. Lancet HIV, the, 2017, 4, e122-e133.	2.1	21
435	Integrating HIV Surveillance and Field Services: Data Quality and Care Continuum in King County, Washington, 2010–2015. American Journal of Public Health, 2017, 107, 1938-1943.	1.5	11
436	High rates of viral suppression in adults and children with high CD4+ counts using a streamlined ART delivery model in the SEARCH trial in rural Uganda and Kenya. Journal of the International AIDS Society, 2017, 20, 21673.	1.2	57
437	Pathophysiology of ischaemic heart disease. Current Opinion in HIV and AIDS, 2017, 12, 548-553.	1.5	3
438	Comparing Outcomes of HIV-Infected Chinese Adults on Antiretroviral Therapy by CD4 Count at Treatment Initiation: A Nationwide Retrospective Observational Cohort Study, 2012–2014. AIDS Patient Care and STDs, 2017, 31, 413-420.	1.1	5
439	Multidisciplinary Approach to HIV/AIDS: Historical Perspective. , 2017, , 1-20.		1
440	Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial. The Lancet Global Health, 2017, 5, e1080-e1089.	2.9	128
441	Current Status of Point-of-Care Testing for Human Immunodeficiency Virus Drug Resistance. Journal of Infectious Diseases, 2017, 216, S824-S828.	1.9	23

#	ARTICLE	IF	CITATIONS
442	Declining prevalence of cytological squamous intraepithelial lesions of the cervix among women living with well ontrolled ⟨scp⟩HlV⟨ scp⟩ – Most women living with ⟨scp⟩HlV⟨ scp⟩ do not need annual ⟨scp⟩PAP⟨ scp⟩ smear screening. Acta Obstetricia Et Gynecologica Scandinavica, 2017, 96, 1330-1337.	1.3	8
443	Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Annals of Internal Medicine, 2017, 167, 618.	2.0	18
444	Human Immunodeficiency Virus and Aging in the Era of Effective Antiretroviral Therapy. Infectious Disease Clinics of North America, 2017, 31, 791-810.	1.9	40
445	Longitudinal Viral Suppression Among a Cohort of Adolescents and Young Adults with Behaviorally Acquired Human Immunodeficiency Virus. AIDS Patient Care and STDs, 2017, 31, 377-383.	1.1	24
446	Combining CD4 recovery and CD4: CD8 ratio restoration as an indicator for evaluating the outcome of continued antiretroviral therapy: an observational cohort study. BMJ Open, 2017, 7, e016886.	0.8	21
447	Trends in contraceptive use according to HIV status among privately insured women in the United States. American Journal of Obstetrics and Gynecology, 2017, 217, 676.e1-676.e11.	0.7	23
448	Out of focus: tailoring the cascade of care to the needs of women living with HIV. HIV Medicine, 2017, 18, 3-17.	1.0	8
449	Mortality under plausible interventions on antiretroviral treatment and depression in HIV-infected women: an application of the parametric g-formula. Annals of Epidemiology, 2017, 27, 783-789.e2.	0.9	10
450	58-Year-Old Woman With Diarrhea, Weakness, and Memory Loss. Mayo Clinic Proceedings, 2017, 92, 1706-1710.	1.4	0
451	The changing face of an epidemic: healthy old age with HIV. British Journal of Hospital Medicine (London, England: 2005), 2017, 78, 516-522.	0.2	3
452	IP-10 Levels as an Accurate Screening Tool to Detect Acute HIV Infection in Resource-Limited Settings. Scientific Reports, 2017, 7, 8104.	1.6	26
453	Time from HIV infection to virological suppression. Aids, 2017, 31, 2377-2385.	1.0	10
454	Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. New England Journal of Medicine, 2017, 377, 233-245.	13.9	156
455	HIV Treatment and Re-infection Beliefs Predict Sexual Risk Behavior of Men Who Have Sex With Men. AIDS Education and Prevention, 2017, 29, 218-227.	0.6	5
456	Effect of Immediate Initiation of Antiretroviral Treatment in HIV-Positive Individuals Aged 50 Years or Older. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 311-318.	0.9	12
457	Neurocognitive Impairment in a Chronically Well-Suppressed HIV-Infected Population: The Dutch TREVI Cohort Study. AIDS Patient Care and STDs, 2017, 31, 329-334.	1.1	26
458	Cost-effectiveness of screening for HIV in primary care: a health economics modelling analysis. Lancet HIV,the, 2017, 4, e465-e474.	2.1	50
459	Cost-effectiveness of early identification of HIV infection. Lancet HIV, the, 2017, 4, e431-e432.	2.1	0

#	Article	IF	CITATIONS
460	The effect of engagement in an <scp>HIV</scp> / <scp>AIDS</scp> integrated health programme on plasma <scp>HIV</scp> â€1 <scp>RNA</scp> suppression among <scp>HIV</scp> â€positive people who use illicit drugs: a marginal structural modelling analysis. HIV Medicine, 2017, 18, 580-586.	1.0	13
461	Online-to-offline models in HIV service delivery. Current Opinion in HIV and AIDS, 2017, 12, 447-457.	1.5	17
462	Clinical and scientific challenges in HIV-associated malignancies. Current Opinion in HIV and AIDS, 2017, 12, 1-5.	1.5	2
463	"All Generalizations Are Dangerous, Even This One.â€â€"Alexandre Dumas. Epidemiology, 2017, 28, 562-566.	1.2	9
464	Patient-reported barriers and facilitators to antiretroviral adherence in sub-Saharan Africa. Aids, 2017, 31, 995-1007.	1.0	110
465	Antiretroviral Drug Use in a Cross-Sectional Population Survey in Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 158-165.	0.9	8
466	Implementation of Antiretroviral Therapy for Life in Pregnant/Breastfeeding HIV+ Women (Option B+) Alongside Rollout and Changing Guidelines for ART Initiation in Rural Zimbabwe: The Lablite Project Experience. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 508-516.	0.9	17
467	Multidisciplinary Point-of-Care Testing in South African Primary Health Care Clinics Accelerates HIV ART Initiation but Does Not Alter Retention in Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 65-73.	0.9	22
468	HIV Care Initiation Delay Among Rural Residents in the Southeastern United States, 1996 to 2012. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 171-176.	0.9	18
469	Facing new challenges to promote long-term health for people living with HIV. Current Opinion in Infectious Diseases, 2017, 30, 1-3.	1.3	12
470	The evolving role of CD4 cell counts in HIV care. Current Opinion in HIV and AIDS, 2017, 12, 123-128.	1.5	106
471	Brief Report: Drop in CD4+ Counts Below 200 Cells/νL After Reaching (or Starting From) Values Higher than 350 Cells/Ĩ¼L in HIV-Infected Patients With Virological Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 417-422.	0.9	2
472	Epidemiology of ischemic heart disease in HIV. Current Opinion in HIV and AIDS, 2017, 12, 540-547.	1.5	35
473	Missed Opportunities: Adapting the HIV Care Continuum to Reduce HIV-Related Deaths. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 231-240.	0.9	3
474	Antiretroviral Therapy Initiation Is Not Associated With Risky Sexual Behavior Among Heterosexual Human Immunodeficiency Virus–Infected Persons in Serodiscordant Partnerships. Sexually Transmitted Diseases, 2017, 44, 58-62.	0.8	8
475	Post-treatment control or treated controllers? Viral remission in treated and untreated primary HIV infection. Aids, 2017, 31, 477-484.	1.0	51
476	Increasing HIV Treatment Optimism but No Changes in HIV Risk Behavior Among Men Who Have Sex With Men in Vancouver, Canada. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, e98-e101.	0.9	6
477	HIV and AIDS: An overview of the current issues, treatment and prevention. Nursing Standard (Royal) Tj ETQq1 1 (0.784314	rgBT /Overl

#	Article	IF	Citations
478	Durability of antiretroviral therapy regimens and determinants for change in HIV-1-infected patients in the TREAT Asia HIV Observational Database (TAHOD-LITE). Antiviral Therapy, 2017, 23, 167-178.	0.6	9
479	Charting the Course to End HIV Transmission in the United States. Public Health Reports, 2017, 132, 603-605.	1.3	3
480	A Review of HIV and Headache: A Crossâ€Sectional Study. Headache, 2017, 57, 1631-1632.	1.8	3
481	Primary HIV infection in patients with acute hepatitis B: a report of two cases. Antiviral Therapy, 2017, 23, 197-200.	0.6	0
482	The pharmacological treatment of acute HIV infections in neonates. Expert Review of Clinical Pharmacology, 2017, 10, 1353-1361.	1.3	4
483	Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial. Journal of Bone and Mineral Research, 2017, 32, 1945-1955.	3.1	38
484	The ART Advantage: Health Care Utilization for Diabetes and Hypertension in Rural South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 561-567.	0.9	74
485	Management of Newly Diagnosed HIV Infection. Annals of Internal Medicine, 2017, 167, ITC1.	2.0	7
486	Inflammation and Immune Activation in Antiretroviral-Treated Human Immunodeficiency Virus Type 1â€"Infected African Infants and Rotavirus Vaccine Responses. Journal of Infectious Diseases, 2017, 215, 928-932.	1.9	13
487	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. Aids, 2017, 31, 835-846.	1.0	14
488	Increases in CD4+ T-cell count at antiretroviral therapy initiation among HIV-positive illicit drug users during a treatment-as-prevention initiative in Canada. Antiviral Therapy, 2017, 22, 403-411.	0.6	7
489	Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. International Journal of Antimicrobial Agents, 2017, 50, 453-460.	1.1	19
490	Antiretroviral dose optimization. Current Opinion in HIV and AIDS, 2017, 12, 339-342.	1.5	9
491	Mortality in patients with HIV-1 and tuberculosis co-infection in Rio de Janeiro, Brazil - associated factors and causes of death. BMC Infectious Diseases, 2017, 17, 373.	1.3	47
492	Immunological and virological characterization of HIV-1 viremia controllers in the North Region of Brazil. BMC Infectious Diseases, 2017, 17, 381.	1.3	11
493	Antiretroviral therapy initiation within seven days of enrolment: outcomes and time to undetectable viral load among children at an urban HIV clinic in Uganda. BMC Infectious Diseases, 2017, 17, 439.	1.3	9
494	Teriflunomide and monomethylfumarate target HIV-induced neuroinflammation and neurotoxicity. Journal of Neuroinflammation, 2017, 14, 51.	3.1	31
495	Late presentation increases risk and costs of non-infectious comorbidities in people with HIV: an Italian cost impact study. AIDS Research and Therapy, 2017, 14, 8.	0.7	31

#	ARTICLE	IF	CITATIONS
496	Factors associated with loss to follow-up after occupational HIV exposure in Cape Town, South Africa: a retrospective cohort study. AIDS Research and Therapy, 2017, 14, 23.	0.7	3
497	Validating a self-report measure of HIV viral suppression: an analysis of linked questionnaire and clinical data from the Canadian HIV Women's Sexual and Reproductive Health Cohort Study. BMC Research Notes, 2017, 10, 138.	0.6	27
498	Antiretroviral therapy related adverse effects: Can sub-Saharan Africa cope with the new "test and treat―policy of the World Health Organization?. Infectious Diseases of Poverty, 2017, 6, 24.	1.5	32
499	Cardiovascular risk in an HIV-infected population in India. Heart Asia, 2017, 9, e010893.	1.1	13
500	Early antiretroviral therapy and potent second-line drugs could decrease HIV incidence of drug resistance. Proceedings of the Royal Society B: Biological Sciences, 2017, 284, 20170525.	1.2	10
501	Therapeutic Immune Recovery and Reduction of CXCR4-Tropic HIV-1. Clinical Infectious Diseases, 2017, 64, 295-300.	2.9	14
502	Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. Clinical Infectious Diseases, 2017, 64, 124-131.	2.9	200
503	Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. Lancet HIV,the, 2017, 4, e21-e30.	2.1	163
504	Associations between cognitive impairment and patientâ€reported measures of physical/mental functioning in older people living with HIV. HIV Medicine, 2017, 18, 363-369.	1.0	24
505	Ideal Cardiovascular Health and Carotid Atherosclerosis in a Mixed Cohort of HIV-Infected and Uninfected Ugandans. AIDS Research and Human Retroviruses, 2017, 33, 49-56.	0.5	33
506	Uptake of HIV Preexposure Prophylaxis Among Commercially Insured Persons—United States, 2010–2014. Clinical Infectious Diseases, 2017, 64, 144-149.	2.9	109
507	Retention, Antiretroviral Therapy Use and Viral Suppression by History of Injection Drug Use Among HIV-Infected Patients in an Urban HIV Clinical Cohort. AIDS and Behavior, 2017, 21, 1016-1024.	1.4	30
508	Early antiretroviral therapy initiation: access and equity of viral load testing for HIV treatment monitoring. Lancet Infectious Diseases, The, 2017, 17, e26-e29.	4.6	50
509	Time Until Emergence of HIV Test Reactivity Following Infection With HIV-1: Implications for Interpreting Test Results and Retesting After Exposure. Clinical Infectious Diseases, 2017, 64, 53-59.	2.9	81
510	Changing Clinician Practices and Attitudes Regarding the Use of Antiretroviral Therapy for HIV Treatment and Prevention. Journal of the International Association of Providers of AIDS Care, 2017, 16, 81-90.	0.6	5
511	Very Early ART and Persistent Inflammation in Treated HIV. Clinical Infectious Diseases, 2017, 64, 132-133.	2.9	13
512	HIV Rapid Testing Programs in Non-Clinical Settings have the Potential to Constitute a Major Diagnostic Option for MSM in Spain. AIDS and Behavior, 2017, 21, 525-533.	1.4	10
513	Poor retention in early care increases risk of mortality in a Brazilian HIV-infected clinical cohort. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 263-267.	0.6	11

#	Article	IF	CITATIONS
514	Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Research, 2017, 239, 1-9.	1.1	50
515	Barriers and Facilitators to Interventions Improving Retention in HIV Care: A Qualitative Evidence Meta-Synthesis. AIDS and Behavior, 2017, 21, 1755-1767.	1.4	80
516	Evaluation of <scp>HIV</scp> testing recommendations in specialty guidelines for the management of <scp>HIV</scp> indicator conditions. HIV Medicine, 2017, 18, 300-304.	1.0	20
517	Review of functional MRI in HIV: effects of aging and medication. Journal of NeuroVirology, 2017, 23, 20-32.	1.0	49
518	Principles of Management of HIV in the Industrialized World. , 2017, , 912-917.e2.		3
519	Antiviral Therapy. , 2017, , 918-926.e1.		1
520	Issues in the Aging HIV-Positive Patient. , 2017, , 927-930.e1.		0
521	Antiretroviral Management in Low- and Middle-Income Countries. , 2017, , 936-937.e1.		0
522	Efficacy of imidazolquinoline on treatment of condyloma acuminatum of the buccal mucosa. Special Care in Dentistry, 2017, 37, 51-54.	0.4	5
523	Heart aging measured with coronary artery calcium scoring and cardiovascular risk assessment algorithms in HIV infected patients. Virulence, 2017, 8, 539-544.	1.8	3
524	Lung microbiome in human immunodeficiency virus infection. Translational Research, 2017, 179, 97-107.	2.2	25
525	High frequency of potential interactions between directâ€acting antivirals and concomitant therapy in <scp>HIV</scp> /hepatitis C virusâ€coinfected patients in clinical practice. HIV Medicine, 2017, 18, 445-451.	1.0	11
526	Understanding the delay in starting antiretroviral therapy despite recent guidelines for HIV patients retained in care. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2017, 29, 564-569.	0.6	10
527	Factors associated with non-retention in HIV care in an era of widespread antiretroviral therapy. International Journal of STD and AIDS, 2017, 28, 679-684.	0.5	3
528	Misdiagnosed HIV infection in pregnant women initiating universal ART in South Africa. Journal of the International AIDS Society, 2017, 20, 21758.	1.2	9
529	HIV viral load as an independent risk factor for tuberculosis in South Africa: collaborative analysis of cohort studies. Journal of the International AIDS Society, 2017, 20, 21327.	1.2	38
530	Financial Barriers and Lapses in Treatment and Care of HIV-Infected Adults in a Southern State in the United States. AIDS Patient Care and STDs, 2017, 31, 463-469.	1.1	22
531	Key Factors Influencing the Emergence of Human Immunodeficiency Virus Drug Resistance in Low- and Middle-Income Countries. Journal of Infectious Diseases, 2017, 216, S851-S856.	1.9	22

#	Article	IF	Citations
532	Attrition From Human Immunodeficiency Virus Treatment Programs in Africa: A Longitudinal Ecological Analysis Using Data From 307 144 Patients Initiating Antiretroviral Therapy Between 2005 and 2010. Clinical Infectious Diseases, 2017, 64, 1309-1316.	2.9	7
533	Retention in Care among Patients with Early HIV Disease in Haiti. Journal of the International Association of Providers of AIDS Care, 2017, 16, 523-526.	0.6	5
534	Predictors of timely linkageâ€toâ€ART within universal test and treat in the HPTN 071 (PopART) trial in Zambia and South Africa: findings from a nested caseâ€control study. Journal of the International AIDS Society, 2017, 20, e25037.	1.2	36
535	Human immunodeficiency virus and liver disease: A comprehensive update. Hepatology Communications, 2017, 1, 987-1001.	2.0	29
536	Systemic Inflammation, Coagulation, and Clinical Risk in the START Trial. Open Forum Infectious Diseases, 2017, 4, ofx262.	0.4	65
537	Risk of HIV transmission during combined ART initiation for HIV-infected persons with severe immunosuppression. Journal of Antimicrobial Chemotherapy, 2017, 72, 3172-3176.	1.3	5
538	Protocol for a randomised controlled implementation trial of point-of-care viral load testing and task shifting: the Simplifying HIV TREAtment and Monitoring (STREAM) study. BMJ Open, 2017, 7, e017507.	0.8	19
539	Testing the effectiveness of a motivational interviewing-based brief intervention for substance use as an adjunct to usual care in community-based AIDS service organizations: study protocol for a multisite randomized controlled trial. Addiction Science & Emp; Clinical Practice, 2017, 12, 31.	1.2	14
540	Immunologic Pathways That Predict Mortality in HIV-Infected Ugandans Initiating Antiretroviral Therapy. Journal of Infectious Diseases, 2017, 215, 1270-1274.	1.9	33
541	Implementing National HIV/AIDS Strategy 2015 Treatment Targets Is Cost-effective and Would Save Lives: What Other Evidence Do We Need?. Journal of Infectious Diseases, 2017, 216, 787-789.	1.9	1
542	"l will take ARVs once my body deteriorates― an analysis of Swazi men's perceptions and acceptability of Test and Start. African Journal of AIDS Research, 2017, 16, 295-303.	0.3	20
543	The Clinical and Economic Impact of Attaining National HIV/AIDS Strategy Treatment Targets in the United States. Journal of Infectious Diseases, 2017, 216, 798-807.	1.9	22
545	Towards an ideal antiretroviral regimen for the global HIV epidemic. Journal of Virus Eradication, 2017, 3, 111-116.	0.3	2
546	Pursuing ethical coherence in the prevention of vertical transmission of HIV: justice and injustice in Option B+. Journal of Virus Eradication, 2017, 3, 163-166.	0.3	1
547	Tuberculosis Associated with HIV Infection. , 2017, , 577-594.		1
548	One-year mortality of HIV-positive patients treated for rifampicin- and isoniazid-susceptible tuberculosis in Eastern Europe, Western Europe, and Latin America. Aids, 2017, 31, 375-384.	1.0	5
549	Applying Historical Responses to Infectious Disease for Future Disease Control. Journal of Infectious Diseases and Treatment, 2017, 03, .	0.0	1
550	HIV Futures 8: Protocol for a Repeated Cross-sectional and Longitudinal Survey of People Living with HIV in Australia. Frontiers in Public Health, 2017, 5, 50.	1.3	10

#	Article	IF	CITATIONS
551	Editorial: HIV and Antiretroviral Drugs: Current Status and New Challenges. Current Pharmaceutical Design, 2017, 23, 2551.	0.9	0
552	Assessing the danger of self-sustained HIV epidemics in heterosexuals by population based phylogenetic cluster analysis. ELife, 2017, 6, .	2.8	16
553	The Immunoregulatory Potential of Particle Radiation in Cancer Therapy. Frontiers in Immunology, 2017, 8, 99.	2.2	52
554	Missed Testing Opportunities for HIV Screening and Early Diagnosis in an Urban Tertiary Care Center. AIDS Research and Treatment, 2017, 2017, 1-6.	0.3	6
555	Universal antiretroviral therapy for HIVâ€infected children: a review of the benefits and risks to consider during implementation. Journal of the International AIDS Society, 2017, 20, 21552.	1.2	26
556	Antiretroviral Therapy Initiation Alters the Redox System of Asymptomatic HIV-Infected Individuals: A Longitudinal Study. Oxidative Medicine and Cellular Longevity, 2017, 2017, 1-10.	1.9	10
559	Effect of frequency of clinic visits and medication pickâ€up on antiretroviral treatment outcomes: a systematic literature review and metaâ€analysis. Journal of the International AIDS Society, 2017, 20, 21647.	1.2	55
560	Pulmonary tuberculosis diagnostic practices among people living with the human immunodeficiency virus in Lesotho. International Journal of Tuberculosis and Lung Disease, 2017, 21, 1133-1138.	0.6	O
561	Undiagnosed acute HIV infection identified through RNA testing of pooled serum samples obtained during a dengue outbreak in São Paulo, Brazil. Revista Da Sociedade Brasileira De Medicina Tropical, 2017, 50, 110-112.	0.4	5
562	Risk factors associated with sexually transmitted infections among HIV infected men who have sex with men. PLoS ONE, 2017, 12, e0170635.	1.1	5
563	A randomized trial comparing concise and standard consent forms in the START trial. PLoS ONE, 2017, 12, e0172607.	1.1	28
564	Spontaneous clearance of chronic hepatitis C is rare in HIV-infected patients after effective use of combination antiretroviral therapy. PLoS ONE, 2017, 12, e0177141.	1.1	4
565	Pilot study of a multi-pronged intervention using social norms and priming to improve adherence to antiretroviral therapy and retention in care among adults living with HIV in Tanzania. PLoS ONE, 2017, 12, e0177394.	1.1	17
566	High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d'Ivoire. PLoS ONE, 2017, 12, e0177440.	1.1	10
567	A decade of viral mutations and associated drug resistance in a population of HIV-1+ Puerto Ricans: 2002–2011. PLoS ONE, 2017, 12, e0177452.	1.1	4
568	A decade of HAART in Latin America: Long term outcomes among the first wave of HIV patients to receive combination therapy. PLoS ONE, 2017, 12, e0179769.	1.1	13
569	Risk factors for delayed antiretroviral therapy initiation among HIV-seropositive patients. PLoS ONE, 2017, 12, e0180843.	1.1	10
570	A decade of HIV care in rural Tanzania: Trends in clinical outcomes and impact of clinic optimisation in an open, prospective cohort. PLoS ONE, 2017, 12, e0180983.	1.1	29

#	Article	IF	CITATIONS
571	Delays in HIV diagnosis and associated factors among patients presenting with advanced disease at a tertiary care hospital in Beijing, China. PLoS ONE, 2017, 12, e0182335.	1.1	8
572	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS ONE, 2017, 12, e0186549.	1.1	29
573	Implementing universal HIV treatment in a high HIV prevalence and rural South African setting $\hat{a} \in \hat{b}$ Field experiences and recommendations of health care providers. PLoS ONE, 2017, 12, e0186883.	1.1	14
574	Towards control of the global HIV epidemic: Addressing the middle-90 challenge in the UNAIDS 90–90–90 target. PLoS Medicine, 2017, 14, e1002293.	3.9	12
575	Status and methodology of publicly available national HIV care continua and 90-90-90 targets: A systematic review. PLoS Medicine, 2017, 14, e1002253.	3.9	88
576	Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ≥ 400 cells/mm3. PLoS ONE, 2017, 12, e0176009.	1.1	23
577	Time from HIV diagnosis to commencement of antiretroviral therapy as an indicator to supplement the HIV cascade: Dramatic fall from 2011 to 2015. PLoS ONE, 2017, 12, e0177634.	1.1	17
578	Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study. PLoS Medicine, 2017, 14, e1002424.	3.9	17
579	Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa. PLoS Medicine, 2017, 14, e1002463.	3.9	60
580	Research on HIV cure: Mapping the ethics landscape. PLoS Medicine, 2017, 14, e1002470.	3.9	22
581	Trial and error: evaluating and refining a community model of HIV testing in Australia. BMC Health Services Research, 2017, 17, 692.	0.9	9
582	HIV status and treatment influence on fertility desires among women newly becoming eligible for antiretroviral therapy in western Kenya: insights from a qualitative study. Reproductive Health, 2017, 14, 93.	1.2	11
583	Impact of early initiation versus national standard of care of antiretroviral therapy in Swaziland's public sector health system: study protocol for a stepped-wedge randomized trial. Trials, 2017, 18, 383.	0.7	69
584	Antiretroviral therapy for pregnant women living with HIV or hepatitis B: a systematic review and meta-analysis. BMJ Open, 2017, 7, e019022.	0.8	19
585	Antiretroviral therapy in pregnant women living with HIV: a clinical practice guideline. BMJ: British Medical Journal, 2017, 358, j3961.	2.4	16
586	HIV testing week 2015: lowering barriers for HIV testing among high-risk groups in Amsterdam. BMC Infectious Diseases, 2017, 17, 529.	1.3	10
587	Patterns of HIV testing, drug use, and sexual behaviors in people who use drugs: findings from a community-based outreach program in Phnom Penh, Cambodia. Addiction Science & Dinical Practice, 2017, 12, 27.	1.2	9
588	Latest advances in the efficacy, tolerability, and monotherapy of integrase inhibitors. BioScience Trends, 2017, 11, 490-495.	1.1	6

#	Article	IF	CITATIONS
590	Two-Year Complete Remission of Diffuse Large B-Cell Lymphoma in an Immunological Nonresponder HIV-Infected Patient: Case Report. Case Reports in Oncology, 2017, 10, 356-360.	0.3	0
591	Pilot Integration of HIV Screening and Healthcare Settings with Multi - Component Social Network and Partner Testing for HIV Detection. Current HIV Research, 2017, 15, 372-381.	0.2	2
592	Knowledge of Human Immunodeficiency Virus Status and Seropositivity After a Recently Negative Test in Malawi. Open Forum Infectious Diseases, 2017, 4, ofw231.	0.4	4
593	A public health approach to addressing and preventing misdiagnosis in the scale-up of HIV rapid testing programmes. Journal of the International AIDS Society, 2017, 20, 22190.	1.2	2
594	Meeting the WHO 90% target: antiretroviral treatment efficacy in Poland is associated with baseline clinical patient characteristics. Journal of the International AIDS Society, 2017, 20, 21847.	1.2	10
595	The Palliative Care and Hospice for the People Living with HIV. The Korean Journal of Hospice and Palliative Care, 2017, 20, 159-166.	0.2	2
596	Phased implementation of spaced clinic visits for stable HIVâ€positive patients in Rwanda to support Treat All. Journal of the International AIDS Society, 2017, 20, 21635.	1.2	14
597	Causes of death and factors associated with early mortality of HIV-infected adults admitted to Korle-Bu Teaching Hospital. Pan African Medical Journal, 2017, 27, 48.	0.3	24
598	Awareness and perceived fairness of option B+ in Malawi: a populationâ€level perspective. Journal of the International AIDS Society, 2017, 20, 21467.	1.2	6
599	Immune activation despite preserved CD4 T cells in perinatally HIV-infected children and adolescents. PLoS ONE, 2017, 12, e0190332.	1.1	21
600	HIV-associated neurocognitive disorders: recent advances in pathogenesis, biomarkers, and treatment. F1000Research, 2017, 6, 312.	0.8	79
601	Novel approaches to HIV therapy. F1000Research, 2017, 6, 759.	0.8	9
602	Impatto Economico Dei Regimi Semplificati a Base di Raltegravir Nel Trattamento di Mantenimento Dei Pazienti HIV-1 Infetti in Soppressione Virologica. Global & Regional Health Technology Assessment, 2017, 4, grhta.5000266.	0.2	0
603	A Conditional Economic Incentive Fails to Improve Linkage to Care and Antiretroviral Therapy Initiation Among HIV-Positive Adults in Cape Town, South Africa. AIDS Patient Care and STDs, 2018, 32, 70-78.	1.1	30
604	The Evolving Landscape of HIV Screening in the Emergency Department. Annals of Emergency Medicine, 2018, 72, 54-56.	0.3	19
605	Serious Non-AIDS Conditions in HIV: Benefit of Early ART. Current HIV/AIDS Reports, 2018, 15, 162-171.	1.1	16
606	Predictors of retention in care in HIV-infected patients in a large hospital cohort in Italy. Epidemiology and Infection, 2018, 146, 606-611.	1.0	12
607	A multiplexed RT-LAMP assay for detection of group M HIV-1 in plasma or whole blood. Journal of Virological Methods, 2018, 255, 91-97.	1.0	56

#	Article	IF	CITATIONS
608	The Cost-Effectiveness of Human Immunodeficiency Virus Testing and Treatment Engagement Initiatives in British Columbia, Canada: 2011–2013. Clinical Infectious Diseases, 2018, 66, 765-777.	2.9	15
609	Whose Responsibility Is It? Beliefs About Preventing HIV Transmission Among Men Who Have Sex With Men. Sexually Transmitted Diseases, 2018, 45, e43-e48.	0.8	5
610	The high frequency of autoantibodies in HIV patients declines on antiretroviral therapy. Pathology, 2018, 50, 313-316.	0.3	8
612	Sensitivity Analyses for Misclassification of Cause of Death in the Parametric G-Formula. American Journal of Epidemiology, 2018, 187, 1808-1816.	1.6	5
613	Incomplete Recovery of CD4 Cell Count, CD4 Percentage, and CD4/CD8 Ratio in Patients With Human Immunodeficiency Virus Infection and Suppressed Viremia During Long-term Antiretroviral Therapy. Clinical Infectious Diseases, 2018, 67, 927-933.	2.9	34
614	Changes in cerebral function parameters with maraviroc-intensified antiretroviral therapy in treatment naive HIV-positive individuals. Aids, 2018, 32, 1007-1015.	1.0	7
615	Viruses, Aging, and Chronic Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1520-1521.	2.5	1
616	What is new in perinatal HIV prevention?. Current Opinion in Pediatrics, 2018, 30, 144-151.	1.0	12
617	Socioâ€economic status and time trends associated with early <scp>ART</scp> initiation following primary <scp>HIV</scp> infection in Montreal, Canada: 1996 to 2015. Journal of the International AIDS Society, 2018, 21, e25034.	1.2	24
618	Current and emerging two-drug approaches for HIV-1 therapy in ART-naÃ-ve and ART-experienced, virologically suppressed patients. Expert Opinion on Pharmacotherapy, 2018, 19, 713-738.	0.9	34
619	Experiences of stigma and health care engagement among Black MSM newly diagnosed with HIV/STI. Journal of Behavioral Medicine, 2018, 41, 458-466.	1.1	57
620	Challenges Across the HIV Care Continuum for Patients With HIV/TB Co-infection in Atlanta, GA. Open Forum Infectious Diseases, 2018, 5, ofy063.	0.4	5
621	Optimal breastfeeding durations for HIVâ€exposed infants: the impact of maternal <scp>ART</scp> use, infant mortality and replacement feeding risk. Journal of the International AIDS Society, 2018, 21, e25107.	1.2	10
622	Molecular Analysis of Human Immunodeficiency Virus Type 1 (HIV-1)â€"Infected Individuals in a Network-Based Intervention (Transmission Reduction Intervention Project): Phylogenetics Identify HIV-1â€"Infected Individuals With Social Links. Journal of Infectious Diseases, 2018, 218, 707-715.	1.9	18
623	Exploring acceptability of oral PrEP prior to implementation among female sex workers in South Africa. Journal of the International AIDS Society, 2018, 21, e25081.	1.2	58
624	Factors associated with delivering premature and/or low birth weight infants among pregnant HIV-positive women on antiretroviral treatment at Dr George Mukhari Hospital, South Africa. Southern African Journal of Infectious Diseases, 2018, 33, 42-45.	0.3	1
625	Malignant lymphoma in the <scp>HIV</scp> â€positive patient. European Journal of Haematology, 2018, 101, 119-126.	1.1	25
626	Revealing geographical and population heterogeneity in <scp>HIV</scp> incidence, undiagnosed <scp>HIV</scp> prevalence and time to diagnosis to improve prevention and care: estimates for France. Journal of the International AIDS Society, 2018, 21, e25100.	1.2	50

#	Article	IF	Citations
627	Is home-based HIV testing universally acceptable? Findings from a case-control study nested within the HPTN 071 (PopART) trial. Tropical Medicine and International Health, 2018, 23, 678-690.	1.0	3
628	Caspase-1-associated immune activation in an accelerated SIV-infected rhesus macaque model. Journal of NeuroVirology, 2018, 24, 420-431.	1.0	12
629	Multivariate Pattern Analysis of Volumetric Neuroimaging Data and Its Relationship With Cognitive Function in Treated HIV Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 429-436.	0.9	15
630	Two diseases, same person: moving toward a combined HIV and tuberculosis continuum of care. International Journal of STD and AIDS, 2018, 29, 873-883.	0.5	3
631	Providing antiretroviral therapy to all who are <scp>HIV</scp> positive: the clinical, public health and programmatic benefits of <i>Treat All</i> . Journal of the International AIDS Society, 2018, 21, e25078.	1,2	21
632	Prioritization of antiretroviral therapy in patients with high CD4 counts, and retention in care: lessons from the START and Temprano trials. Journal of the International AIDS Society, 2018, 21, e25077.	1.2	5
633	Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial. Lancet HIV,the, 2018, 5, e172-e180.	2.1	28
634	Indications for starting ART. Lancet HIV,the, 2018, 5, e157-e158.	2.1	2
636	Vertical Transmission of HIV-1 in the Metropolitan Area of Belo Horizonte, Brazil: 2006–2014. Revista Brasileira De Ginecologia E Obstetricia, 2018, 40, 059-065.	0.3	7
637	Immediate Antiretroviral Therapy Decreases Mortality Among Patients With High CD4 Counts in China: A Nationwide, Retrospective Cohort Study. Clinical Infectious Diseases, 2018, 66, 727-734.	2.9	46
638	Care continuum entry interventions. Aids, 2018, 32, 407-417.	1.0	14
639	Risk network approaches to locating undiagnosed <scp>HIV</scp> cases in Odessa, Ukraine. Journal of the International AIDS Society, 2018, 21, e25040.	1.2	38
640	Comparative assessment of five trials of universal <scp>HIV</scp> testing and treatment in subâ€Saharan Africa. Journal of the International AIDS Society, 2018, 21, e25048.	1.2	81
641	High Levels of Viral Suppression Among East African HIV-Infected Women and Men in Serodiscordant Partnerships Initiating Antiretroviral Therapy with High CD4 Counts and During Pregnancy. AIDS Research and Human Retroviruses, 2018, 34, 140-147.	0.5	4
642	All About the Albumin? Prognostic Capacity of Serum Albumin in Patients With Treated HIV Infection. Journal of Infectious Diseases, 2018, 217, 347-349.	1.9	2
643	Towards a cure for human immunodeficiency virus. Internal Medicine Journal, 2018, 48, 12-15.	0.5	2
644	Comparison of Self-report to Biomarkers of Recent HIV Infection: Findings from the START Trial. AIDS and Behavior, 2018, 22, 2277-2283.	1.4	3
645	No neurocognitive advantage for immediate antiretroviral treatment in adults with greater than 500 CD4+ T-cell counts. Aids, 2018, 32, 985-997.	1.0	15

#	Article	IF	CITATIONS
646	Brief Report: Higher ART Adherence Is Associated With Lower Systemic Inflammation in Treatment-Naive Ugandans Who Achieve Virologic Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 507-513.	0.9	30
647	Baseline Neurocognitive Functioning Predicts Viral Load Suppression at 1-Year Follow-Up Among Newly Diagnosed HIV Infected Patients. AIDS and Behavior, 2018, 22, 3209-3213.	1.4	2
648	Perceptions of Equipoise, Risk–Benefit Ratios, and "Otherwise Healthy Volunteers―in the Context of Early-Phase HIV Cure Research in the United States: A Qualitative Inquiry. Journal of Empirical Research on Human Research Ethics, 2018, 13, 3-17.	0.6	30
649	2016 United Kingdom national guideline on the sexual health care of men who have sex with men. International Journal of STD and AIDS, 2018, , 095646241774689.	0.5	40
650	Optimization of the EC26-2A4 Epitope in the gp41 Membrane Proximal External Region Targeted by Neutralizing Antibodies from an Elite Controller. AIDS Research and Human Retroviruses, 2018, 34, 365-374.	0.5	8
651	Prevention of HIV-1 Transmission Through Breastfeeding: Efficacy and Safety of Maternal Antiretroviral Therapy Versus Infant Nevirapine Prophylaxis for Duration of Breastfeeding in HIV-1-Infected Women With High CD4 Cell Count (IMPAACT PROMISE): A Randomized, Open-Label, Clinical Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 383-392.	0.9	115
652	Acceptability and HIV Prevention Benefits of a Peer-Based Model of Rapid Point of Care HIV Testing for Australian Gay, Bisexual and Other Men Who Have Sex with Men. AIDS and Behavior, 2018, 22, 178-189.	1.4	24
653	Nanotechnologies for early diagnosis, in situ disease monitoring, and prevention. , 2018, , 1-92.		10
654	Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma. Journal of the National Cancer Institute, 2018, 110, 598-607.	3.0	12
655	Acute Appendicitis as the Initial Clinical Presentation of Primary HIV-1 Infection. Open Forum Infectious Diseases, 2018, 5, ofy006.	0.4	4
656	HIV Drug Resistance in Adults Receiving Early vs. Delayed Antiretroviral Therapy: HPTN 052. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 484-491.	0.9	10
657	Brief Report: Racial Comparison of D-Dimer Levels in US Male Military Personnel Before and After HIV Infection and Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 502-506.	0.9	4
658	Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV,the, 2018, 5, e116-e125.	2.1	187
659	Acute HIV Discovered During Routine HIV Screening With HIV Antigen-Antibody Combination Tests in 9 US Emergency Departments. Annals of Emergency Medicine, 2018, 72, 29-40.e2.	0.3	32
660	Excess Clinical Comorbidity Among HIV-Infected Patients Accessing Primary Care in US Community Health Centers. Public Health Reports, 2018, 133, 109-118.	1.3	41
661	Darunavir/ritonavir monotherapy at a low dose (600/100 mg/day) in HIV-1-infected individuals with suppressed HIV viraemia. Journal of Antimicrobial Chemotherapy, 2018, 73, 490-493.	1.3	6
662	"lt's Never Just About the HIV:―HIV Primary Care Providers' Perception of Substance Use in the Era of "Universal―Antiretroviral Medication Treatment. AIDS and Behavior, 2018, 22, 1006-1017.	1.4	10
663	Development and evaluation of a blended educational programme for general practitioners' trainers to stimulate proactive HIV testing. BMC Family Practice, 2018, 19, 36.	2.9	9

#	Article	IF	CITATIONS
664	The increasing burden and complexity of multi-morbidity and polypharmacy in geriatric HIV patients: a cross sectional study of people aged 65 \hat{a} \in 74 years and more than 75 years. BMC Geriatrics, 2018, 18, 99.	1.1	117
665	Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial. BMC Public Health, 2018, 18, 210.	1.2	49
666	Challenges and successes in the implementation of option B+ to prevent mother-to-child transmission of HIV in southern Swaziland. BMC Public Health, 2018, 18, 374.	1.2	23
667	Barriers and Facilitators for Clinical Care Engagement Among HIV-Positive African American and Latino Men Who Have Sex with Men. AIDS Patient Care and STDs, 2018, 32, 191-201.	1.1	21
668	Perceived HIV-related stigma among university students in South Africa: implications for HIV testing. African Journal of AIDS Research, 2018, 17, 109-118.	0.3	13
669	Exploring Treatment Needs and Expectations for People Living with HIV in South Africa: A Qualitative Study. AIDS and Behavior, 2018, 22, 2543-2552.	1.4	20
670	Exchange sex among people receiving medical care for HIV in the United States – medical monitoring project 2009–2013. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1315-1321.	0.6	4
671	HIV Care After Jail: Low Rates of Engagement in a Vulnerable Population. Journal of Urban Health, 2018, 95, 488-498.	1.8	20
672	Treatment and prevention of HIV infection with long-acting antiretrovirals. Expert Review of Clinical Pharmacology, 2018, 11, 507-517.	1.3	38
673	HIV care in Central and Eastern Europe: How close are we to the target?. International Journal of Infectious Diseases, 2018, 70, 121-130.	1.5	37
674	Case 9-2018: A 55-Year-Old Man with HIV Infection and a Mass on the Right Side of the Face. New England Journal of Medicine, 2018, 378, 1143-1152.	13.9	3
675	Next generation fixed dose combination pharmacotherapies for treating HIV. Expert Opinion on Pharmacotherapy, 2018, 19, 589-596.	0.9	17
676	Understanding the Targeting and Uptake of HIV Testing Among Gay and Bisexual Men Attending Sexual Health Clinics. AIDS and Behavior, 2018, 22, 513-521.	1.4	1
677	Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan Africa. Aids, 2018, 32, 1043-1051.	1.0	47
678	HIV Infection Is Not Associated With Aortic Stiffness. Traditional Cardiovascular Risk Factors Are the Main Determinantsâ€"Cross-sectional Results of INI-ELSA-BRASIL. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 73-81.	0.9	5
679	Time Spent with HIV Viral Load > 1500 Copies/mL Among Persons Engaged in Continuity HIV Care in an Urban Clinic in the United States, 2010–2015. AIDS and Behavior, 2018, 22, 3443-3450.	1.4	10
680	Acceptability of Peer-Delivered HIV Testing and Counselling Among Men Who Have Sex with Men (MSM) and Transgender Women (TW) in Myanmar. AIDS and Behavior, 2018, 22, 2426-2434.	1.4	12
681	Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial. Clinical Infectious Diseases, 2018, 67, 420-429.	2.9	18

#	Article	IF	CITATIONS
682	Serum Albumin as a Prognostic Marker for Serious Non-AIDS Endpoints in the Strategic Timing of Antiretroviral Treatment (START) Study. Journal of Infectious Diseases, 2018, 217, 405-412.	1.9	17
683	Early treatment gains for antibiotic administration and within human host time series data. Mathematical Medicine and Biology, 2018, 35, 203-224.	0.8	1
684	Beliefs in Antiretroviral Treatment and Self-Efficacy in HIV Management are Associated with Distinctive HIV Treatment Trajectories. AIDS and Behavior, 2018, 22, 887-895.	1.4	4
685	Effects of Brief Messages About Antiretroviral Therapy and Condom Use Benefits Among Black and Latino MSM in Three U.S. Cities. Journal of Homosexuality, 2018, 65, 154-166.	1.3	7
686	Acceptability of Early Antiretroviral Therapy Among South African Women. AIDS and Behavior, 2018, 22, 1018-1024.	1.4	22
687	Consensus statement: Supporting Safer Conception and Pregnancy For Men And Women Living with and Affected by HIV. AIDS and Behavior, 2018, 22, 1713-1724.	1.4	50
688	Informing Targeted Interventions to Optimize the Cascade of HIV Care Using Cluster Analyses of Health Resource Use Among People Living with HIV/AIDS. AIDS and Behavior, 2018, 22, 234-244.	1.4	3
689	The Role of Financial Incentives Along the Antiretroviral Therapy Adherence Continuum: A Qualitative Sub-study of the HPTN 065 (TLC-Plus) Study. AIDS and Behavior, 2018, 22, 245-257.	1.4	11
690	Changing clinical phenotypes of HIV-associated neurocognitive disorders. Journal of NeuroVirology, 2018, 24, 141-145.	1.0	83
691	"We Need to Deploy Them Very Thoughtfully and Carefully― Perceptions of Analytical Treatment Interruptions in HIV Cure Research in the United States—A Qualitative Inquiry. AIDS Research and Human Retroviruses, 2018, 34, 67-79.	0.5	53
692	Improving Laboratory Efficiency in the Caribbean to Attain the World Health Organization HIV Treat All Recommendations. AIDS Research and Human Retroviruses, 2018, 34, 132-139.	0.5	4
693	Management of MDR-TB in HIV co-infected patients in Eastern Europe: Results from the TB:HIV study. Journal of Infection, 2018, 76, 44-54.	1.7	16
694	The WHO public health approach to HIV treatment and care: looking back and looking ahead. Lancet Infectious Diseases, The, 2018, 18, e76-e86.	4.6	87
695	Effects of antiretroviral treatment and nadir CD4 count in progression to cardiovascular events and related comorbidities in a HIV Brazilian cohort: a multi-stage approach. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 551-559.	0.6	13
696	CD8+CD28â^CD127loCD39+ regulatory T-cell expansion: AÂnew possible pathogenic mechanism for HIV infection?. Journal of Allergy and Clinical Immunology, 2018, 141, 2220-2233.e4.	1.5	22
697	Increasing HIV Testing in Inpatient Psychiatry. Psychosomatics, 2018, 59, 186-192.	2.5	7
698	Utility of Mobile Communication Devices as a Tool to Improve Adherence to Antiretroviral Treatment in HIV-infected Children and Young Adults in Argentina. Pediatric Infectious Disease Journal, 2018, 37, 345-348.	1.1	16
699	Inflammation-Related Morbidity and Mortality Among HIV-Positive Adults: How Extensive Is It?. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 1-7.	0.9	49

#	ARTICLE	IF	CITATIONS
700	Exploring the views and experiences of HIV positive patients treated for cancer: a systematic review of the literature. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 535-543.	0.6	6
701	Incidence of Tuberculosis Among HIV-Positive Individuals Initiating Antiretroviral Treatment at Higher CD4 Counts in the HPTN 071 (PopART) Trial in South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 93-101.	0.9	21
702	Early detection of HIV infection and of asymptomatic sexually transmitted infections among men who have sex with men. Clinical Microbiology and Infection, 2018, 24, 540-545.	2.8	13
703	Moving forward with treatment options for HIV-infected children. Expert Opinion on Pharmacotherapy, 2018, 19, 27-37.	0.9	4
704	Management of HIV Infection. , 2018, , 681-689.e2.		2
705	Estimation of the Percentage of Newly Diagnosed HIV-Positive Persons Linked to HIV Medical Care in CDC-Funded HIV Testing Programs. Evaluation and the Health Professions, 2018, 41, 474-492.	0.9	1
706	Internal pilot design for balanced repeated measures. Statistics in Medicine, 2018, 37, 375-389.	0.8	0
707	Risk factors for mortality among tuberculosis patients co-infected with HIV. Infectious Diseases, 2018, 50, 399-402.	1.4	0
708	Discontinuation of Efavirenz in Paediatric Patients: Why do Children Switch?. Clinical Drug Investigation, 2018, 38, 231-238.	1.1	7
709	Evaluating the Evidence for More Frequent Than Annual HIV Screening of Gay, Bisexual, and Other Men Who Have Sex With Men in the United States: Results From a Systematic Review and CDC Expert Consultation. Public Health Reports, 2018, 133, 3-21.	1.3	21
710	Hepatitis in the traveller. Medicine, 2018, 46, 20-23.	0.2	3
711	Contemporary protease inhibitors and cardiovascular risk. Current Opinion in Infectious Diseases, 2018, 31, 8-13.	1.3	28
712	Predictors of <scp>CD</scp> 4 cell recovery following initiation of antiretroviral therapy among <scp>HIV</scp> â€1 positive patients with wellâ€estimated dates of seroconversion. HIV Medicine, 2018, 19, 184-194.	1.0	41
713	A Therapeutic Perspective of Living with Human Immunodeficiency Virus/AIDS inÂ2017. Nursing Clinics of North America, 2018, 53, 97-110.	0.7	5
714	Social networks, migration, and HIV testing among Latinos in aÂnew immigrant destination: Insights from a qualitative study. Global Public Health, 2018, 13, 1507-1519.	1.0	22
715	High percentage of undiagnosed HIV cases within a hyperendemic South African community: a population-based study. Journal of Epidemiology and Community Health, 2018, 72, 168-172.	2.0	25
716	Pulmonary disease in HIV-infected adults in the era of antiretroviral therapy. Aids, 2018, 32, 277-292.	1.0	56
717	A New Face of Cardiac Emergencies. Cardiology Clinics, 2018, 36, 161-170.	0.9	5

#	Article	IF	CITATIONS
718	Quantification of sexual HIV transmission risk in Africa. International Journal of Infectious Diseases, 2018, 66, 135-136.	1.5	0
719	Trends in antiretroviral therapy prescription, durability and modification. Aids, 2018, 32, 347-355.	1.0	25
720	Influence of Injection Drug Use–Related HIV Acquisition on CD4 Response to First Antiretroviral Therapy Regimen Among Virally Suppressed Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, 317-324.	0.9	1
721	Impact of antiretroviral drugs on the microbiome. Current Opinion in HIV and AIDS, 2018, 13, 53-60.	1.5	74
723	Benefits and risks of rapid initiation of antiretroviral therapy. Aids, 2018, 32, 17-23.	1.0	191
724	Effect of immediate initiation of antiretroviral treatment on the risk of acquired HIV drug resistance. Aids, 2018, 32, 327-335.	1.0	13
725	Understanding mechanisms to promote successful aging in persons living with HIV. International Journal of Infectious Diseases, 2018, 66, 56-64.	1.5	30
726	Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034. Leukemia and Lymphoma, 2018, 59, 1851-1860.	0.6	21
727	Failure to initiate HIV treatment in patients with high CD 4 counts: evidence from demographic surveillance in rural SouthÂAfrica. Tropical Medicine and International Health, 2018, 23, 206-220.	1.0	21
728	Targeted HIV Screening in Eight Emergency Departments: The DICI-VIH Cluster-Randomized Two-Period Crossover Trial. Annals of Emergency Medicine, 2018, 72, 41-53.e9.	0.3	21
729	High CXCL10/IP-10 levels are a hallmark in the clinical evolution of the HIV infection. Infection, Genetics and Evolution, 2018, 57, 51-58.	1.0	30
7 30	Predictors of HIV Testing and Their Influence on PrEP Acceptance in Men Who Have Sex with Men: A Cross-Sectional Study. AIDS and Behavior, 2018, 22, 1150-1157.	1.4	18
731	â€~Test and Treat' Among Women at High Risk for HIV-infection in Kampala, Uganda: Antiretroviral Therapy Initiation and Associated Factors. AIDS and Behavior, 2018, 22, 1053-1061.	1.4	11
732	People Born in Non–Main English Speaking Countries Are Less Likely to Start HIV Treatment Early in Australia: A National Cohort Analysis, 2014–15. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 77, e31-e34.	0.9	9
733	Does rapid HIV testing result in an early diagnosis and reduce the waiting time for patients to receive medical care?. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 40-46.	0.6	2
734	Effectiveness of antiretroviral therapy in the single-tablet regimen era. Revista De Saude Publica, 2018, 52, 87.	0.7	25
735	Antiretroviral Drug Use and HIV Drug Resistance Among Young Women in Rural South Africa: HPTN 068. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 315-322.	0.9	4
736	Modelling the human immunodeficiency virus (HIV) epidemic: A review of the substance and role of models in South Africa. Southern African Journal of HIV Medicine, 2018, 19, 756.	0.3	5

#	Article	IF	Citations
737	Factors Influencing the Initiation of Treatment after the Diagnosis of Korean Patients with HIV. Journal of Korean Academy of Community Health Nursing, 2018, 29, 279.	0.1	1
738	Using Financial Incentives to Improve Rates of Viral Suppression and Engagement in Care of Patients Receiving HIV Care at 3 Health Clinics in Louisiana: The Health Models Program, 2013-2016. Public Health Reports, 2018, 133, 75S-86S.	1.3	19
739	The prevalence of HIV co-infection among patients newly diagnosed with chronic hepatitis B or C in Denmark – a nationwide cohort study. Open Forum Infectious Diseases, 2018, 5, ofy310.	0.4	1
740	Impact of "test and treat" recommendations on eligibility for antiretroviral treatment: Cross sectional population survey data from three high HIV prevalence countries. PLoS ONE, 2018, 13, e0207656.	1.1	16
741	CD4:CD8 ratio and CD8+ cell count for prognosticating mortality in HIV-infected patients on antiretroviral therapy. Journal of Laboratory and Precision Medicine, 2018, 3, 8-8.	1.1	9
742	Public prescription drug plan coverage for antiretrovirals and the potential cost to people living with HIV in Canada: a descriptive study. CMAJ Open, 2018, 6, E551-E560.	1.1	12
743	Targeting the third â€~90': introducing the viral load champion. Public Health Action, 2018, 8, 225-231.	0.4	19
744	Cascade of care for people living with HIV infection in Southern Brazil: results from a public health network. Cadernos De Saude Publica, 2018, 34, e00009718.	0.4	5
745	Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naìve human immunodeficiency virus–infected patients compared to non-nucleoside and protease inhibitor–based regimens in a real-world clinical setting. Medicine (United States), 2018, 97, e13016.	0.4	44
746	Maternal health outcomes among HIV-infected breastfeeding women with high CD4 counts: results of a treatment strategy trial. HIV Clinical Trials, 2018, 19, 209-224.	2.0	10
747	HIV Testing With and Without a Clinical Consultation Among Men Who Have Sex With Men: A Randomized Controlled Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, 406-412.	0.9	3
748	Propelling the Pediatric HIV Therapeutic Agenda With Science, Innovation, and Collaboration. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 78, S32-S39.	0.9	8
749	Impact of Protease Inhibitors on HIV-Associated Kaposi Sarcoma Incidence: A Systematic Review. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 141-148.	0.9	6
7 50	Perceptions of HIV testing venues among men who have sex with men in London and the Midlands, United Kingdom. Journal of Gay and Lesbian Social Services, 2018, 30, 336-355.	0.9	6
751	Effect of an Electronic Alert on Targeted HIV Testing Among High-Risk Populations., 2018, 22, 18-015.		3
752	Internalized <scp>HIV</scp> stigma, <scp>ART</scp> initiation and <scp>HIV</scp> â€1 <scp>RNA</scp> suppression in South Africa: exploring avoidant coping as a longitudinal mediator. Journal of the International AIDS Society, 2018, 21, e25198.	1.2	51
753	Re-engagement in HIV care following a missed visit in rural Uganda. BMC Research Notes, 2018, 11, 762.	0.6	17
754	Traiter tÃ't l'infection à VIH : Pourquoi ?. Bulletin De L'Academie Nationale De Medecine, 2018, 202, 1413-1420.	0.0	0

#	ARTICLE	IF	CITATIONS
755	HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. Journal of Virus Eradication, 2018, 4, 55-58.	0.3	25
757	Mental health and HIV: research priorities related to the implementation and scale up of  treat all' in sub-Saharan Africa. Journal of Virus Eradication, 2018, 4, 16-25.	0.3	29
758	Mathematical modelling to inform â€~treat all' implementation in sub-Saharan Africa: a scoping review. Journal of Virus Eradication, 2018, 4, 47-54.	0.3	5
759	The contribution of observational studies in supporting the WHO †treat all' recommendation for HIV/AIDS. Journal of Virus Eradication, 2018, 4, 5-8.	0.3	13
760	Strategies for Prevention of Mother-to-Child Transmission Adopted in the "Real-World―Setting: Data From the Italian Register for HIV-1 Infection in Children. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 54-61.	0.9	3
761	"Treatment is not yet necessary― delays in seeking access to HIV treatment in Uganda and Zimbabwe. African Journal of AIDS Research, 2018, 17, 217-225.	0.3	21
762	HIV-1 update 2018. Pharmacy Today, 2018, 24, 51-69.	0.0	1
763	Brief Report: Intimate Partner Violence and Antiretroviral Therapy Initiation Among Female Sex Workers Newly Diagnosed With HIV in Zambia: A Prospective Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 435-439.	0.9	11
764	Duration of Human Immunodeficiency Virus Infection at Diagnosis among New Human Immunodeficiency Virus Cases in Dehong, Yunnan, China, 2008–2015. Chinese Medical Journal, 2018, 131, 1936-1943.	0.9	9
765	Limitations of the International HIV Dementia Scale in the current era. Aids, 2018, 32, 2477-2483.	1.0	30
766	Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results From NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination With Tenofovir/Emtricitabine or Raltegravir. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 519-526.	0.9	5
767	HIV care continuum for key populations in Indonesia. Lancet HIV, the, 2018, 5, e539-e540.	2.1	7
768	Missed Opportunities for Engagement in the Prevention Continuum in a Predominantly Black and Latino Community in New York City. AIDS Patient Care and STDs, 2018, 32, 432-437.	1.1	13
769	Retention in care among clinically stable antiretroviral therapy patients following a sixâ€monthly clinical consultation schedule: findings from a cohort study in rural Malawi. Journal of the International AIDS Society, 2018, 21, e25207.	1.2	20
770	Diagnosis of Human Immunodeficiency Virus Infection. Clinical Microbiology Reviews, 2018, 32, .	5.7	51
771	Serum concentration of anti-Cytomegalovirus IgG and ischaemic stroke in patients with advanced HIV infection in Malawi. PLoS ONE, 2018, 13, e0208040.	1.1	7
772	Rationale for an Association Between PD1 Checkpoint Inhibition and Therapeutic Vaccination Against HIV. Frontiers in Immunology, 2018, 9, 2447.	2.2	1
774	The effect of demand-side financial incentives for increasing linkage into HIV treatment and voluntary medical male circumcision: A systematic review and meta-analysis of randomised controlled trials in low- and middle-income countries. PLoS ONE, 2018, 13, e0207263.	1.1	20

#	Article	IF	CITATIONS
775	Human Immunodeficiency Virus and the Nervous System. Neurologic Clinics, 2018, 36, 751-765.	0.8	11
776	Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain. PLoS ONE, 2018, 13, e0206755.	1.1	11
778	Calculating indirect costs from international PEPFAR implementing partners. PLoS ONE, 2018, 13, e0206425.	1.1	3
779	Symtuza® (DRV/c/FTC/TAF) en el abordaje de pacientes que han recibido tratamiento antirretroviral previamente. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2018, 36, 22-30.	0.3	0
780	Acute HIV Infection and CD4/CD8 Ratio Normalization After Antiretroviral Therapy Initiation. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 510-518.	0.9	29
781	Reduction of inflammation and T cell activation after 6Âmonths of cART initiation during acute, but not in early chronic HIV-1 infection. Retrovirology, 2018, 15, 76.	0.9	32
782	New antiretroviral agent use affects prevalence of HIV drug resistance in clinical care populations. Aids, 2018, 32, 2593-2603.	1.0	21
783	Persons living with <scp>HIV</scp> with advanced <scp>HIV</scp> disease: need for novel care models. Journal of the International AIDS Society, 2018, 21, e25210.	1.2	11
784	Human Immunodeficiency Virus and Tuberculosis Coinfection in a Tertiary Hospital in Southern Brazil: Clinical Profile and Outcomes. Microbiology Insights, 2018, 11, 117863611881336.	0.9	6
785	Delays and gaps in HIV programmes in Pakistan. Lancet HIV,the, 2018, 5, e678-e679.	2.1	10
786	The importance of serostatus awareness in arresting the spread of HIV. Journal of the International AIDS Society, 2018, 21, e25217.	1.2	1
787	In Reply: Latent tuberculous infection testing among HIV-infected persons in clinical care. International Journal of Tuberculosis and Lung Disease, 2018, 22, 468-469.	0.6	0
788	The impact of population dynamics on the population <scp>HIV</scp> care cascade: results from the <scp>ANRS</scp> 12249 Treatment as Prevention trial in rural KwaZuluâ€Natal (South Africa). Journal of the International AIDS Society, 2018, 21, e25128.	1.2	34
789	Variation in antiretroviral treatment coverage and virological suppression among three HIV key populations. Aids, 2018, 32, 2807-2819.	1.0	13
790	Adverse effects of antiretroviral therapy in pregnant women infected with HIV in Brazil from 2000 to 2015: a cohort study. BMC Infectious Diseases, 2018, 18, 485.	1.3	13
791	Effects of a brief video intervention on treatment initiation and adherence among patients attending human immunodeficiency virus treatment clinics. PLoS ONE, 2018, 13, e0204599.	1.1	19
792	The palatine tonsil bacteriome, but not the mycobiome, is altered in HIV infection. BMC Microbiology, 2018, 18, 127.	1.3	19
793	Low HIV testing rates among US women who report anal sex and other HIV sexual risk behaviors, 2011–2015. American Journal of Obstetrics and Gynecology, 2018, 219, 383.e1-383.e7.	0.7	6

#	Article	IF	CITATIONS
794	Missed Opportunities for HIV Testing of Patients Tested for Sexually Transmitted Infections at a Large Urban Health Care System From 2010 to 2015. Open Forum Infectious Diseases, 2018, 5, ofy165.	0.4	7
795	The dawn of precision medicine in HIV: state of the art of pharmacotherapy. Expert Opinion on Pharmacotherapy, 2018, 19, 1581-1595.	0.9	14
796	How has the cost of antiretroviral therapy changed over the years? A database analysis in Italy. BMC Health Services Research, 2018, 18, 691.	0.9	7
797	Improving the clinical relevance of a mouse pregnancy model of antiretroviral toxicity; a pharmacokinetic dosing-optimization study of current HIV antiretroviral regimens. Antiviral Research, 2018, 159, 45-54.	1.9	15
798	Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1. Lancet HIV,the, 2018, 5, e723-e731.	2.1	10
799	Gender Differences in HIV Testing, Diagnosis, and Linkage to Care in Healthcare Settings: Identifying African American Women with HIV in Chicago. AIDS Patient Care and STDs, 2018, 32, 399-407.	1.1	12
800	Attrition when providing antiretroviral treatment at CD4 counts >500cells/ \hat{l}_4 L at three government clinics included in the HPTN 071 (PopART) trial in South Africa. PLoS ONE, 2018, 13, e0195127.	1.1	14
801	Protocol, rationale and design of SELPHI: a randomised controlled trial assessing whether offering free HIV self-testing kits via the internet increases the rate of HIV diagnosis. BMC Infectious Diseases, 2018, 18, 531.	1.3	15
802	Influence of geographic origin on AIDS and serious non-AIDS morbidity/mortality during cART among heterosexual HIV-infected men and women in France. PLoS ONE, 2018, 13, e0205385.	1.1	1
803	Linkage to Care, Antiretroviral Treatment Initiation, and Viral Suppression of Acute HIV-Infected Individuals Identified From an Emergency Department–Based HIV Screening and Linkage-to-Care Program. Annals of Emergency Medicine, 2018, 72, 621-623.	0.3	3
804	HIV testing within general practices in Europe: a mixed-methods systematic review. BMC Public Health, 2018, 18, 1191.	1.2	24
805	Anal cancer in high-income countries: Increasing burden of disease. PLoS ONE, 2018, 13, e0205105.	1.1	71
806	Implementation of a Rapid Entry Program Decreases Time to Viral Suppression Among Vulnerable Persons Living With HIV in the Southern United States. Open Forum Infectious Diseases, 2018, 5, ofy104.	0.4	68
807	CD4+ cell count recovery after combined antiretroviral therapy in the modern combined antiretroviral therapy era. Aids, 2018, 32, 2605-2614.	1.0	38
808	A System-Level Approach to Improve HIV Screening in an Urban Pediatric Primary Care Setting. Pediatrics, 2018, 142, e20180506.	1.0	8
809	HIV Glasgow 2018, 28–31 October 2018, Glasgow, UK. Journal of the International AIDS Society, 2018, 21, e25187.	1.2	15
810	Financial mobilization for antiretroviral therapy program: multi-level predictors of willingness to pay among patients with HIV/AIDS in Vietnam. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1488-1497.	0.6	4
811	Understanding reasons for discontinued antiretroviral treatment among clients in test and treat: a qualitative study in Swaziland. Journal of the International AIDS Society, 2018, 21, e25120.	1.2	30

#	ARTICLE	IF	CITATIONS
812	Nicotinic Acetylcholine Receptors in HIV: Possible Roles During HAND and Inflammation. Cellular and Molecular Neurobiology, 2018, 38, 1335-1348.	1.7	9
813	Modulatory Effects of Nicotine on neuroHIV/neuroAIDS. Journal of NeuroImmune Pharmacology, 2018, 13, 467-478.	2.1	7
814	Prediction of Liver Disease, AIDS, and Mortality Based on Discordant Absolute and Relative Peripheral CD4 T Lymphocytes in HIV/Hepatitis C Virus-Coinfected Individuals. AIDS Research and Human Retroviruses, 2018, 34, 1058-1066.	0.5	2
815	The latest evidence for possible HIV-1 curative strategies. Drugs in Context, 2018, 7, 1-14.	1.0	26
816	Towards 90-90: Findings after two years of the HPTN 071 (PopART) cluster-randomized trial of a universal testing-and-treatment intervention in Zambia. PLoS ONE, 2018, 13, e0197904.	1.1	40
817	High uptake of antiretroviral therapy among HIV-positive TB patients receiving co-located services in Swaziland. PLoS ONE, 2018, 13, e0196831.	1.1	17
818	Substantial Heterogeneity in Progress Toward Reaching the 90-90-90 HIV Target in the WHO European Region. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 28-37.	0.9	29
819	Estimating retention in HIV care accounting for patient transfers: A national laboratory cohort study in South Africa. PLoS Medicine, 2018, 15, e1002589.	3.9	80
820	Effective linkage from point of HIV testing to care and treatment in Tanga region, Tanzania. PLoS ONE, 2018, 13, e0201644.	1.1	8
821	Retaining HIV-positive patients in HIV care: a personalised approach for those at risk of loss to follow-up at an inner city sexual health service. Sexual Health, 2018, 15, 91.	0.4	2
822	High discordance in blood and genital tract HIV-1 drug resistance in Indian women failing first-line therapy. Journal of Antimicrobial Chemotherapy, 2018, 73, 2152-2161.	1.3	2
823	Effects of Immunonutrition in Advanced Human Immunodeficiency Virus Disease: A Randomized Placebo-controlled Clinical Trial (Promaltia Study). Clinical Infectious Diseases, 2019, 68, 120-130.	2.9	31
824	Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive. Sexual Health, 2018, 15, 13.	0.4	5
825	How I treat Burkitt lymphoma in children, adolescents, and young adults in sub-Saharan Africa. Blood, 2018, 132, 254-263.	0.6	39
826	Antiretroviral Therapy and Mortality in Rural South Africa: A Comparison of Causal Modeling Approaches. American Journal of Epidemiology, 2018, 187, 1772-1779.	1.6	3
827	The high incidence of late presenters for HIV/AIDS infection in the Lodz province, Poland in the years 2009–2016: we are still far from the UNAIDS 90% target. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1538-1541.	0.6	15
829	Prioritisation of subgroups for immediate antiretroviral therapy – Authors' reply. Lancet HIV,the, 2018, 5, e206.	2.1	0
831	Improving Estimation of HIV Viral Suppression in the United States: A Method to Adjust HIV Surveillance Estimates From the Medical Monitoring Project Using Cohort Data. American Journal of Epidemiology, 2018, 187, 1962-1969.	1.6	2

#	Article	IF	CITATIONS
832	Firstâ€line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. HIV Medicine, 2018, 19, 475-484.	1.0	13
833	Late Presentation With HIV in Africa: Phenotypes, Risk, and Risk Stratification in the REALITY Trial. Clinical Infectious Diseases, 2018, 66, S140-S146.	2.9	26
834	Neurologic sequelae of primary HIV infection. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 152, 65-74.	1.0	17
835	HIV infection and stroke. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 152, 187-200.	1.0	16
836	Imaging studies of the HIV-infected brain. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 152, 229-264.	1.0	42
837	HIV Primary Care Curriculum Improves HIV Knowledge, Confidence and Attitudes. Journal for Nurse Practitioners, 2018, 14, e113-e120.	0.4	3
838	Adverse fetal and infant outcomes among HIV-infected women who received either nonnucleoside reverse transcriptase inhibitor-based or protease inhibitor-based antiretroviral therapy for prevention of mother-to-child transmission. Aids, 2018, 32, 1625-1632.	1.0	4
839	Previously Diagnosed HIV-Positive Persons: The Role of Centers for Disease Control and Prevention⢓Funded HIV Testing Programs in Addressing Their Needs. Sexually Transmitted Diseases, 2018, 45, 377-381.	0.8	4
840	Why do people living with HIV not initiate treatment? A systematic review of qualitative evidence from low- and middle-income countries. Social Science and Medicine, 2018, 213, 72-84.	1.8	81
841	Time spent with HIV viral load above 1500 copies/ml among patients in HIV care, 2000–2014. Aids, 2018, 32, 2033-2042.	1.0	8
842	Universal test and treat is not associated with subâ€optimal antiretroviral therapy adherence in rural South Africa: the ANRS 12249 TasP trial. Journal of the International AIDS Society, 2018, 21, e25112.	1.2	34
844	The diagnosis of symptomatic acute antiretroviral syndrome during the window period with antigen/antibody testing and HIV viral load. IDCases, 2018, 12, 157-160.	0.4	2
845	Do HIV treatment eligibility expansions crowd out the sickest? Evidence from rural South Africa. Tropical Medicine and International Health, 2018, 23, 968-979.	1.0	11
846	Comprehensive nationwide analysis of mother-to-child HIV transmission in Finland from 1983 to 2013. Epidemiology and Infection, 2018, 146, 1301-1307.	1.0	6
848	90-90-90 for HIV-2? Ending the HIV-2 epidemic by enhancing care and clinical management of patients infected with HIV-2. Lancet HIV,the, 2018, 5, e390-e399.	2.1	57
849	Induction of a Na ⁺ /K ⁺ -ATPase-dependent form of autophagy triggers preferential cell death of human immunodeficiency virus type-1-infected macrophages. Autophagy, 2018, 14, 1359-1375.	4.3	26
850	High CD4 counts associated with better economic outcomes for HIV-positive adults and their HIV-negative household members in the SEARCH Trial. PLoS ONE, 2018, 13, e0198912.	1.1	7
851	Eliminating Mother-to-Child Transmission of HIV by 2030: 5 Strategies to Ensure Continued Progress. Global Health, Science and Practice, 2018, 6, 249-256.	0.6	53

#	Article	IF	Citations
852	Early HIV Infection Predictions: Role of Viral Replication Errors. SIAM Journal on Applied Mathematics, 2018, 78, 1863-1890.	0.8	7
853	Inflammation Associates With Impaired Small Arterial Elasticity Early in HIV Disease. Open Forum Infectious Diseases, 2018, 5, ofy117.	0.4	7
854	Active Case Finding for Communicable Diseases in Prison Settings: Increasing Testing Coverage and Uptake Among the Prison Population in the European Union/European Economic Area. Epidemiologic Reviews, 2018, 40, 105-120.	1.3	35
855	Quantifying the drivers of <scp>HIV</scp> transmission and prevention in men who have sex with men: a population modelâ€based analysis in Switzerland. HIV Medicine, 2018, 19, 688-697.	1.0	6
856	Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. The Cochrane Library, 2018, 2018, CD009012.	1.5	23
857	High <scp>HIV</scp> and active tuberculosis prevalence and increased mortality risk in adults with symptoms of <scp>TB</scp> : a systematic review and metaâ€analyses. Journal of the International AIDS Society, 2018, 21, e25162.	1.2	22
858	Implementation and assessment of a model to increase HIV testing among men who have sex with men and transgender women in Thailand, 2011–2016. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1239-1245.	0.6	22
859	<scp>CD</scp> 4: <scp>CD</scp> 8 ratio in children with perinatally acquired <scp>HIV</scp> â€1 infection. HIV Medicine, 2018, 19, 668-672.	1.0	6
860	Estimation of delay to diagnosis and incidence in HIV using indirect evidence of infection dates. BMC Medical Research Methodology, 2018, 18, 65.	1.4	8
861	HIV. Lancet, The, 2018, 392, 685-697.	6.3	219
862	The cascade of care following community-based detection of HIV in sub-Saharan Africa – A systematic review with 90-90-90 targets in sight. PLoS ONE, 2018, 13, e0200737.	1.1	29
863	Expert consensus statement on the science of $\langle scp \rangle HIV \langle scp \rangle$ in the context of criminal law. Journal of the International AIDS Society, 2018, 21, e25161.	1.2	59
864	Association of Viral Suppression With Lower AIDS-Defining and Non–AIDS-Defining Cancer Incidence in HIV-Infected Veterans. Annals of Internal Medicine, 2018, 169, 87.	2.0	54
865	Clinical and Economic Effects of a Pharmacist-Administered Antiretroviral Therapy Adherence Clinic for Patients Living with HIV. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 165-172.	0.5	20
866	HIV Treatment Substantially Decreases Hospitalization Rates: Evidence From Rural South Africa. Health Affairs, 2018, 37, 997-1004.	2.5	2
867	Dynamics of CD4 and CD8 T-Cell Subsets and Inflammatory Biomarkers during Early and Chronic HIV Infection in Mozambican Adults. Frontiers in Immunology, 2017, 8, 1925.	2.2	23
868	From CD4-Based Initiation to Treating All HIV-Infected Adults Immediately: An Evidence-Based Meta-analysis. Frontiers in Immunology, 2018, 9, 212.	2.2	24
869	Chronic and Occult Hepatitis B Virus Infection in Pregnant Women in Botswana. Genes, 2018, 9, 259.	1.0	21

#	Article	IF	CITATIONS
870	Diffusion of complementary evolving pharmaceutical innovations: The case of Abacavir and its pharmacogenetic companion diagnostic in Italy. Technological Forecasting and Social Change, 2018, 134, 223-233.	6.2	5
871	Centring †being undetectable†as the new face of HIV: Transforming subjectivities via the discursive practices of HIV treatment as prevention. BioSocieties, 2018, 13, 470-493.	0.8	14
872	Prediction of extended high viremia among newly HIV-1-infected persons in sub-Saharan Africa. PLoS ONE, 2018, 13, e0192785.	1.1	4
873	DNA Nanotweezers and Graphene Transistor Enable Labelâ€Free Genotyping. Advanced Materials, 2018, 30, e1802440.	11.1	73
874	Estimating the real-world effects of expanding antiretroviral treatment eligibility: Evidence from a regression discontinuity analysis in Zambia. PLoS Medicine, 2018, 15, e1002574.	3.9	20
875	Comparing Australian gay and bisexual men with undiagnosed and recently diagnosed HIV infection to those in the National HIV Registry. Sexual Health, 2018, 15, 276.	0.4	1
876	Medication costs associated with early initiation of antiretroviral therapy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2018, 30, 1512-1516.	0.6	1
878	Treatment of HIV for the Prevention of Transmission in Discordant Couples and at the Population Level. Advances in Experimental Medicine and Biology, 2018, 1075, 125-162.	0.8	12
879	AIDS incidence trends at presentation and during follow-up among HIV-at-risk populations: a 15-year nationwide cohort study in Taiwan. BMC Public Health, 2018, 18, 589.	1.2	10
880	Prediction of HIV-associated neurocognitive disorder (HAND) from three genetic features of envelope gp120 glycoprotein. Retrovirology, 2018, 15, 12.	0.9	15
881	Evidence of reduced treatment adherence among HIV infected paediatric and adolescent populations in Nairobi at the onset of the UNAIDS Universal Test and Treat Program. BMC Research Notes, 2018, 11, 134.	0.6	8
882	Gaps Up To 9 Months Between HIV Primary Care Visits Do Not Worsen Viral Load. AIDS Patient Care and STDs, 2018, 32, 157-164.	1.1	3
883	Adverse effects in children exposed to maternal HIV and antiretroviral therapy during pregnancy in Brazil: a cohort study. Reproductive Health, 2018, 15, 76.	1.2	26
884	HIV-1 RNA testing of pooled dried blood spots is feasible to diagnose acute HIV infection in resource limited settings. Southern African Journal of Infectious Diseases, 2018, 33, 50-53.	0.3	1
885	Current Treatment Options for HIV Elite Controllers: a Review. Current Treatment Options in Infectious Diseases, 2018, 10, 302-309.	0.8	12
886	Evaluating Antiretroviral Therapy Initiation in HIV-Associated Malignancy: Is There Enough Evidence to Inform Clinical Guidelines?. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 927-932.	2.3	4
887	Adverse drug reactions to antiretroviral drugs and impact on treatment adherence among HIV patients in northwestern Nigeria. Drugs and Therapy Perspectives, 2018, 34, 488-495.	0.3	0
888	The cascade of HIV care among key populations in Indonesia: a prospective cohort study. Lancet HIV,the, 2018, 5, e560-e568.	2.1	63

#	Article	IF	CITATIONS
889	Spectrum of disease in HIV-positive patients presenting to a tertiary care hospital: a retrospective, cross-sectional review in Kumasi, Ghana. BMC Infectious Diseases, 2018, 18, 419.	1.3	3
890	Implementation of a Test, Treat, and Prevent HIV program among men who have sex with men and transgender women in Thailand, 2015-2016. PLoS ONE, 2018, 13, e0201171.	1.1	30
891	The Effectiveness and Cost-Effectiveness of Screening for HIV in Migrants in the EU/EEA: A Systematic Review. International Journal of Environmental Research and Public Health, 2018, 15, 1700.	1.2	28
892	The Extended Impact of Human Immunodeficiency Virus/AIDS Research. Journal of Infectious Diseases, 2019, 219, 6-9.	1.9	13
893	Improving Linkage, Retention, and Reengagement in HIV Care in 12 Metropolitan Areas. Health Promotion Practice, 2018, 19, 704-713.	0.9	2
894	UNICEF's contribution to the adoption and implementation of option B+ for preventing mother-to-child transmission of HIV: a policy analysis. Globalization and Health, 2018, 14, 55.	2.4	8
895	Substance Use and Adherence to Antiretroviral Therapy: What Is Known and What Is Unknown. Current Infectious Disease Reports, 2018, 20, 36.	1.3	25
896	Evolving Paradigms in HIV Malignancies: Review of Ongoing Clinical Trials. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1018-1026.	2.3	7
897	Non-AIDS Mortality Is Higher Among Successfully Treated People Living with HIV Compared with Matched HIV-Negative Control Persons: A 15-Year Follow-Up Cohort Study in Sweden. AIDS Patient Care and STDs, 2018, 32, 297-305.	1.1	36
898	Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality. AIDS Research and Human Retroviruses, 2018, 34, 936-941.	0.5	7
899	Association of antiretroviral therapy with brain aging changes among HIV-infected adults. Aids, 2018, 32, 2005-2015.	1.0	31
900	Linkage to HIV care following diagnosis in the WHO European Region: A systematic review and meta-analysis, 2006-2017. PLoS ONE, 2018, 13, e0192403.	1.1	25
901	ART and lifelong IPT for health care workers with HIV: a priority for infection control. International Journal of Tuberculosis and Lung Disease, 2018, 22, 356-356.	0.6	0
902	Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015. PLoS ONE, 2018, 13, e0192805.	1.1	26
903	HIV viral suppression in Oman: Encouraging progress toward achieving the United Nations †third 90â€. International Journal of Infectious Diseases, 2018, 71, 94-99.	1.5	7
904	A Cluster Randomized Evaluation of a Health Department Data to Care Intervention Designed to Increase Engagement in HIV Care and Antiretroviral Use. Sexually Transmitted Diseases, 2018, 45, 361-367.	0.8	26
905	Analysis of drug–drug interactions among patients receiving antiretroviral regimens using data from a large open-source prescription database. American Journal of Health-System Pharmacy, 2018, 75, 1132-1139.	0.5	13
906	Performance of the Alere Determineâ,,¢ HIV-1/2 Ag/Ab Combo Rapid Test with algorithm-defined acute HIV-1 infection specimens. Journal of Clinical Virology, 2018, 104, 89-91.	1.6	18

#	Article	IF	Citations
907	Factors associated with late presentation for HIV care in a single Belgian reference center: 2006–2017. Scientific Reports, 2018, 8, 8594.	1.6	32
908	A new approach to hierarchical data analysis: Targeted maximum likelihood estimation for the causal effect of a cluster-level exposure. Statistical Methods in Medical Research, 2019, 28, 1761-1780.	0.7	22
909	The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. Journal of Infectious Diseases, 2019, 219, 254-263.	1.9	13
910	2018 Belgian guidelines for the screening for latent tuberculosis in HIV-infected patients. Acta Clinica Belgica, 2019, 74, 242-251.	0.5	3
911	Nationwide Cohort Study of Antiretroviral Therapy Timing: Treatment Dropout and Virological Failure in China, 2011–2015. Clinical Infectious Diseases, 2019, 68, 43-50.	2.9	21
912	Adverse Pregnancy Outcomes Among Women Who Conceive on Antiretroviral Therapy. Clinical Infectious Diseases, 2019, 68, 273-279.	2.9	14
913	Duration Since Never in HIV Care and Immediate Blood-Draw After HIV Diagnosis are Associated with Willingness to Link to Care Following Health Department Outreach, New York City. AIDS and Behavior, 2019, 23, 386-394.	1.4	2
914	Missed opportunities for earlier diagnosis of human immunodeficiency virus infection among adults presenting to Auckland District Health Board hospital services. Internal Medicine Journal, 2019, 49, 495-501.	0.5	4
915	Human Immunodeficiency Virus Drug Resistance: 2018 Recommendations of the International Antiviral Society–USA Panel. Clinical Infectious Diseases, 2019, 68, 177-187.	2.9	156
916	Undetectable = Untransmittable and Your Health: The Personal Benefits of Early and Continuous Therapy for HIV Infection. Journal of Infectious Diseases, 2019, 219, 173-176.	1.9	14
917	Making the Connection: Using Videoconferencing to Increase Linkage to Care for Incarcerated Persons Living with HIV Post-release. AIDS and Behavior, 2019, 23, 32-40.	1.4	22
918	The Social Psychology of Gay Men. , 2019, , .		24
919	IsÂincreased screening and early antiretroviral treatment for HIV â€1 worth the investment?ÂAn analysis of the public health and economic impact of improvementÂin the UK. HIV Medicine, 2019, 20, 668-680.	1.0	5
920	Slow Acceptance of Universal Antiretroviral Therapy (ART) Among Mothers Enrolled in IMPAACT PROMISE Studies Across the Globe. AIDS and Behavior, 2019, 23, 2522-2531.	1.4	5
921	VITAL Start: Video-Based Intervention to Inspire Treatment Adherence for Lifeâ€"Pilot of a Novel Video-Based Approach to HIV Counseling for Pregnant Women Living with HIV. AIDS and Behavior, 2019, 23, 3140-3151.	1.4	11
922	Implementation of "Treatâ€ell―at adult <scp>HIV</scp> care and treatment sites in the Global le <scp>DEA</scp> Consortium: results from the Site Assessment Survey. Journal of the International AIDS Society, 2019, 22, e25331.	1.2	32
923	Use and Acceptability of HIV Self-Testing Among First-Time Testers at Risk for HIV in Senegal. AIDS and Behavior, 2019, 23, 130-141.	1.4	35
924	Depression Prevalence, Antidepressant Treatment Status, and Association with Sustained HIV Viral Suppression Among Adults Living with HIV in Care in the United States, 2009–2014. AIDS and Behavior, 2019, 23, 3452-3459.	1.4	42

#	Article	IF	CITATIONS
925	The disconnect between individual-level and population-level HIV prevention benefits of antiretroviral treatment. Lancet HIV,the, 2019, 6, e632-e638.	2.1	69
926	Effects of malaria/helminthic coinfections on cervical cancer progression among sub Saharan African women on highly active antiretroviral therapy: A scoping review. Gynecologic Oncology Reports, 2019, 29, 64-69.	0.3	1
927	Trends in baseline CD4 count at presentation to care among HIV-positive patients in Sungai Buloh Hospital, Malaysia. HIV and AIDS Review, 2019, 18, 85-91.	0.1	0
928	Effectiveness of antiretroviral therapy in treatment-na \tilde{A} -ve patients. Results at 24 and 48 weeks. HIV and AIDS Review, 2019, 18, 100-106.	0.1	0
929	Mental Health and Sexual Health. , 2019, , 137-157.		0
930	Antiretroviral therapy partially improves the abnormalities of dendritic cells and lymphoid and myeloid regulatory populations in recently infected HIV patients. Scientific Reports, 2019, 9, 11654.	1.6	3
931	HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. New England Journal of Medicine, 2019, 381, 219-229.	13.9	174
932	Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. New England Journal of Medicine, 2019, 381, 230-242.	13.9	163
933	Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART). New England Journal of Medicine, 2019, 381, 207-218.	13.9	255
934	Advanced HIV Disease among Males and Females Initiating HIV Care in Rural Ethiopia. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821984719.	0.6	13
935	Determinants of chronic energy deficiency among adults living with HIV in Shebel Berenta District, East Gojjam, Amhara region, North West Ethiopia, 2017: case control study. BMC Research Notes, 2019, 12, 431.	0.6	1
936	Neurocognitive Complications of HIV Infection in Low-Income Countries. Current Topics in Behavioral Neurosciences, 2019, 50, 225-244.	0.8	0
937	Model-based prediction of CD4 cells counts in HIV-infected adults on antiretroviral therapy in Northwest Ethiopia: A flexible mixed effects approach. PLoS ONE, 2019, 14, e0218514.	1.1	5
938	The Pattern of Non-AIDS-defining Cancers in the HIV Population: Epidemiology, Risk Factors and Prognosis. A Review. Current HIV Research, 2019, 17, 1-12.	0.2	40
939	Evaluation of the clinical outcomes of the Test and Treat strategy to implement Treat All in Nigeria: Results from the Nigeria Multi-Center ART Study. PLoS ONE, 2019, 14, e0218555.	1.1	38
940	Nonâ€nucleoside reverse transcriptase inhibitor levels among HIV â€exposed uninfected infants at the time of HIV PCR testing – findings from a tertiary healthcare facility in Pretoria, South Africa. Journal of the International AIDS Society, 2019, 22, e25284.	1.2	4
941	Conceptualizing the Risks of Coronary Heart Disease and Heart Failure Among People Aging with HIV: Sex-Specific Considerations. Current Treatment Options in Cardiovascular Medicine, 2019, 21, 41.	0.4	12
942	Antiretroviral drug reduction in highly experienced HIV-infected patients receiving a multidrug regimen: the ECOVIR study. Journal of Antimicrobial Chemotherapy, 2019, 74, 2716-2722.	1.3	6

#	Article	IF	CITATIONS
943	Therapeutic Vaccination Refocuses T-cell Responses Towards Conserved Regions of HIV-1 in Early Treated Individuals (BCN 01 study). EClinicalMedicine, 2019, 11, 65-80.	3.2	52
944	Incidence of select chronic comorbidities among a population-based cohort of HIV-positive individuals receiving highly active antiretroviral therapy. Current Medical Research and Opinion, 2019, 35, 1955-1963.	0.9	12
945	Negative and Positive Selection Pressure During Sexual Transmission of Transmitted Founder HIV-1. Frontiers in Immunology, 2019, 10, 1599.	2.2	14
946	Community beliefs, HIV stigma, and depression among adolescents living with HIV in rural Uganda. African Journal of AIDS Research, 2019, 18, 169-180.	0.3	45
947	Treating bacterial pneumonia in people living with HIV. Expert Review of Respiratory Medicine, 2019, 13, 771-786.	1.0	4
948	Cost-effectiveness and budget impact of immediate antiretroviral therapy initiation for treatment of HIV infection in CÑte d'Ivoire: A model-based analysis. PLoS ONE, 2019, 14, e0219068.	1.1	5
949	Incomplete ART adherence is associated with higher inflammation in individuals who achieved virologic suppression in the START study. Journal of the International AIDS Society, 2019, 22, e25297.	1.2	26
950	Why Everyone (Almost) with HIV Needs to Be on Treatment. Infectious Disease Clinics of North America, 2019, 33, 663-679.	1.9	8
951	HIV Initial Assessment and Routine Follow-up. Infectious Disease Clinics of North America, 2019, 33, 647-662.	1.9	1
952	Life expectancy and disparities in survival among HIV-infected people receiving antiretroviral therapy: an observational cohort study in Kathmandu, Nepal. BMJ Global Health, 2019, 4, e001319.	2.0	8
953	Decline in reported AIDS cases in Brazil after implementation of the test and treat initiative. BMC Infectious Diseases, 2019, 19, 579.	1.3	9
954	How to Evolve the Response to the Global HIV Epidemic With New Metrics and Targets Based on Pre-Treatment CD4 Counts. Current HIV/AIDS Reports, 2019, 16, 304-313.	1.1	16
955	Implementation of Nurseâ€Driven HIV Screening Targeting Key Populations in Emergency Departments: A Multilevel Analysis From the DIClâ€VIH Trial. Worldviews on Evidence-Based Nursing, 2019, 16, 444-453.	1.2	10
956	Self-reported non-receipt of HIV test results: A silent barrier to HIV epidemic control in Mozambique. PLoS ONE, 2019, 14, e0224102.	1.1	6
957	Stable prevalence of transmitted drug resistance mutations and increased circulation of non-B subtypes in antiretroviral-naive chronically HIV-infected patients in 2015/2016 in France. Journal of Antimicrobial Chemotherapy, 2019, 74, 1417-1424.	1.3	12
958	Incidence of tuberculosis in HIV-infected adults on first- and second-line antiretroviral therapy in India. BMC Infectious Diseases, 2019, 19, 914.	1.3	7
959	Human immunodeficiency disease in new diagnoses of head and neck squamous cell cancer: are we testing?. Journal of Laryngology and Otology, 2019, 133, 1038-1040.	0.4	2
960	HIV Infection. , 2019, , 18-28.		0

#	Article	IF	CITATIONS
961	Cumulative viral load as a predictor of CD4+ T-cell response to antiretroviral therapy using Bayesian statistical models. PLoS ONE, 2019, 14, e0224723.	1.1	11
962	Distribution of advanced HIV disease from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data from three population-based cross-sectional surveys in Eshowe (South) Tj ETQq1 1 0.784	13 0: 7rgBT	/Oxærlock 10
963	Interim monitoring in a treatment strategy trial with a composite primary endpoint. Contemporary Clinical Trials, 2019, 86, 105846.	0.8	0
964	Evolution of an Electronic Health Record Based–Human Immunodeficiency Virus (HIV) Screening Program in an Urban Emergency Department for Diagnosing Acute and Chronic HIV Infection. Journal of Emergency Medicine, 2019, 57, 732-739.	0.3	8
966	Increasing HIV treatment access, uptake and use among men who have sex with men in urban Indonesia: evidence from a qualitative study in three cities. Health Policy and Planning, 2020, 35, 16-25.	1.0	11
967	Cure and Control: What Will It Take to Eliminate HCV?. Topics in Medicinal Chemistry, 2019, , 447-490.	0.4	2
968	Gender Norms and HIV Testing/Treatment Uptake: Evidence from a Large Population-Based Sample in South Africa. AIDS and Behavior, 2019, 23, 162-171.	1.4	29
969	Persistence of cervical high-risk human papillomavirus in women living with HIV in Denmark – the SHADE. BMC Infectious Diseases, 2019, 19, 740.	1.3	8
970	Heart Failure among People with HIV: Evolving Risks, Mechanisms, and Preventive Considerations. Current HIV/AIDS Reports, 2019, 16, 371-380.	1.1	26
971	Factors Associated with HIV Antiretroviral Therapy among Men Who Have Sex with Men in 20 US Cities, 2014. Journal of Urban Health, 2019, 96, 868-877.	1.8	9
972	Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: A prospective cohort study. International Journal of Infectious Diseases, 2019, 88, 73-79.	1.5	5
973	Neurological disorders in HIV in Africa: a review. African Health Sciences, 2019, 19, 1953.	0.3	18
974	A push for 90-90-90: Initial treatment with INSTI-based regimens against HIV-1 infection. EClinicalMedicine, 2019, 13, 4-5.	3.2	0
975	Implementation of an Immediate HIV Treatment Initiation Program in a Public/Academic Medical Center in the U.S. South: The Miami Test and Treat Rapid Response Program. AIDS and Behavior, 2019, 23, 287-295.	1.4	19
976	Barriers and Facilitators for Antiretroviral Treatment Adherence Among HIV-Positive African American and Latino Men Who Have Sex With Men. AIDS Education and Prevention, 2019, 31, 306-324.	0.6	8
977	Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients. International Journal of Antimicrobial Agents, 2019, 54, 728-734.	1.1	40
978	A prospective randomized trial on abacavir/lamivudine plus darunavir/ritonavir or raltegravir in HIV-positive drug-naÃ-ve patients with CD4<200 cells/uL (the PRADAR study). PLoS ONE, 2019, 14, e0222650.	1.1	11
979	Use of Dolutegravir for Antiretroviral Therapy for Women of Childbearing Age. JOGNN - Journal of Obstetric, Gynecologic, and Neonatal Nursing, 2019, 48, 664-673.	0.2	0

#	Article	IF	CITATIONS
980	Optimising treatment in the test-and-treat strategy: what are we waiting for?. Lancet HIV, the, 2019, 6, e715-e722.	2.1	8
981	Too fast to stay on track? Shorter time to first anti-retroviral regimen is not associated with better retention in care in the French Dat'AIDS cohort. PLoS ONE, 2019, 14, e0222067.	1.1	11
982	A Youth Participatory Project to Address STIs and HIV among Homeless Youth. Comprehensive Child and Adolescent Nursing, 2019, 42, 222-240.	0.4	4
983	Trends and predictors of nonâ€communicable disease multimorbidity among adults living with <scp>HIV</scp> and receiving antiretroviral therapy in Brazil. Journal of the International AIDS Society, 2019, 22, e25233.	1.2	26
984	Diabetes mellitus burden among people living with <scp>HIV</scp> from the Asiaâ€Pacific region. Journal of the International AIDS Society, 2019, 22, e25236.	1.2	25
985	Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted Pls in HIV-1 positive individuals with virologic suppression: a retrospective study from the clinical practice. BMC Infectious Diseases, 2019, 19, 59.	1.3	23
986	Research priorities to inform "Treat All―policy implementation for people living with <scp>HIV</scp> in subâ€Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate <scp>AIDS</scp> (le <scp>DEA</scp>). Journal of the International AIDS Society, 2019, 22, e25218.	1.2	32
987	Subclinical tuberculosis among adults with HIV: clinical features and outcomes in a South African cohort. BMC Infectious Diseases, 2019, 19, 14.	1.3	22
988	Antiretroviral Treatment of Acute HIV Infection Normalizes Levels of Cerebrospinal Fluid Markers of Central Nervous System (CNS) Inflammation: A Consequence of a Reduced CNS Reservoir?. Journal of Infectious Diseases, 2019, 220, 1867-1869.	1.9	10
989	Are European HIV cohort data within EuroCoord representative of the diagnosed HIV population?. Aids, 2019, 33, 133-143.	1.0	20
990	Stimulant Use and Viral Suppression in the Era of Universal Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 89-93.	0.9	41
991	Physical activity and quality of life in people living with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 589-598.	0.6	24
992	Success and failure of initial antiretroviral therapy in adults. Aids, 2019, 33, 443-453.	1.0	11
993	Mechanisms of Cardiovascular Disease in the Setting of HIV Infection. Canadian Journal of Cardiology, 2019, 35, 238-248.	0.8	41
994	Investigation of HIV/AIDS prevalence and associated risk factors among female sex workers from 2010 to 2017: a meta-analysis study. HIV/AIDS - Research and Palliative Care, 2019, Volume 11, 105-117.	0.4	15
995	Intention to initiate antiretroviral therapy (ART) among people living with HIV in China under the scaling-up of ART: the role of healthcare workers' recommendations. BMC Health Services Research, 2019, 19, 314.	0.9	6
996	Harambee!: A pilot mixed methods study of integrated residential HIV testing among African-born individuals in the Seattle area. PLoS ONE, 2019, 14, e0216502.	1.1	10
997	Screening for retroviruses and hepatitis viruses using dried blood spots reveals a high prevalence of occult hepatitis B in Ghana. Therapeutic Advances in Infectious Disease, 2019, 6, 204993611985146.	1.1	7

#	Article	IF	Citations
998	HIV, Cancer, and the Microbiota: Common Pathways Influencing Different Diseases. Frontiers in Immunology, 2019, 10, 1466.	2.2	15
999	Two decades of surveillance data show late presentation among a diverse group of women diagnosed with HIV in Victoria, Australia. Australian and New Zealand Journal of Public Health, 2019, 43, 413-418.	0.8	5
1000	Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy–Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial. Journal of Infectious Diseases, 2019, 220, 1325-1334.	1.9	18
1001	HIV infection and coronary heart disease: mechanisms and management. Nature Reviews Cardiology, 2019, 16, 745-759.	6.1	128
1002	HIV Screening and Preexposure Prophylaxis Guidelines. JAMA - Journal of the American Medical Association, 2019, 321, 2172.	3.8	6
1003	Screening for HIV Infection in Asymptomatic, Nonpregnant Adolescents and Adults. JAMA - Journal of the American Medical Association, 2019, 321, 2337.	3.8	12
1004	Screening for HIV Infection. JAMA - Journal of the American Medical Association, 2019, 321, 2326.	3.8	137
1005	Effectiveness of a Viral Load Suppression Intervention for Highly Vulnerable People Living with HIV. AIDS and Behavior, 2019, 23, 2443-2452.	1.4	8
1006	Increased monocyte activation with age among <scp>HIV</scp> â€infected long term nonâ€progressor children: implications for early treatment initiation. HIV Medicine, 2019, 20, 513-522.	1.0	2
1007	Limited Sustained Local Transmission of HIV-1 CRF01_AE in New South Wales, Australia. Viruses, 2019, 11, 482.	1.5	4
1008	Influence of Hepatitis C virus coinfection on immune reconstitution in HIV subjects. Medical Microbiology and Immunology, 2019, 208, 747-756.	2.6	3
1009	Losses to follow-up of HIV-infected people in the Spanish VACH cohort over the period between 2013 and 2014: The importance of sociodemographic factors. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 361-366.	0.2	0
1010	Initiation and completion rates of isoniazid preventive therapy among people living with HIV in Far-Western Region of Nepal: a retrospective cohort study. BMJ Open, 2019, 9, e029058.	0.8	7
1011	Re-thinking Linkage to Care in the Era of Universal Test and Treat: Insights from Implementation and Behavioral Science for Achieving the Second 90. AIDS and Behavior, 2019, 23, 120-128.	1.4	24
1012	Characteristics, Prevention, and Management of Cardiovascular Disease in People Living With HIV: A Scientific Statement From the American Heart Association. Circulation, 2019, 140, e98-e124.	1.6	376
1013	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2019, 37, 373-379.	0.2	3
1014	High Yield of Active Tuberculosis Case Finding Among HIV-Infected Patients Using Xpert MTB/RIF Testing. Open Forum Infectious Diseases, 2019, 6, ofz233.	0.4	13
1015	Investigation of the Proportion of Diagnosed People Living with HIV/AIDS among Foreign Residents in Japan. Journal of Clinical Medicine, 2019, 8, 804.	1.0	8

#	Article	IF	CITATIONS
1016	Older age at initiation of antiretroviral therapy predicts low bone mineral density in children with perinatally-infected HIV in Zimbabwe. Bone, 2019, 125, 96-102.	1.4	19
1017	Effect Estimates in Randomized Trials and Observational Studies: Comparing Apples With Apples. American Journal of Epidemiology, 2019, 188, 1569-1577.	1.6	7 5
1018	Delayed Antiretroviral Therapy (ART) Initiation among Hospitalized Adults in a Resource-Limited Settings: A Challenge to the Global Target of ART for 90% of HIV-Infected Individuals. AIDS Research and Treatment, 2019, 2019, 1-8.	0.3	16
1019	Planning <scp>HIV</scp> therapy to prevent future comorbidities: patient years for tenofovir alafenamide. HIV Medicine, 2019, 20, 1-16.	1.0	8
1021	Viremia Trajectories of HIV in HIV-Positive Women in the United States, 1994-2017. JAMA Network Open, 2019, 2, e193822.	2.8	13
1022	Incidence and Risk Factors for Renal Disease in an Outpatient Cohort of HIV-Infected Patients on Antiretroviral Therapy. Kidney International Reports, 2019, 4, 1075-1084.	0.4	6
1023	Interpretation of the Individual Effect Under Treatment Spillover. American Journal of Epidemiology, 2019, 188, 1407-1409.	1.6	6
1024	Timeliness of Human Immunodeficiency Virus Diagnosis and Antiretroviral Treatment Initiation in the Era of Universal Testing and Treatment. Journal of Infectious Diseases, 2019, 220, 648-656.	1.9	13
1025	Earlier Initiation of Antiretroviral Treatment Coincides With an Initial Control of the HIV-1 Sub-Subtype F1 Outbreak Among Men-Having-Sex-With-Men in Flanders, Belgium. Frontiers in Microbiology, 2019, 10, 613.	1.5	21
1026	Early outcomes after implementation of <i>treat all</i> in Rwanda: an interrupted time series study. Journal of the International AIDS Society, 2019, 22, e25279.	1.2	20
1027	Assessment of antiretroviral third agent virologic durability after initiation of first antiretroviral regimen. International Journal of STD and AIDS, 2019, 30, 680-688.	0.5	4
1028	Designing an Individually Tailored Multilevel Intervention to Increase Engagement in HIV and Substance Use Treatment Among People Who Inject Drugs With HIV: HPTN 074. AIDS Education and Prevention, 2019, 31, 95-110.	0.6	9
1029	Current and emerging therapies to combat persistent intracellular pathogens. Current Opinion in Pharmacology, 2019, 48, 33-39.	1.7	9
1030	Paediatric Integrase Inhibitor Use in a Real-Life Setting: A Single-Centre Cohort Experience 2009–2018. Clinical Drug Investigation, 2019, 39, 585-590.	1.1	8
1031	Cryptococcal meningitis after ART: Need for proper baseline evaluation in the era of †Test & Treat'. Medical Mycology Case Reports, 2019, 24, 58-60.	0.7	2
1032	Multicenter evaluation of the cobas \hat{A}^{\otimes} HIV-1 quantitative nucleic acid test for use on the cobas \hat{A}^{\otimes} 4800 system for the quantification of HIV-1 plasma viral load. Journal of Clinical Virology, 2019, 114, 43-49.	1.6	9
1033	Incidence of and risk factors for medical care interruption in people living with HIV in recent years. PLoS ONE, 2019, 14, e0213526.	1.1	7
1034	Effect of antiretroviral therapy on longitudinal lung function trends in older children and adolescents with HIV-infection. PLoS ONE, 2019, 14, e0213556.	1.1	12

#	Article	IF	CITATIONS
1036	Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. PLoS Medicine, 2019, 16, e1002767.	3.9	20
1037	Earlier diagnoses and faster treatment of HIV in the District of Columbia: HIVÂsurveillance analysis, 2006–2016. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1476-1483.	0.6	3
1039	Ancillary service needs among persons new to HIV care and the relationship between needs and late presentation to care. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1131-1139.	0.6	3
1040	Is HIV a provoking factor for venous thrombotic events?. Lancet HIV, the, 2019, 6, e144-e146.	2.1	1
1041	HIV Infection in Transgender Persons. Contemporary Endocrinology, 2019, , 239-281.	0.3	0
1042	"l don't want them to know― how stigma creates dilemmas for engagement with Treat-all HIV care for people living with HIV in Eswatini. African Journal of AIDS Research, 2019, 18, 27-37.	0.3	35
1043	Determinants of survival of people living with HIV/AIDS on antiretroviral therapy in Brazil 2006–2015. BMC Infectious Diseases, 2019, 19, 206.	1.3	41
1044	Predictors of treatment failure, time to switch and reasons for switching to second line antiretroviral therapy in HIV infected children receiving first line anti-retroviral therapy at a Tertiary Care Hospital in Ethiopia. BMC Pediatrics, 2019, 19, 37.	0.7	22
1045	Contribution of specific diseases and injuries to changes in health adjusted life expectancy in 187 countries from 1990 to 2013: retrospective observational study. BMJ: British Medical Journal, 2019, 364, 1969.	2.4	44
1046	Risks and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies in Patients with HIV Infection. Biology of Blood and Marrow Transplantation, 2019, 25, e260-e267.	2.0	11
1047	Late HIV Diagnosis but Earlier Antiretroviral Treatment Initiation in Northwest Spain: Impact of Current Treatment Guidelines. Journal of the International Association of Providers of AIDS Care, 2019, 18, 232595821882194.	0.6	3
1048	Gonorrhoea and chlamydia diagnosis as an entry point for HIV pre-exposure prophylaxis: a modelling study. BMJ Open, 2019, 9, e023453.	0.8	5
1049	Mortality among pediatric patients on HIV treatment in sub-Saharan African countries: a systematic review and meta-analysis. BMC Public Health, 2019, 19, 149.	1.2	19
1050	Increased uptake of early initiation of antiretroviral therapy and baseline drug resistance testing in San Francisco between 2001 and 2015. PLoS ONE, 2019, 14, e0213167.	1.1	4
1051	British HIV Association guidelines for the management of HIV in pregnancy and postpartum 2018. HIV Medicine, 2019, 20, s2-s85.	1.0	31
1052	Challenges and opportunities to prevent tuberculosis in people living with HIV in low-income countries. International Journal of Tuberculosis and Lung Disease, 2019, 23, 241-251.	0.6	16
1053	The clinical features and prognosis of 100 AIDS-related lymphoma cases. Scientific Reports, 2019, 9, 5381.	1.6	16
1054	Incidence of a first venous thrombotic event in people with HIV in the Netherlands: a retrospective cohort study. Lancet HIV,the, 2019, 6, e173-e181.	2.1	18

#	Article	IF	CITATIONS
1055	Reducing the gap between the diagnosis and treatment of <scp>HIV</scp> infection. Medical Journal of Australia, 2019, 210, 261-262.	0.8	0
1056	HIV Incidence and Risk Behaviours of People Who Inject Drugs in Bangkok, 1995–2012. EClinicalMedicine, 2019, 9, 44-51.	3.2	13
1057	Health outcomes of asymptomatic HIV-infected pregnant women initiating antiretroviral therapy at different baseline CD4 counts in Ethiopia. International Journal of Infectious Diseases, 2019, 82, 89-95.	1.5	5
1058	Identifying, linking, and treating people who inject drugs and were recently infected with HIV in the context of a network-based intervention. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 1376-1383.	0.6	9
1059	"ls it making any difference?―A qualitative study examining the treatmentâ€ŧaking experiences of asymptomatic people living with HIV in the context of Treatâ€all in Eswatini. Journal of the International AIDS Society, 2019, 22, e25220.	1.2	13
1061	Behavioral Intention to Initiate Antiretroviral Therapy (ART) Among Chinese HIV-Infected Men Who Have Sex With Men Having High CD4 Count in the Era of "Treatment for All― American Journal of Men's Health, 2019, 13, 155798831982861.	0.7	11
1062	Uterine Cervical Cancer in Women with HIV Infection., 2019,, 89-105.		0
1064	Rapid antiretroviral therapy initiation in low- and middle-income countries: A resource-based approach. PLoS Medicine, 2019, 16, e1002723.	3.9	16
1065	Viral suppression among persons in HIV care in the United States during 2009–2013: sampling bias in Medical Monitoring Project surveillance estimates. Annals of Epidemiology, 2019, 31, 3-7.	0.9	7
1066	Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Medicine, 2019, 20, 3-11.	1.0	68
1067	Accurate and reproducible enumeration of T-, B-, and NK lymphocytes using the BD FACSLyric 10-color system: A multisite clinical evaluation. PLoS ONE, 2019, 14, e0211207.	1.1	9
1068	The dynamic association between Frailty, CD4 and CD4/CD8 ratio in people aging with HIV. PLoS ONE, 2019, 14, e0212283.	1.1	24
1069	The Impact of ACA and Medicaid Expansion on Progress Toward UNAIDS 90-90-90 Goals. Current HIV/AIDS Reports, 2019, 16, 105-112.	1.1	8
1070	Retention on antiretroviral therapy during Universal Test and Treat implementation in Zomba district, Malawi: a retrospective cohort study. Journal of the International AIDS Society, 2019, 22, e25239.	1.2	38
1071	Navigating HIV citizenship: identities, risks and biological citizenship in the treatment as prevention era. Health, Risk and Society, 2019, 21, 1-16.	0.9	37
1072	How all-type dementia risk factors and modifiable risk interventions may be relevant to the first-generation aging with HIV infection?. European Geriatric Medicine, 2019, 10, 227-238.	1.2	11
1073	Early initiation of antiretroviral therapy for people newly diagnosed with <scp>HIV</scp> infection in Australia: trends and predictors, 2004–2015. Medical Journal of Australia, 2019, 210, 269-275.	0.8	8
1075	HIV Prevention Practices and Non-Federal Funding Among U.S. States and Non-State Regions: A Survey of HIV/AIDS Directors. AIDS Education and Prevention, 2019, 31, 82-94.	0.6	1

#	Article	IF	CITATIONS
1076	ART adherence and viral suppression are high among most nonâ€pregnant individuals with earlyâ€stage, asymptomatic HIV infection: an observational study from Uganda and South Africa. Journal of the International AIDS Society, 2019, 22, e25232.	1.2	46
1077	HIV testing and HIV knowledge among men who have sex with men in Natal, Northeast Brazil. Brazilian Journal of Infectious Diseases, 2019, 23, 2-7.	0.3	8
1078	Preoperative serum lactate dehydrogenase level as a predictor of major complications following thoracoscopic lobectomy: a propensity-adjusted analysis. European Journal of Cardio-thoracic Surgery, 2019, 56, 294-300.	0.6	5
1079	†Just another vial† ': a qualitative study to explore the acceptability and feasibility of routine blood-borne virus testing in an emergency department setting in the UK. BMJ Open, 2019, 9, e024085.	0.8	9
1080	Evaluating the reactivation of herpesviruses and inflammation as cardiovascular and cerebrovascular risk factors in antiretroviral therapy initiators in an African HIV-infected population (RHICCA): a protocol for a longitudinal cohort study. BMJ Open, 2019, 9, e025576.	0.8	1
1081	Opt-out bloodborne virus screening: a cross-sectional observational study in an acute medical unit. BMJ Open, 2019, 9, e022777.	0.8	1
1082	Cohort profile: Development and profile of a population-based, retrospective cohort of diagnosed people living with HIV in Ontario, Canada (Ontario HIV Laboratory Cohort). BMJ Open, 2019, 9, e027325.	0.8	0
1083	Trends in HIV testing in the UK primary care setting: a 15-year retrospective cohort study from 2000 to 2015. BMJ Open, 2019, 9, e027744.	0.8	4
1084	Decreased HIV-associated mortality rates during scale-up of antiretroviral therapy, 2011–2016. Aids, 2019, 33, 2423-2430.	1.0	9
1085	Impact of early antiretroviral treatment on sexual behaviour. Aids, 2019, 33, 2337-2350.	1.0	2
1086	Human immunodeficiency virus: A review into treatment. Journal of Prescribing Practice, 2019, 1, 596-601.	0.1	0
1087	How heterogeneous are MSM from Brazilian cities? An analysis of sexual behavior and perceived risk and a description of trends in awareness and willingness to use pre-exposure prophylaxis. BMC Infectious Diseases, 2019, 19, 1067.	1.3	40
1088	HIV research in South Africa: Advancing life. South African Medical Journal, 2019, 109, 36.	0.2	6
1089	Short-term outcomes of rapid initiation of antiretroviral therapy among HIV-positive patients: real-world experience from a single-centre retrospective cohort in Taiwan. BMJ Open, 2019, 9, e033246.	0.8	25
1090	Feasibility of antiretroviral therapy initiation under the treatâ€all policy under routine conditions: a prospective cohort study from Eswatini. Journal of the International AIDS Society, 2019, 22, e25401.	1.2	10
1091	Temporal trends of population viral suppression in the context of Universal Test and Treat: the ANRS 12249 TasP trial in rural South Africa. Journal of the International AIDS Society, 2019, 22, e25402.	1.2	7
1092	Coauthor Country Affiliations in International Collaborative Research Funded by the US National Institutes of Health, 2009 to 2017. JAMA Network Open, 2019, 2, e1915989.	2.8	9
1093	Algorithmic prediction of HIV status using nation-wide electronic registry data. EClinicalMedicine, 2019, 17, 100203.	3.2	31

#	Article	IF	CITATIONS
1094	The Management of HIV Infection, Opportunistic Infections and Complications of Other Causes of Immunocompromise. , 2019, , 187-209.		0
1095	Safety and efficacy of elvitegravir, dolutegravir, and raltegravir in a real-world cohort of treatment-naÃ-ve and -experienced patients. Medicine (United States), 2019, 98, e16721.	0.4	26
1096	The effect of primary drug resistance on CD4+ cell decline and the viral load set-point in HIV-positive individuals before the start of antiretroviral therapy. Aids, 2019, 33, 315-326.	1.0	4
1097	The benefit of immediate compared with deferred antiretroviral therapy on CD4+ cell count recovery in early HIV infection. Aids, 2019, 33, 1335-1344.	1.0	16
1098	Predictors of Failure to Reach Viral Suppression Within 1 Year After Human Immunodeficiency Virus Diagnosis: A Surveillance-Based Analysis. Sexually Transmitted Diseases, 2019, 46, 728-732.	0.8	1
1099	Temporal changes in ART initiation in adults with high CD4 counts in Latin America: a cohort study. Journal of the International AIDS Society, 2019, 22, e25413.	1.2	4
1100	Challenges of HIV diagnosis and management in the context of preâ€exposure prophylaxis (Prep), postâ€exposure prophylaxis (PEP), test and start and acute HIV infection: a scoping review. Journal of the International AIDS Society, 2019, 22, e25419.	1.2	49
1101	Hyperglycemia and insulin function in antiretroviral treatment-naive HIV patients in Ethiopia. Aids, 2019, 33, 1595-1602.	1.0	7
1102	Sexual and reproductive health considerations among transgender and gender-expansive youth. Current Problems in Pediatric and Adolescent Health Care, 2019, 49, 100684.	0.8	25
1103	How Big Data Science Can Improve Linkage and Retention in Care. Infectious Disease Clinics of North America, 2019, 33, 807-815.	1.9	7
1104	Cost-effectiveness of increased HIV testing among MSM in The Netherlands. Aids, 2019, 33, 1807-1817.	1.0	6
1105	A Patient-Centered Multicomponent Strategy for Accelerated Linkage to Care Following Community-Wide HIV Testing in Rural Uganda and Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 414-422.	0.9	23
1106	Risk Factors for Low CD4+ Count Recovery Despite Viral Suppression Among Participants Initiating Antiretroviral Treatment With CD4+ Counts > 500 Cells/mm3: Findings From the Strategic Timing of AntiRetroviral Therapy (START) Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 10-17.	0.9	13
1107	Treatment as prevention trials and ending AIDS. Current Opinion in HIV and AIDS, 2019, 14, 514-520.	1.5	2
1108	Associations between baseline biomarkers and lung function in HIV-positive individuals. Aids, 2019, 33, 655-664.	1.0	16
1109	Understanding the role of resilience resources, antiretroviral therapy initiation, and HIV-1 RNA suppression among people living with HIV in South Africa. Aids, 2019, 33, S71-S79.	1.0	14
1110	Serious clinical events in HIV-positive persons with chronic kidney disease. Aids, 2019, 33, 2173-2188.	1.0	7
1111	Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 182-189.	0.9	35

#	Article	IF	CITATIONS
1112	Using HIV Surveillance and Clinic Data to Optimize Data to Care Efforts in Community Health Centers in Massachusetts: The Massachusetts Partnerships for Care Project. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, S33-S41.	0.9	11
1113	Short-Term Outcomes and Lessons Learned From the Federal HIV Health Improvement Affinity Group for State Medicaid/Children's Health Insurance Program Agencies and State Health Departments. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, S62-S68.	0.9	1
1114	$Na\tilde{A}^-ve/Effector\ CD4\ T\ cell\ ratio\ as\ a\ useful\ predictive\ marker\ of\ immune\ reconstitution\ in\ late\ presenter\ HIV\ patients:\ A\ multicenter\ study.\ PLoS\ ONE,\ 2019,\ 14,\ e0225415.$	1.1	15
1115	Global variations in mortality in adults after initiating antiretroviral treatment. Aids, 2019, 33, S283-S294.	1.0	16
1116	Virological Outcome of Patients With HIV Drug Resistance Attending an Urban Outpatient Clinic in Uganda: A Need for Structured Adherence Counseling and Third-Line Treatment Options. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 481-487.	0.9	2
1117	Decreases in Self-Reported ART Adherence Predict HIV Viremia Among Pregnant and Postpartum South African Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 247-254.	0.9	14
1118	Rationing of Antiretrovirals. A Step Backward. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, e39-e40.	0.9	0
1119	A generalizable method for estimating duration of HIV infections using clinical testing history and HIV test results. Aids, 2019, 33, 1231-1240.	1.0	18
1120	Beyond one pill, once daily: current challenges of antiretroviral therapy management in the United States. Expert Review of Clinical Pharmacology, 2019, 12, 1129-1143.	1.3	16
1121	CE: HIV Update: An Epidemic Transformed. American Journal of Nursing, 2019, 119, 30-39.	0.2	3
1122	Detecting Disengagement From HIV Care Before It Is Too Late: Development and Preliminary Validation of a Novel Index of Engagement in HIV Care. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 145-152.	0.9	18
1123	Starting Antiretroviral Therapy in Treatment-Naive Persons Living With HIV. Journal of the Association of Nurses in AIDS Care, 2019, 30, 255-258.	0.4	O
1124	Prevalence of hypertension among patients aged 50 and older living with human immunodeficiency virus. Medicine (United States), 2019, 98, e15024.	0.4	11
1125	Impact of an HIV Care Coordination Program on Durable Viral Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 80, 46-55.	0.9	33
1126	ART in HIV-Positive Persons With Low Pretreatment Viremia: Results From the START Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 456-462.	0.9	8
1127	RAPID antiretroviral therapy. Aids, 2019, 33, 825-832.	1.0	83
1128	Risk factors for antiretroviral therapy (ART) discontinuation in a large multinational trial of early ART initiators. Aids, 2019, 33, 1385-1390.	1.0	3
1129	Brief Report: Durability of the Effect of Financial Incentives on HIV Viral Load Suppression and Continuity in Care: HPTN 065 Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 300-303.	0.9	6

#	Article	IF	CITATIONS
1130	No effect of test and treat on sexual behaviours at population level in rural South Africa. Aids, 2019, 33, 709-722.	1.0	3
1131	External validation of a prediction tool to estimate the risk of human immunodeficiency virus infection amongst men who have sex with men. Medicine (United States), 2019, 98, e16375.	0.4	7
1132	Effect of incident hepatitis C infection on CD4+ cell count and HIV RNA trajectories based on a multinational HIV seroconversion cohort. Aids, 2019, 33, 327-337.	1.0	5
1133	Tenofovir concentrations in hair strongly predict virologic suppression in breastfeeding women. Aids, 2019, 33, 1657-1662.	1.0	11
1134	HIV Diagnoses and the HIV Care Continuum Among Women and Girls Aged ≥13 Years–39 States and the District of Columbia, 2015–2016. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 81, 251-256.	0.9	11
1136	Low-level viremia and virologic failure in persons with HIV infection treated with antiretroviral therapy. Aids, 2019, 33, 2005-2012.	1.0	68
1137	Low nadir CD4+ T-cell counts predict gut dysbiosis in HIV-1 infection. Mucosal Immunology, 2019, 12, 232-246.	2.7	56
1138	Association Between Cognitive Tests and Antiretroviral Medication Adherence in Older Adults With HIV. Annals of Pharmacotherapy, 2019, 53, 151-158.	0.9	11
1139	Factors associated with delayed and late ART initiation among people living with HIV in BC: results from the engage study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2019, 31, 885-892.	0.6	9
1140	HIV infection epidemiology: a change of scenery. European Geriatric Medicine, 2019, 10, 169-174.	1.2	4
1141	Why are people with HIV considered "older adults―in their fifties?. European Geriatric Medicine, 2019, 10, 183-188.	1.2	13
1142	Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. Lancet Infectious Diseases, The, 2019, 19, e65-e76.	4.6	35
1143	Rate of cardiovascular, renal and bone disease and their major risks factors in HIV-infected individuals on antiretroviral therapy in Spain. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 373-379.	0.3	21
1144	Dolutegravir Monotherapy Versus Dolutegravir/Abacavir/Lamivudine for Virologically Suppressed People Living With Chronic Human Immunodeficiency Virus Infection: The Randomized Noninferiority MONotherapy of TiviCAY Trial. Clinical Infectious Diseases, 2019, 69, 1498-1505.	2.9	49
1145	Early HIV treatment and labour outcomes: A case study of mining workers in South Africa. Health Economics (United Kingdom), 2019, 28, 204-218.	0.8	6
1146	The Cost-Effectiveness of Financial Incentives for Viral Suppression: HPTN 065 Study. Value in Health, 2019, 22, 194-202.	0.1	20
1147	External quality assessment of point-of-care CD4 testing in Thailand and Southeast Asia. Accreditation and Quality Assurance, 2019, 24, 145-150.	0.4	0
1148	HIV and the liver. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 1-2.	8.2	29

#	Article	IF	CITATIONS
1149	Antiretroviral treatment indications and adherence to the German-Austrian treatment initiation guidelines in the German ClinSurv HIV Cohort between 1999 and 2016. Infection, 2019, 47, 247-255.	2.3	9
1150	Late diagnosis, delayed presentation and late presentation among persons enrolled in a clinical HIV cohort in Ontario, Canada (1999–2013). HIV Medicine, 2019, 20, 110-120.	1.0	27
1151	Hepatitis B assessment without hepatitis B virus DNA quantification: a prospective cohort study in Uganda. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2019, 113, 11-17.	0.7	5
1152	Cardiac Surgery in HIV Patients: State of the Art. Canadian Journal of Cardiology, 2019, 35, 320-325.	0.8	8
1153	Proposing a New Indicator for the National Human Immunodeficiency Virus/AIDS Strategy: Percentage of Newly Diagnosed Persons Achieving Viral Suppression Within 3 Months of Diagnosis. Journal of Infectious Diseases, 2019, 219, 851-855.	1.9	12
1154	It's Time to Make the Time to Viral Suppression After HIV Diagnosis a Metric of HIV Care Success. Journal of Infectious Diseases, 2019, 219, 845-847.	1.9	7
1155	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaÃve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004–2014. HIV Medicine, 2019, 20, 99-109.	1.0	19
1156	A Review of Non-Alcoholic Fatty Liver Disease in HIV-Infected Patients: The Next Big Thing?. Infectious Diseases and Therapy, 2019, 8, 33-50.	1.8	50
1157	Experiences of the HIV Cascade of Care Among Indigenous Peoples: A Systematic Review. AIDS and Behavior, 2019, 23, 984-1003.	1.4	26
1158	A systematic review and cost-effectiveness analyses of the new World Health Organization guidelines for the treatment of HIV-positive adults in India. Medical Journal Armed Forces India, 2019, 75, 31-40.	0.3	5
1159	Trends in HIV care cascade engagement among diagnosed people living with HIV in Ontario, Canada: A retrospective, population-based cohort study. PLoS ONE, 2019, 14, e0210096.	1.1	16
1160	HIV/AIDS in Sierra Leone: Characterizing the Hidden Epidemic. AIDS Reviews, 2019, 20, 104-113.	0.5	16
1161	Simplification of combination antiretroviral therapy (cART) and the brainâ€"a real-life experience. Journal of NeuroVirology, 2019, 25, 174-182.	1.0	8
1162	Impact of three decades of antiretroviral therapy in a longitudinal population cohort study. Antiviral Therapy, 2019, 24, 153-165.	0.6	6
1163	Pérdidas de seguimiento de personas con infección por el VIH en la cohorte española VACH en el periodo 2013-2014: importancia de los factores sociodemográficos. Enfermedades Infecciosas Y MicrobiologÃa ClÃnica, 2019, 37, 361-366.	0.3	6
1164	Reasons for delayed antiretroviral therapy (ART) initiation in the era of early ART initiation guidelines: a retrospective service evaluation. International Journal of STD and AIDS, 2019, 30, 415-418.	0.5	13
1165	Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel. HIV Medicine, 2019, 20, 33-37.	1.0	9
1166	Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trial. Journal of Antimicrobial Chemotherapy, 2019, 74, 480-488.	1.3	1

#	Article	IF	CITATIONS
1167	Epidemiology and Biostatistics. , 2019, , .		11
1168	The ART of Antiretroviral Therapy in Critically Ill Patients With HIV. Journal of Intensive Care Medicine, 2019, 34, 897-909.	1.3	5
1169	Understanding the Time Needed to Link to Care and Start ART in Seven HPTN 071 (PopART) Study Communities in Zambia and South Africa. AIDS and Behavior, 2019, 23, 929-946.	1.4	45
1170	Coronary Artery Disease Manifestations in HIV: What, How, and Why. Canadian Journal of Cardiology, 2019, 35, 270-279.	0.8	26
1171	Prevalence of HIV indicator conditions in late presenting patients with HIV: a missed opportunity for diagnosis?. QJM - Monthly Journal of the Association of Physicians, 2019, 112, 17-21.	0.2	19
1172	Benefit of Early versus Deferred Antiretroviral Therapy on Progression of Liver Fibrosis among People with HIV in the START Randomized Trial. Hepatology, 2019, 69, 1135-1150.	3.6	15
1173	Distribution of HIV Self-tests by HIV-Positive Men Who Have Sex with Men to Social and Sexual Contacts. AIDS and Behavior, 2019, 23, 893-899.	1.4	19
1174	Developing a Patient Navigation Program to Improve Engagement in HIV Medical Care and Viral Suppression: A Demonstration Project Protocol. AIDS and Behavior, 2019, 23, 5-13.	1.4	10
1175	Aging, Health, and Quality of Life for Older People Living With HIV in Sub-Saharan Africa: A Review and Proposed Conceptual Framework. Journal of Aging and Health, 2019, 31, 109-138.	0.9	30
1176	HIV seroprevalence, self-reported STIs and associated risk factors among men who have sex with men: a cross-sectional study in Rwanda, 2015. Sexually Transmitted Infections, 2019, 95, 71-74.	0.8	15
1177	Impact of initiation of combination antiretroviral therapy according to the WHO recommendations on the survival of HIV-positive patients in Taiwan. Journal of Microbiology, Immunology and Infection, 2020, 53, 936-945.	1.5	14
1178	Incentives Versus Defaults: Cost-Effectiveness of Behavioral Approaches for HIV Screening. AIDS and Behavior, 2020, 24, 379-386.	1.4	10
1179	Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clinical Infectious Diseases, 2020, 70, 1636-1642.	2.9	27
1180	Impact of ART-induced viral suppression on the HIV epidemic in Italy. Mathematical Medicine and Biology, 2020, 37, 183-211.	0.8	2
1181	Gender, HIV-Related Stigma, and Health-Related Quality of Life Among Adults Enrolling in HIV Care in Tanzania. AIDS and Behavior, 2020, 24, 142-150.	1.4	21
1182	The current state of qualitative research on sexual functioning with HIV in developed nations: a thematic synthesis. Sexual and Relationship Therapy, 2020, 35, 400-418.	0.7	3
1183	Awareness and Understanding of HIV Non-disclosure Case Law and the Role of Healthcare Providers in Discussions About the Criminalization of HIV Non-disclosure Among Women Living with HIV in Canada. AIDS and Behavior, 2020, 24, 95-113.	1.4	13
1184	Better Virological Outcomes Among People Living With Human Immunodeficiency Virus (HIV) Initiating Early Antiretroviral Treatment (CD4 Counts ≥500 Cells/µL) in the HIV Prevention Trials Network 071 (PopART) Trial in South Africa. Clinical Infectious Diseases, 2020, 70, 395-403.	2.9	12

#	ARTICLE	IF	CITATIONS
1185	RE: "EFFECT ESTIMATES IN RANDOMIZED TRIALS AND OBSERVATIONAL STUDIES: COMPARING APPLES WITH APPLES― American Journal of Epidemiology, 2020, 189, 77-78.	1.6	7
1186	Impact of ART on dynamics of growth factors and cytokines in primary HIV infection. Cytokine, 2020, 125, 154839.	1.4	12
1187	Hospitalization Rates and Outcomes Among Persons Living With Human Immunodeficiency Virus in the Southeastern United States, 1996–2016. Clinical Infectious Diseases, 2020, 71, 1616-1623.	2.9	18
1188	Factors associated with erectile dysfunction among men living with HIV: a systematic review. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 275-285.	0.6	12
1189	Immunodeficiency at Antiretroviral Therapy Start: Five-Year Adult Data (2012–2017) Based on Evolving National Policies in Rural Mozambique. AIDS Research and Human Retroviruses, 2020, 36, 39-47.	0.5	2
1190	Tracking linkage to care in an anonymous HIV testing context: A field assessment in Mozambique. Journal of Evaluation in Clinical Practice, 2020, 26, 1005-1012.	0.9	1
1191	Heart Failure and Human Immunodeficiency Virus. , 2020, , 395-402.e3.		0
1192	Human Immunodeficiency Virus Infection. , 2020, , 232-266.		3
1193	Prospective International Study of Incidence and Predictors of Immune Reconstitution Inflammatory Syndrome and Death in People Living With Human Immunodeficiency Virus and Severe Lymphopenia. Clinical Infectious Diseases, 2020, 71, 652-660.	2.9	44
1195	Short Communication: Early Antiretroviral Therapy Is Associated with Better Viral Suppression and Less HIV Drug Resistance After Implementation of Universal Treatment in South Africa. AIDS Research and Human Retroviruses, 2020, 36, 297-299.	0.5	8
1196	Prevention of HIV Transmission and the HPTN 052 Study. Annual Review of Medicine, 2020, 71, 347-360.	5.0	25
1197	Role of Inflammatory Biomarkers in the Prevalence and Incidence of Hypertension Among HIV-Positive Participants in the START Trial. American Journal of Hypertension, 2020, 33, 43-52.	1.0	6
1198	Safety of tenofovir during pregnancy: early growth outcomes and hematologic side effects in HIV-exposed uninfected infants. European Journal of Pediatrics, 2020, 179, 99-109.	1.3	9
1199	Acceptance and Feasibility of Partner Notification to HIV Infected Individuals in Guinea-Bissau. AIDS and Behavior, 2020, 24, 1476-1485.	1.4	7
1200	HIV testing strategies outside of health care settings in the European Union (EU)/European Economic Area (EEA): a systematic review to inform European Centre for Disease Prevention and Control guidance. HIV Medicine, 2020, 21, 142-162.	1.0	22
1201	HIV in Pregnancy. Journal of Fetal Medicine, 2020, 7, 73-79.	0.1	О
1203	I wanted it as soon as possible: a qualitative exploration of reactions to access to same-day ART start among participants in San Diego's ART-NET project. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 1191-1197.	0.6	8
1204	The rate of bone loss slows after 1–2Âyears of initial antiretroviral therapy: final results of the Strategic Timing of Antiretroviral Therapy (<scp>START</scp>) bone mineral density substudy. HIV Medicine, 2020, 21, 64-70.	1.0	10

#	Article	IF	CITATIONS
1205	Women living with HIV in highâ€income settings and breastfeeding. Journal of Internal Medicine, 2020, 287, 19-31.	2.7	13
1206	A randomized evaluation of on-site monitoring nested in a multinational randomized trial. Clinical Trials, 2020, 17, 3-14.	0.7	16
1207	Incidence and Risk Factors for Invasive Pneumococcal Disease and Community-acquired Pneumonia in Human Immunodeficiency Virus–Infected Individuals in a High-income Setting. Clinical Infectious Diseases, 2020, 71, 41-50.	2.9	28
1208	Review of HIV testing recommendations in Australian specialty guidelines for HIV indicator conditions: a missed opportunity for recommending testing?. Internal Medicine Journal, 2020, 50, 293-298.	0.5	8
1209	Pneumococcal vaccination in adult people living with HIV on suppressive antiretroviral therapy: a case–control study. International Journal of STD and AIDS, 2020, 31, 174-182.	0.5	1
1210	Effect of TDF-containing regimens on creatinine clearance in HIV patients in Namibia with a baseline CrCl <60ml/min; findings and implications. Hospital Practice (1995), 2020, 48, 35-40.	0.5	2
1211	No progression of subclinical atherosclerosis in HIV-infected patients starting an initial regimen including tenofovir alafenamide/emtricitabine plus raltegravir, dolutegravir or elvitegravir/cobicistat during a two-year follow-up. Infectious Diseases, 2020, 52, 249-256.	1.4	1
1212	HIV screening in men and women in Senegal: coverage and associated factors; analysis of the 2017 demographic and health survey. BMC Infectious Diseases, 2020, 20, 1.	1.3	300
1213	Lung Function Decline in Early HIV Infection: Impact of Antiretroviral Drug Timing and Drug Regimen. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 739-741.	2.5	10
1214	Cardiovascular disease risk and its determinants in people living with HIV across different settings in South Africa. HIV Medicine, 2020, 21, 386-396.	1.0	10
1215	Pharmacist impact on the HIV Care Continuum: Decreasing time to care. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 586-592.	0.5	0
1216	Impact of an HIV Care Coordination Program on the Timeliness of Viral Suppression and Immune Recovery Among Clients Newly Diagnosed with HIV. AIDS and Behavior, 2020, 24, 1237-1242.	1.4	8
1217	Factors Associated with General Sexual Functioning and Sexual Satisfaction among People Living with HIV: A Systematic Review. Journal of Sex Research, 2020, 57, 824-835.	1.6	14
1218	Early Antiretroviral Therapy May Preserve Vaccine Responses in Human Immunodeficiency Virus-Infected Patients by Preventing Damage to Long-Lived Plasma Cells. Journal of Infectious Diseases, 2020, 222, 176-179.	1.9	2
1219	Probiotics to manage inflammation in HIV infection. Current Opinion in Infectious Diseases, 2020, 33, 34-43.	1.3	19
1220	Estimates of the Time From Seroconversion to Antiretroviral Therapy Initiation Among People Newly Diagnosed With Human Immunodeficiency Virus From 2006 to 2015, New York City. Clinical Infectious Diseases, 2020, 71, e308-e315.	2.9	9
1221	Plasma tissue factor and immune activation are associated with carotid intima–media thickness progression in treated HIV infection. Aids, 2020, 34, 519-528.	1.0	4
1222	HIV treatment and prevention 2019. Current Opinion in HIV and AIDS, 2020, 15, 4-12.	1.5	52

#	Article	IF	CITATIONS
1223	Rapid Initiation of Antiretroviral Therapy Following Diagnosis of Human Immunodeficiency Virus Among Patients with Commercial Insurance Coverage. Journal of Managed Care & Decialty Pharmacy, 2020, 26, 129-141.	0.5	2
1224	Developing a Typology of HIV/STI Testing Patterns Among Gay, Bisexual, and Queer Men: A Framework to Guide Interventions. Qualitative Health Research, 2020, 30, 610-621.	1.0	4
1225	Long-Term Benefits of Rapid Antiretroviral Therapy Initiation in Reducing Medical and Overall Health Care Costs Among Medicaid-Covered Patients with Human Immunodeficiency Virus. Journal of Managed Care & Decialty Pharmacy, 2020, 26, 117-128.	0.5	1
1226	Immune Status and Associated Mortality After Cancer Treatment Among Individuals With HIV in the Antiretroviral Therapy Era. JAMA Oncology, 2020, 6, 227.	3.4	23
1227	Association between quality-of-care indicators for HIV infection and healthcare resource utilization and costs. Aids, 2020, 34, 291-300.	1.0	1
1228	The Time Is Now to End the HIV Epidemic. American Journal of Public Health, 2020, 110, 22-24.	1.5	47
1229	Patterns of presentation and survival of HIVâ€infected patients admitted to a tertiaryâ€level intensive care unit. HIV Medicine, 2020, 21, 334-341.	1.0	11
1230	Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry. Open Forum Infectious Diseases, 2020, 7, ofaa456.	0.4	16
1231	Changes in the HIV continuum of care following expanded access to HIV testing and treatment in Indonesia: A retrospective population-based cohort study. PLoS ONE, 2020, 15, e0239041.	1.1	3
1232	The Role of Human Immunodeficiency Virus Molecular Diagnostics in Ending the Epidemic. Advances in Molecular Pathology, 2020, 3, 97-105.	0.2	1
1233	Why do AIDS Sufferers on Antiretroviral Therapy Die Early?—Evidence from Jharkhand in India. Research in the Sociology of Health Care, 2020, , 199-216.	0.1	0
1234	Practical Guidance for the Evaluation and Management of Drug Hypersensitivity: Specific Drugs. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, S16-S116.	2.0	107
1235	Outcomes of Coronavirus Disease 2019 (COVID-19) Related Hospitalization Among People With Human Immunodeficiency Virus (HIV) in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK): A Prospective Observational Study. Clinical Infectious Diseases, 2021, 73, e2095-e2106.	2.9	218
1236	Non-uptake of viral load testing among people receiving HIV treatment in Gomba district, rural Uganda. BMC Infectious Diseases, 2020, 20, 727.	1.3	10
1237	Impact of Pharmacy Type on HIV Viral Suppression: A Retrospective Cross-Sectional Cohort Study. Open Forum Infectious Diseases, 2020, 7, ofaa351.	0.4	0
1238	Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?. Clinical Infectious Diseases, 2020, 71, 2905-2916.	2.9	16
1239	Quantifying the reduction in sexual transmission of HIV-1 among MSM by early initiation of ART: A mathematical model. PLoS ONE, 2020, 15, e0236032.	1.1	2
1240	Population-level viral suppression among pregnant and postpartum women in a universal test and treat trial. Aids, 2020, 34, 1407-1415.	1.0	4

#	Article	IF	CITATIONS
1241	Social Support is Key to Retention in Care during Covid-19 Pandemic among Older People with HIV and Substance Use Disorders in Ukraine. Substance Use and Misuse, 2020, 55, 1902-1904.	0.7	23
1242	Effect of AIDS-defining events at initiation of antiretroviral therapy on long-term mortality of HIV/AIDS patients in Southwestern China: a retrospective cohort study. AIDS Research and Therapy, 2020, 17, 44.	0.7	3
1243	Trends and causes of mortality in a population-based cohort of HIV-infected adults in Spain: comparison with the general population. Scientific Reports, 2020, 10, 8922.	1.6	39
1244	Assessing the psychometric properties of the French WHOQOL-HIV BREF within the ANRS CO3 Aquitaine Cohort's QuAliV ancillary study. Health and Quality of Life Outcomes, 2020, 18, 220.	1.0	6
1245	Prevalence of and factors associated with advanced HIV disease among newly diagnosed people living with HIV in Guangdong Province, China. Journal of the International AIDS Society, 2020, 23, e25642.	1.2	10
1246	The last Black man with HIV in San Francisco: the potential role of gentrification on HIV getting to zero achievements. Lancet HIV,the, 2020, 7, e853-e856.	2.1	7
1248	Effectiveness of same-day antiretroviral therapy initiation in retention outcomes among people living with human immunodeficiency virus in Ethiopia: empirical evidence. BMC Public Health, 2020, 20, 1802.	1.2	8
1249	HIV stigma in UK press reporting of a case of intentional HIV transmission. Health (United Kingdom), 2022, 26, 319-337.	0.9	7
1250	Clinical Effectiveness of Integrase Strand Transfer Inhibitor–Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada. Clinical Infectious Diseases, 2020, 73, e1408-e1414.	2.9	6
1251	Characteristics of suboptimal immune response after initiating antiretroviral therapy among people living with HIV with a pre-treatment CD4 T cell count <200Aâ€∢cells/mm3 in Thailand. Journal of Virus Eradication, 2020, 6, 100005.	0.3	7
1252	A mathematical model to estimate the state-specific impact of the Health Resources and Services Administration's Ryan White HIV/AIDS Program. PLoS ONE, 2020, 15, e0234652.	1.1	3
1253	Association between cellular HIV-1 DNA level and mortality in HIV-1 infected African adults starting ART with high CD4 counts. EBioMedicine, 2020, 56, 102815.	2.7	7
1254	Sociodemographic and psychosocial predictors of longitudinal antiretroviral therapy (ART) adherence among first-time ART initiators in Cape Town, South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 1394-1403.	0.6	7
1255	Methamphetamine and cardiac disease among people with HIV infection. HIV Medicine, 2020, 21, 635-641.	1.0	1
1256	Unique Needs for the Implementation of Emergency Department Human Immunodeficiency Virus Screening in Adolescents. Academic Emergency Medicine, 2020, 27, 984-994.	0.8	3
1257	Population uptake of HIV testing, treatment, viral suppression, and male circumcision following a community-based intervention in Botswana (Ya Tsie/BCPP): a cluster-randomised trial. Lancet HIV,the, 2020, 7, e422-e433.	2.1	17
1258	Trends and Sex Differences in Access to HIV Care with Scale Up of National HIV Treatment Guidelines in Pune, India. Journal of the International Association of Providers of AIDS Care, 2020, 19, 232595822093173.	0.6	1
1259	Periconceptional exposure to lopinavir, but not darunavir, impairs decidualization: a potential mechanism leading to poor birth outcomes in HIV-positive pregnancies. Human Reproduction, 2020, 35, 1781-1796.	0.4	16

#	Article	IF	CITATIONS
1260	Sexual risk and HIV testing disconnect in men who have sex with men (MSM) recruited to an online HIV selfâ€testing trial. HIV Medicine, 2020, 21, 588-598.	1.0	7
1261	Early Treatment of COVID-19 Disease: A Missed Opportunity. Infectious Diseases and Therapy, 2020, 9, 715-720.	1.8	18
1262	Substantial decline in heavily treated therapy-experienced persons with HIV with limited antiretroviral treatment options. Aids, 2020, 34, 2051-2059.	1.0	16
1263	Potential Contributions of Clinical and Community Testing in Identifying Persons with Undiagnosed HIV Infection in the United States. Journal of the International Association of Providers of AIDS Care, 2020, 19, 232595822095090.	0.6	1
1264	Sustained, Low Prevalence of Undiagnosed HIV Among Gay and Bisexual Men in Sydney, Australia Coincident With Increased Testing and Pre-exposure Prophylaxis Use: Results From Repeated, Bio-Behavioral Studies 2014–2018. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, e41-e47.	0.9	O
1265	Use of awareness raising campaigns to expand HIV testing: experiences in the Bronx, NY and Washington, DC (HPTN 065 study). Journal of Social Marketing, 2020, 10, 339-356.	1.3	3
1266	Estimating the burden of HIV late presentation and its attributable morbidity and mortality across Europe 2010–2016. BMC Infectious Diseases, 2020, 20, 728.	1.3	46
1267	Acute and early HIV infection screening among men who have sex with men, a systematic review and metaâ€analysis. Journal of the International AIDS Society, 2020, 23, e25590.	1.2	12
1268	Pharmacist's role in HIV care in France. Implication for clinical improvement of people living with HIV worldwide. Pharmacology Research and Perspectives, 2020, 8, e00629.	1.1	5
1269	Potency and timing of antiviral therapy as determinants of duration of SARS-CoV-2 shedding and intensity of inflammatory response. Science Advances, 2020, 6, .	4.7	128
1270	Impact of Age and HIV Status on Immune Activation, Senescence and Apoptosis. Frontiers in Immunology, 2020, 11, 583569.	2.2	11
1271	New strategies for prevention of HIV among Japanese men who have sex with men: a mathematical model. Scientific Reports, 2020, 10, 18187.	1.6	10
1272	Assisters Succeed in Insurance Navigation for People Living with HIV and People at Increased Risk of HIV in a Complex Coverage Landscape. AIDS Research and Human Retroviruses, 2020, 36, 842-851.	0.5	4
1273	Outcomes After Being Lost to Follow-up Differ for Pregnant and Postpartum Women When Compared With the General HIV Treatment Population in Rural South Africa. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 127-137.	0.9	9
1274	A model for bringing TB expertise to HIV providers: Medical consultations to the CDC-funded Regional Tuberculosis Training and Medical Consultation Centers, 2013–2017. PLoS ONE, 2020, 15, e0236933.	1.1	0
1275	Trends in Time From HIV Diagnosis to First Viral Suppression Following Revised US HIV Treatment Guidelines, 2012–2017. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 85, 46-50.	0.9	9
1276	Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort. HIV Medicine, 2020, 21, 613-615.	1.0	6
1277	Global prevalence and burden of HIV-associated neurocognitive disorder. Neurology, 2020, 95, e2610-e2621.	1.5	172

#	Article	IF	CITATIONS
1278	The burden of HIV infection among men who purchase sex in low- and middle-income countries $\hat{a} \in \text{``a}$ systematic review and meta-analysis. PLoS ONE, 2020, 15, e0238639.	1.1	5
1279	Evaluation of HIV-specific T-cell responses in HIV-infected older patients with controlled viremia on long-term antiretroviral therapy. PLoS ONE, 2020, 15, e0236320.	1.1	8
1280	Asymptomatic Adolescent HIV: Identifying a Role for Universal HIV Screening in the Pediatric Emergency Department. AIDS Patient Care and STDs, 2020, 34, 373-379.	1.1	13
1281	The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy. Viruses, 2020, 12, 934.	1.5	9
1282	HIV-1 Integrase Inhibitors: A Comparative Review of Efficacy and Safety. Drugs, 2020, 80, 1649-1676.	4.9	62
1283	Cognitive and Neurologic Rehabilitation Strategies for Central Nervous System HIV Infection. Current HIV/AIDS Reports, 2020, 17, 514-521.	1.1	10
1284	First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines. Aids, 2020, 34, 1823-1831.	1.0	11
1285	Early Antiretroviral Therapy Prevents Viral Infection of Monocytes and Inflammation in Simian Immunodeficiency Virus-Infected Rhesus Macaques. Journal of Virology, 2020, 94, .	1.5	7
1286	Implementation of Universal HIV Testing and Treatment to Reduce HIV Incidence in Botswana: the Ya Tsie Study. Current HIV/AIDS Reports, 2020, 17, 478-486.	1.1	6
1287	Implementing Rapid Initiation of Antiretroviral Therapy for Acute HIV Infection Within a Routine Testing and Linkage to Care Program in Chicago. Journal of the International Association of Providers of AIDS Care, 2020, 19, 232595822093975.	0.6	7
1288	The Changing Landscape of Lymphoma Associated with HIV Infection. Current Oncology Reports, 2020, 22, 111.	1.8	10
1289	"Protective Oxygen Therapy―for Critically III Patients. Chest, 2020, 158, 1286-1287.	0.4	0
1290	Critically Ill and Newly Diagnosed HIV Patients. Chest, 2020, 158, 1285-1286.	0.4	0
1291	What we talk about when we talk about durable viral suppression. Aids, 2020, 34, 1683-1686.	1.0	5
1292	Variation in estimated viral suppression associated with the definition of viral suppression used. Aids, 2020, 34, 1519-1526.	1.0	15
1293	Metabolic syndrome and 10-year cardiovascular risk among HIV-positive and HIV-negative adults. Medicine (United States), 2020, 99, e20845.	0.4	21
1294	ART uptake and adherence among female sex workers (FSW) globally: A scoping review. Global Public Health, 2022, 17, 254-284.	1.0	11
1295	Primary Care Guidance for Persons With Human Immunodeficiency Virus: 2020 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases, 2021, 73, e3572-e3605.	2.9	123

#	Article	IF	CITATIONS
1296	Immunogenicity of pneumococcal vaccination in HIV infected individuals: A systematic review and meta-analysis. EClinicalMedicine, 2020, 29-30, 100576.	3.2	17
1297	Temporal trends of early mortality and its risk factors in HIV-infected adults initiating antiretroviral therapy in Uganda. EClinicalMedicine, 2020, 28, 100600.	3.2	6
1298	Investigation of the efficacy of the short regimen for rifampicin-resistant TB from the STREAM trial. BMC Medicine, 2020, 18, 314.	2.3	7
1300	Adapting HIV services for pregnant and breastfeeding women, infants, children, adolescents and families in resourceâ€constrained settings during the COVIDâ€19 pandemic. Journal of the International AIDS Society, 2020, 23, e25622.	1.2	24
1301	Association of Viral Persistence and Atherosclerosis in Adults With Treated HIV Infection. JAMA Network Open, 2020, 3, e2018099.	2.8	20
1302	Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study. Emerging Microbes and Infections, 2020, 9, 2550-2561.	3.0	23
1303	Immediate Antiretroviral Therapy: The Need for a Health Equity Approach. International Journal of Environmental Research and Public Health, 2020, 17, 7345.	1.2	7
1304	HIV, aging, and adherence. Current Opinion in HIV and AIDS, 2020, 15, 134-141.	1.5	10
1305	Treatment advantage in HBV/HIV coinfection compared to HBV monoinfection in a South African cohort. Journal of Infection, 2020, 81, 121-130.	1.7	16
1306	Antiretroviral therapy improves neurocognitive impairment in people living with HIV? A meta-analysis. International Journal of Nursing Sciences, 2020, 7, 238-247.	0.5	11
1307	Reduction of anti-HIV antibody responses in subjects receiving antiretroviral therapy during chronic HIV-1 infection. Journal of Clinical Virology, 2020, 128, 104414.	1.6	3
1308	The effect of "universal test and treat―program on HIV treatment outcomes and patient survival among a cohort of adults taking antiretroviral treatment (ART) in low income settings of Gurage zone, South Ethiopia. AIDS Research and Therapy, 2020, 17, 19.	0.7	31
1309	Uptake and acceptability of assisted and unassisted HIV self-testing among men who purchase sex in brothels in Indonesia: a pilot intervention study. BMC Public Health, 2020, 20, 730.	1.2	18
1311	Effects of Early and Delayed Antiretroviral Therapy on Plasma Anti-CD4 Autoreactive IgG and Its Association With CD4+ T-Cell Recovery in Acute HIV-Infected Individuals. Frontiers in Pharmacology, 2020, 11, 449.	1.6	11
1312	The Changing Global Epidemic of HIV and Ocular Disease. Ocular Immunology and Inflammation, 2020, 28, 1007-1014.	1.0	7
1313	Benefits of antiretroviral therapy initiation during acute HIV infection. Acta Clinica Belgica, 2022, 77, 168-176.	0.5	10
1314	HIV-related outcome disparities between transgender women living with HIV and cisgender people living with HIV served by the Health Resources and Services Administration's Ryan White HIV/AIDS Program: A retrospective study. PLoS Medicine, 2020, 17, e1003125.	3.9	35
1315	A pilot randomized trial of incentive strategies to promote HIV retesting in rural Uganda. PLoS ONE, 2020, 15, e0233600.	1.1	12

#	Article	IF	CITATIONS
1316	Mortality under early access to antiretroviral therapy vs . Eswatini's national standard of care: the MaxART clustered randomized steppedâ€wedge trial. HIV Medicine, 2020, 21, 429-440.	1.0	5
1317	The HIV care continuum and HIV-1 drug resistance among female sex workers: a key population in Guinea-Bissau. AIDS Research and Therapy, 2020, 17, 33.	0.7	8
1318	Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016. JAMA Network Open, 2020, 3, e207954.	2.8	299
1319	Pregnancy Outcomes of Women Conceiving on Antiretroviral Therapy (ART) Compared to Those Commenced on ART During Pregnancy. Clinical Infectious Diseases, 2021, 73, e312-e320.	2.9	18
1320	Early scale-up of antiretroviral therapy at diagnosis for reducing economic burden of cardiometabolic disease in HIV-infected population. Aids, 2020, 34, 903-911.	1.0	2
1321	Toll-like receptor distribution in colonic epithelium and lamina propria is disrupted in HIV viremic, immune success, and failure. Aids, 2020, 34, 815-826.	1.0	6
1322	Retrospective analysis of HIV-1 drug resistance mutations in Suzhou, China from 2009 to 2014. Virus Genes, 2020, 56, 557-563.	0.7	2
1323	Gone But Not Lost. Epidemiology, 2020, 31, 570-577.	1.2	8
1324	Maintenance of Viral Suppression in Human Immunodeficiency Virus Controllers Despite Waning T-Cell Responses During Antiretroviral Therapy. Journal of Infectious Diseases, 2020, 222, 1837-1842.	1.9	3
1325	An Early Test-and-Treat Strategy for Severe Acute Respiratory Syndrome Coronavirus 2. Open Forum Infectious Diseases, 2020, 7, ofaa232.	0.4	16
1326	Empirical Antituberculosis Therapy in Advanced HIV Disease — Too Much, Too Late. New England Journal of Medicine, 2020, 382, 2459-2460.	13.9	3
1327	Implementation opportunities and challenges identified by key stakeholders in scaling up HIV Treatment as Prevention in British Columbia, Canada: a qualitative study. Implementation Science Communications, 2020, 1, 54.	0.8	4
1328	Antiretroviral Adherence, Drug Resistance, and the Impact of Social Determinants of Health in HIV-1 Patients in the US. AIDS and Behavior, 2020, 24, 3562-3573.	1.4	29
1329	HIV Treatment Outcomes Among Patients Initiated on Antiretroviral Therapy Pre and Post-Universal Test and Treat Guidelines in South Africa. Therapeutics and Clinical Risk Management, 2020, Volume 16, 169-180.	0.9	25
1330	Prospective assessment of loss to followâ€up: incidence and associated factors in a cohort of HIVâ€positive adults in rural Tanzania. Journal of the International AIDS Society, 2020, 23, e25460.	1,2	18
1332	Absence of peripapillary retinal nerve-fiber–layer thinning in combined antiretroviral therapy-treated, well-sustained aviremic persons living with HIV. PLoS ONE, 2020, 15, e0229977.	1.1	3
1333	Understanding why people who inject drugs in Indonesia are disengaged from HIV testing and treatment: gaps in the HIV treatment cascade. Journal of Substance Use, 2020, 25, 398-404.	0.3	1
1334	Human Immunodeficiency Virus in Adolescents. Primary Care - Clinics in Office Practice, 2020, 47, 351-365.	0.7	O

#	Article	IF	CITATIONS
1335	Delays in HIV and TB diagnosis and treatment initiation in co-infected patients in Colombia. International Journal of STD and AIDS, 2020, 31, 410-419.	0.5	3
1336	Enrollment and transition challenges in the International Maternal Pediatric and Adolescent AIDS Clinical Trials (IMPAACT) network's PROMISE trial for resource-limited regions. Clinical Trials, 2020, 17, 437-447.	0.7	5
1337	Increases in HIV Testing Frequency in Australian Gay and Bisexual Men are Concentrated Among PrEP Users: An Analysis of Australian Behavioural Surveillance Data, 2013–2018. AIDS and Behavior, 2020, 24, 2691-2702.	1.4	16
1338	Estimated dates of detectable infection (EDDIs) as an improvement upon Fiebig staging for HIV infection dating. Epidemiology and Infection, 2020, 148, e53.	1.0	5
1339	Current and future treatments for tuberculosis. BMJ, The, 2020, 368, m216.	3.0	43
1340	Monitoring progress towards the first UNAIDS 90-90-90 target in key populations living with HIV in Norway. BMC Infectious Diseases, 2020, 20, 451.	1.3	5
1341	Who Accepts and Who Uses Community-Based Secondary Distribution HIV Self-Testing (HIVST) Kits? Findings From the Intervention Arm of a Cluster-Randomized Trial of HIVST Distribution Nested in Four HPTN 071 (PopART) Communities in Zambia. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 355-364.	0.9	16
1342	Associations Between Plasma Immunomodulatory and Inflammatory Mediators With VACS Index Scores Among Older HIV-Infected Adults on Antiretroviral Therapy. Frontiers in Immunology, 2020, 11, 1321.	2.2	15
1343	Initiation of Antiretroviral Therapy in the Hospital Is Associated With Linkage to Human Immunodeficiency Virus (HIV) Care for Persons Living With HIV and Substance Use Disorder. Clinical Infectious Diseases, 2020, 73, e1982-e1990.	2.9	0
1344	Prevalence of Potential Drug–Drug Interactions in Patients of the Swiss HIV Cohort Study in the Era of HIV Integrase Inhibitors. Clinical Infectious Diseases, 2021, 73, e2145-e2152.	2.9	9
1345	Vitamin D and Calcium Supplement Attenuate Bone Loss among HIVInfected Patients Receiving Tenofovir Disoproxil Fumarate/Emtricitabine/ Efavirenz: An Open-Label, Randomized Controlled Trial. Current HIV Research, 2020, 18, 52-62.	0.2	4
1346	Populationâ€wide differentials in HIV service access and outcomes in the Western Cape for men as compared to women, South Africa: 2008 to 2018: a cohort analysis. Journal of the International AIDS Society, 2020, 23, e25530.	1.2	32
1347	Health care issues affecting transgender people living with HIV: an opportunity for improvement. International Journal of STD and AIDS, 2020, 31, 859-865.	0.5	0
1348	Cognitive disorders in people living with HIV. Lancet HIV, the, 2020, 7, e504-e513.	2.1	78
1349	Continuous quality monitoring in the field: an evaluation of the performance of the Fio Deki Readerâ,,¢ for rapid HIV testing in South Africa. BMC Infectious Diseases, 2020, 20, 320.	1.3	4
1350	Prevention of cardiovascular disease among people living with HIV in sub-Saharan Africa. Progress in Cardiovascular Diseases, 2020, 63, 149-159.	1.6	23
1351	HIV-related cardiovascular diseases: the search for a unifying hypothesis. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 318, H731-H746.	1.5	27
1352	A primer on strong vs weak control of familywise error rate. Statistics in Medicine, 2020, 39, 1407-1413.	0.8	10

#	Article	IF	CITATIONS
1353	Individual, interpersonal, and situational factors influencing HIV and other STI risk perception among gay, bisexual, and other men who have sex with men: a qualitative study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 1538-1543.	0.6	6
1354	Predictors of Viremia in Postpartum Women on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 72-80.	0.9	5
1356	Decreasing time to antiretroviral therapy initiation after HIV diagnosis in a clinicâ€based observational cohort study in four African countries. Journal of the International AIDS Society, 2020, 23, e25446.	1.2	16
1357	Opportunities and Challenges in HIV Treatment as Prevention Research: Results from the ANRS 12249 Cluster-Randomized Trial and Associated Population Cohort. Current HIV/AIDS Reports, 2020, 17, 97-108.	1.1	10
1358	What do the Universal Test and Treat trials tell us about the path to HIV epidemic control?. Journal of the International AIDS Society, 2020, 23, e25455.	1.2	96
1359	Closing the Stable Door After the Horse Has Bolted: Should We Be Treating People With Immune-Tolerant Chronic Hepatitis B to Prevent Hepatocellular Carcinoma?. Gastroenterology, 2020, 158, 2028-2032.	0.6	8
1360	Factor Xa Inhibition Reduces Coagulation Activity but Not Inflammation Among People With HIV: A Randomized Clinical Trial. Open Forum Infectious Diseases, 2020, 7, ofaa026.	0.4	10
1361	Association of antiretroviral therapy with anal high-risk human papillomavirus, anal intraepithelial neoplasia, and anal cancer in people living with HIV: a systematic review and meta-analysis. Lancet HIV,the, 2020, 7, e262-e278.	2.1	46
1362	HIV treatment and anal cancer: emerging clarity. Lancet HIV,the, 2020, 7, e220-e221.	2.1	3
1363	To start or to complete? – Challenges in implementing tuberculosis preventive therapy among people living with HIV: a mixed-methods study from Karnataka, India. Global Health Action, 2020, 13, 1704540.	0.7	14
1364	HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study. AIDS Research and Therapy, 2020, 17, 6.	0.7	5
1365	Emerging priorities for HIV service delivery. PLoS Medicine, 2020, 17, e1003028.	3.9	39
1366	Optimizing Treatment for Adults with HIV/AIDS in China: Successes over Two Decades and Remaining Challenges. Current HIV/AIDS Reports, 2020, 17, 26-34.	1.1	83
1367	Antenatal Intracellular Concentrations of Tenofovir Diphosphate and Emtricitabine Triphosphate and Associations Between Tenofovir Diphosphate and Severe Adverse Pregnancy Outcomes: IMPAACT-PROMISE (1077BF) Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 173-180.	0.9	6
1368	Impact of an Antimicrobial Stewardship Team on Reducing Antiretroviral Medication Errors. Annals of Pharmacotherapy, 2020, 54, 767-774.	0.9	3
1369	Impact of Genetic and Nongenetic Factors on Body Mass Index and Waist-Hip Ratio Change in HIV-Infected Individuals Initiating Antiretroviral Therapy. Open Forum Infectious Diseases, 2020, 7, ofz464.	0.4	7
1370	Cancer during HIV infection. Apmis, 2020, 128, 121-128.	0.9	12
1371	Necessary but Not Sufficient: The Need for Innovative Strategies to Enhance Retention and Viral Suppression After Rapid Initiation of Antiretroviral Therapy. Clinical Infectious Diseases, 2020, 71, 2615-2617.	2.9	2

#	Article	IF	Citations
1372	Frequency and Predictors of HIV-Related Cognitive Impairment in East Africa: The Africa Cohort Study (AFRICOS). Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 157-164.	0.9	9
1373	Human Immunodeficiency Virus (HIV)-Negative Men Who Have Sex With Men Have Higher CD8+ T-Cell Counts and Lower CD4+/CD8+ T-Cell Ratios Compared With HIV-Negative Heterosexual Men. Journal of Infectious Diseases, 2021, 224, 1187-1197.	1.9	8
1374	The impact of short term Antiretroviral Therapy (ART) interruptions on longer term maternal health outcomesâ€"A randomized clinical trial. PLoS ONE, 2020, 15, e0228003.	1.1	3
1375	Pericardial Adipose Tissue Volume Is Independently Associated With Human Immunodeficiency Virus Status and Prior Use of Stavudine, Didanosine, or Indinavir. Journal of Infectious Diseases, 2020, 222, 54-61.	1.9	9
1376	Cardiovascular disease in HIV patients: recent advances in predicting and managing risk. Expert Review of Anti-Infective Therapy, 2020, 18, 677-688.	2.0	17
1377	Sustainability of the streamlined ART (START-ART) implementation intervention strategy among ART-eligible adult patients in HIV clinics in public health centers in Uganda: a mixed methods study. Implementation Science Communications, 2020, 1, 37.	0.8	6
1378	The HIV Continuum of Care for Adolescents and Young Adults Attending 13 Urban US HIV Care Centers of the NICHD-ATN-CDC-HRSA SMILE Collaborative. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, 92-100.	0.9	46
1379	The safety and efficacy of immune checkpoint inhibitors in patients with advanced cancers and pre-existing chronic viral infections (Hepatitis B/C, HIV): A review of the available evidence. Cancer Treatment Reviews, 2020, 86, 102011.	3.4	31
1380	HIV treatment outcomes among people with initiation CD4 counts >500Âcells/µL after implementation of <i>Treat All</i> in South African public clinics: a retrospective cohort study. Journal of the International AIDS Society, 2020, 23, e25479.	1.2	9
1381	Rapid point-of-care CD4 testing at mobile units and linkage to HIV care: an evaluation of community-based mobile HIV testing services in South Africa. BMC Public Health, 2020, 20, 528.	1.2	5
1382	Impact of the test and treat policy on delays in antiretroviral therapy initiation among adult HIV positive patients from six clinics in Johannesburg, South Africa: results from a prospective cohort study. BMJ Open, 2020, 10, e030228.	0.8	25
1383	The Role of Human Immunodeficiency Virus (HIV) Asymptomatic Status When Starting Antiretroviral Therapy on Adherence and Treatment Outcomes and Implications for Test and Treat: The Swiss HIV Cohort Study. Clinical Infectious Diseases, 2021, 72, 1413-1421.	2.9	2
1384	Association of adherence to antiretroviral therapy with economic burden of cardiovascular disease in HIV-infected population. European Journal of Preventive Cardiology, 2021, 28, 326-334.	0.8	6
1385	Prevention of HIV transmission with sperm washing within fertile serodiscordant couples undergoing non-stimulated intrauterine insemination. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 478-485.	0.6	4
1386	Hepatotoxicity and Liver-Related Mortality in Women of Childbearing Potential Living With Human Immunodeficiency Virus and High CD4 Cell Counts Initiating Efavirenz-Containing Regimens. Clinical Infectious Diseases, 2021, 72, 1342-1349.	2.9	4
1387	Poor rates of linkage to HIV care and uptake of treatment after home-based HIV testing among newly diagnosed 15-to-49 year-old men and women in a high HIV prevalence setting in South Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 70-79.	0.6	13
1388	Clinical and Immunologic Outcomes After Immediate or Deferred Antiretroviral Therapy Initiation During Primary Human Immunodeficiency Virus Infection: The <i>Sabes</i> Randomized Clinical Study. Clinical Infectious Diseases, 2021, 72, 1042-1050.	2.9	15
1389	Using a Modeling-Based Approach to Assess and Optimize HIV Linkage to Care Services. AIDS and Behavior, 2021, 25, 886-896.	1.4	2

#	ARTICLE	IF	CITATIONS
1390	Timing of Antiretroviral Therapy Initiation and Risk of Cancer Among Persons Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 72, 1900-1909.	2.9	22
1391	Development and Validation of a Sociodemographic and Behavioral Characteristics-Based Risk-Score Algorithm for Targeting HIV Testing Among Adults in Kenya. AIDS and Behavior, 2021, 25, 297-310.	1.4	10
1392	Starting or Switching to an Integrase Inhibitor-Based Regimen Affects PTSD Symptoms in Women with HIV. AIDS and Behavior, 2021, 25, 225-236.	1.4	3
1393	Potential interactions between the pathways to diagnosis of HIV and other STIs and HIV self-testing: insights from a qualitative study of gay, bisexual and other men who have sex with men in Singapore. Sexually Transmitted Infections, 2021, 97, 215-220.	0.8	1
1394	Impact of HIV infection on aging and immune status. Expert Review of Anti-Infective Therapy, 2021, 19, 719-731.	2.0	10
1395	Increased CD4 : CD8 ratio normalization with implementation of current ART management guidelines. Journal of Antimicrobial Chemotherapy, 2021, 76, 729-737.	1.3	8
1396	Outreach HIV testing using oral fluid and online consultation of the results: Pilot intervention in Catalonia. Enfermedades Infecciosas Y Microbiologia Clinica (English Ed), 2021, 39, 3-8.	0.2	2
1397	Universal test and treat in relation to HIV disease progression: results from a steppedâ€wedge trial in Eswatini. HIV Medicine, 2021, 22, 54-59.	1.0	0
1398	Risk of Tumor Onset in HIV+ Patients on Two-Drug Regimens: A Cohort Study in an Italian Hospital. AIDS Research and Human Retroviruses, 2021, 37, 350-356.	0.5	0
1399	The investigation of diabetes in people living with HIV: A systematic review. Diabetic Medicine, 2021, 38, e14454.	1.2	6
1400	Trauma exposure, PTSD, and suboptimal HIV medication adherence among marginalized individuals connected to public HIV care in Miami. Journal of Behavioral Medicine, 2021, 44, 147-158.	1.1	11
1401	Experiences Receiving HIV-Positive Results by Phone: Acceptability and Implications for Clinical and Behavioral Research. AIDS and Behavior, 2021, 25, 709-720.	1.4	9
1402	Utility of CD4 count measurement in the era of universal antiretroviral therapy: an analysis of routine laboratory data in Botswana. HIV Medicine, 2021, 22, 1-10.	1.0	16
1403	Patterns of Prescribing Antiretroviral Therapy Upon Discharge to Psychiatry Inpatients With HIV/AIDS at a Large Urban Hospital. Annals of Pharmacotherapy, 2021, 55, 452-458.	0.9	4
1404	Comparative effectiveness of antiretroviral drug classes for the treatment of HIV infection in patients with high viral loads: a multicentre retrospective cohort study. HIV Medicine, 2021, 22, 28-36.	1.0	1
1405	Occurrence of Accelerated Epigenetic Aging and Methylation Disruptions in Human Immunodeficiency Virus Infection Before Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 223, 1681-1689.	1.9	19
1406	Abnormal Levels of Some Biomarkers of Immune Activation Despite Very Early Treatment of Human Immunodeficiency Virus. Journal of Infectious Diseases, 2021, 223, 1621-1630.	1.9	20
1407	The Impact of Antiretroviral Therapy on Neurocognitive Outcomes Among People Living with HIV in Low- and Middle-Income Countries (LMICs): A Systematic Review. AIDS and Behavior, 2021, 25, 492-523.	1.4	11

#	Article	IF	CITATIONS
1408	Tying Structural Racism to Human Immunodeficiency Virus Viral Suppression. Clinical Infectious Diseases, 2021, 72, e646-e648.	2.9	13
1409	Cryptococcal Immune Reconstitution Inflammatory Syndrome: From Blood and Cerebrospinal Fluid Biomarkers to Treatment Approaches. Life, 2021, 11, 95.	1.1	11
1410	Conditional expanding post-exposure prophylaxis: a potential new tool for tuberculosis control. ERJ Open Research, 2021, 7, 00723-2020.	1.1	0
1411	Molecular Transmission Dynamics of Primary HIV Infections in Lazio Region, Years 2013–2020. Viruses, 2021, 13, 176.	1.5	4
1412	Quality of antiretroviral therapy services in Ghana: Implications for the HIV response in resource-constrained settings. SAGE Open Medicine, 2021, 9, 205031212110361.	0.7	8
1413	Poor quality of life and incomplete self-reported adherence predict second-line ART virological failure in resource-limited settings. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2021, 33, 1340-1349.	0.6	1
1414	Hematological parameters abnormalities and associated factors in HIV-positive adults before and after highly active antiretroviral treatment in Goba Referral Hospital, southeast Ethiopia: A cross-sectional study. SAGE Open Medicine, 2021, 9, 205031212110201.	0.7	8
1415	Inflammation and kidney involvement in human viral diseases caused by SARS-CoV-2, HIV, HCV and HBV. Journal of Venomous Animals and Toxins Including Tropical Diseases, 2021, 27, e20200154.	0.8	5
1416	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2021, , .	1.3	7
1417	Relationship between Endothelial Function, Antiretroviral Treatment and Cardiovascular Risk Factors in HIV Patients of African Descent in South Africa: A Cross-Sectional Study. Journal of Clinical Medicine, 2021, 10, 392.	1.0	8
1418	Microbial mismanagement: how inadequate treatments for vaginal dysbiosis drive the HIV epidemic in women. Seminars in Immunology, 2021, 51, 101482.	2.7	9
1419	United States Ending the Human Immunodeficiency Virus (HIV) Epidemic Plan: Evaluation of the Role of Industry Funding in Published Pre-Exposure Prophylaxis (PrEP) Literature. SSRN Electronic Journal, O, , .	0.4	0
1421	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2021, 76, 2666-2674.	1.3	0
1422	Pre-clinical atherosclerosis is found at post-mortem, in the brains of men with HIV. Journal of NeuroVirology, 2021, 27, 80-85.	1.0	3
1423	Maternidade e HIV: Continuidade do Tratamento e Adesão em Mulheres após Parto. Psico-USF, 2021, 26, 53-65.	0.1	0
1425	A Midwestern Academic HIV Clinic Operation during the COVID-19 Pandemic: Implementation Strategy and Preliminary Outcomes. Journal of the International Association of Providers of AIDS Care, 2021, 20, 232595822110414.	0.6	9
1426	Randomized Pilot Study of an Advanced Smart-Pill Bottle as an Adherence Intervention in Patients With HIV on Antiretroviral Treatment. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 73-80.	0.9	6
1427	Enzephalitis. , 2021, , 113-213.		1

#	Article	IF	CITATIONS
1428	HIV-Infektion – PrÃ v alenz, Bedeutung und Implikationen fÃ⅓r die PrÃ v ention und Gesundheitsförderung. The Springer Reference Pflegerapie, Gesundheit, 2021, , 1001-1006.	0.2	0
1429	Traditional healers as client advocates in the HIV-endemic region of Maputo, Mozambique: results from a qualitative study. Sahara J, 2021, 18, 77-85.	0.4	8
1430	Voltammetric Methods Used in the Determination of Nucleoside Reverse Transcriptase Inhibitors. Current Pharmaceutical Analysis, 2021, 17, 409-420.	0.3	1
1431	Persistent TÂCell Repertoire Perturbation and TÂCell Activation in HIV After Long Term Treatment. Frontiers in Immunology, 2021, 12, 634489.	2.2	15
1432	Development and Evaluation of an Online Education-Entertainment Intervention to Increase Knowledge of HIV and Uptake of HIV Testing among Colombian Men Who Have Sex with Men (MSM). International Journal of Environmental Research and Public Health, 2021, 18, 1811.	1.2	3
1433	Association of Substance Use Disorders with Engagement in Care and Mortality among a Clinical Cohort of People with HIV in Washington, DC. AIDS and Behavior, 2021, 25, 2289-2300.	1.4	8
1434	"Dispense antiretrovirals daily!―restructuring the delivery of HIV services to optimize antiretroviral initiation among men in Malawi. PLoS ONE, 2021, 16, e0247409.	1.1	3
1435	Genome-wide association study of high-sensitivity C-reactive protein, D-dimer, and interleukin-6 levels in multiethnic HIV+ cohorts. Aids, 2021, 35, 193-204.	1.0	6
1436	HIV Prevention Responsibility Beliefs Among Men Who Have Sex with Men in the PrEP Era. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, e222-e228.	0.9	2
1437	The Role of Targeted HIV Screening in the Emergency Department: A Scoping Review. Current HIV Research, 2021, 19, 106-120.	0.2	3
1438	Impact of postpartum tenofovir-based antiretroviral therapy on bone mineral density in breastfeeding women with HIV enrolled in a randomized clinical trial. PLoS ONE, 2021, 16, e0246272.	1.1	6
1439	Trends and predictors of linkage to HIV outpatient care following diagnosis in the era of expanded testing in England, Wales and Northern Ireland: Results of a national cohort study. HIV Medicine, 2021, 22, 491-501.	1.0	2
1440	Benchmarks for HIV Testing: What Is Needed to Achieve Universal Testing Coverage at U.S. Ambulatory Healthcare Facilities. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, e48-e53.	0.9	2
1441	HIV-associated tuberculosis. International Journal of STD and AIDS, 2021, 32, 780-790.	0.5	19
1442	Smartphone Use and Willingness to Pay for HIV Treatment-Assisted Smartphone Applications among HIV-Positive Patients in Urban Clinics of Vietnam. International Journal of Environmental Research and Public Health, 2021, 18, 1467.	1.2	5
1443	Reviewing the oral pigmented lesions of human immunodeficiency virus with emphasis on the effect of highly active antiretroviral therapy. Disease-a-Month, 2021, 67, 101167.	0.4	1
1444	Effect of Medicaid Expansions on HIV Diagnoses and Pre-Exposure Prophylaxis Use. American Journal of Preventive Medicine, 2021, 60, 335-342.	1.6	9
1445	2021 European guideline on HIV testing in genitoâ€urinary medicine settings. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1043-1057.	1.3	4

#	ARTICLE	IF	CITATIONS
1446	Kaposi sarcoma: a fresh look. Aids, 2021, 35, 515-516.	1.0	2
1447	Initiation of Antiretroviral Therapy during Primary HIV Infection: Effects on the Latent HIV Reservoir, Including on Analytic Treatment Interruptions. AIDS Reviews, 2021, 23, 28-39.	0.5	4
1448	Estimation of Health-State Utility Values and Factors Driving Health-Related Quality of Life in People Living with HIV and AIDS and Receiving cART in Germany: Baseline Analysis of a Cohort Study. Applied Research in Quality of Life, 0, , 1.	1.4	1
1449	Health-related quality of life and pain interference in two patient cohorts with neuropathic pain: breast cancer survivors and HIV patients. Scandinavian Journal of Pain, 2021, 21, 512-521.	0.5	3
1450	Negative Consequences of Alcohol Use among People Living with HIV. Substance Use and Misuse, 2021, 56, 871-878.	0.7	1
1451	Changes over time in HIV testing and counselling uptake and associated factors among youth in Zambia: a cross-sectional analysis of demographic and health surveys from 2007 to 2018. BMC Public Health, 2021, 21, 456.	1.2	13
1452	Understanding Reasons for HIV Late Diagnosis: A Qualitative Study Among HIV-Positive Individuals in Amsterdam, The Netherlands. AIDS and Behavior, 2021, 25, 2898-2906.	1.4	8
1453	Recent advances in HIV-associated chronic lung disease clinical research. Current Opinion in HIV and AIDS, 2021, 16, 156-162.	1.5	6
1455	Associations Between Plasma Human Immunodeficiency Virus (HIV) Ribonucleic Acid Levels and Incidence of Invasive Cancer in People With HIV After Initiation of Combination Antiretroviral Therapy. Open Forum Infectious Diseases, 2021, 8, ofab131.	0.4	2
1456	Epidemiological factors associated with recent HIV infection among newly-diagnosed cases in Singapore, 2013–2017. BMC Public Health, 2021, 21, 430.	1.2	6
1457	HIV in acute medicine. Medicine, 2021, 49, 140-144.	0.2	0
1458	Adherence to a Supplemented Mediterranean Diet Drives Changes in the Gut Microbiota of HIV-1-Infected Individuals. Nutrients, 2021, 13, 1141.	1.7	12
1459	Latent infection screening and prevalence in cancer patients born outside of Australia: a universal versus risk-based approach?. Supportive Care in Cancer, 2021, 29, 6193-6200.	1.0	1
1461	First-Line Antiretroviral Regimen Failure and Determinants in an Urban HIV Clinic at Phramongkutklao Hospital, Bangkok, Thailand: 20 Years Experience. HIV/AIDS - Research and Palliative Care, 2021, Volume 13, 261-269.	0.4	1
1462	Racial, ethnic, and gender disparities in hospitalizations among persons with HIV in the United States and Canada, 2005–2015. Aids, 2021, 35, 1229-1239.	1.0	4
1463	Immunophenotypic characterization of TCR γδT cells and MAIT cells in HIV-infected individuals developing Hodgkin's lymphoma. Infectious Agents and Cancer, 2021, 16, 24.	1.2	3
1464	The Impact of Immediate InitiationÂofÂAntiretroviral Therapy on Patients' Healthcare Expenditures: A Stepped-Wedge Randomized Trial in Eswatini. AIDS and Behavior, 2021, 25, 3194-3205.	1.4	3
1465	The pattern of alpha-fetoprotein, CD4+ count, albumin, AST, ALT and ALP in HIV subjects on long term antiretroviral therapy in Nauth Nnewi, Anambra State, Nigeria. Indian Journal of Forensic and Community Medicine, 2021, 8, 45-51.	0.4	2

#	Article	IF	CITATIONS
1466	Brief Report: Impact of ART on Maternal Health After Cessation of Breastfeeding. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 450-454.	0.9	1
1467	Residual immune activation in HIV-Infected individuals expands monocytic-myeloid derived suppressor cells. Cellular Immunology, 2021, 362, 104304.	1.4	5
1468	Evidence Regarding Rapid Initiation of Antiretroviral Therapy in Patients Living with HIV. Current Infectious Disease Reports, 2021, 23, 7.	1.3	13
1469	People living with HIV in Sweden report high levels of sexual satisfaction in a registry-based cohort study. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 559-567.	0.6	4
1470	Preference towards HIV Self-Testing above Other Testing Options in a Sample of Men Who Have Sex with Men from Five European Countries. International Journal of Environmental Research and Public Health, 2021, 18, 4804.	1.2	7
1471	Reversal of Viral Latency and Induction of Gag-Specific T-Cell Responses in HIV-1-Infected Adults Through Cyclic Treatment Interruption of Rosuvastatin: A Proof-of-Concept Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, 500-508.	0.9	0
1472	Impact of immediate initiation of antiretroviral therapy among men who have sex with men infected with HIV in Chengdu, southwest China: trends analysis, 2008–2018. BMC Public Health, 2021, 21, 689.	1.2	7
1473	Chronic HIV infection induces transcriptional and functional reprogramming of innate immune cells. JCI Insight, 2021, 6, .	2.3	33
1474	High Coverage of Antiretroviral Treatment With Annual Home-Based HIV Testing, Follow-up Linkage Services, and Implementation of Test and Start: Findings From the ChókwÃ" Health Demographic Surveillance System, Mozambique, 2014â€"2019. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 86, e97-e105.	0.9	3
1475	Human immunodeficiency virus and infertility treatment: an Ethics Committee opinion. Fertility and Sterility, 2021, 115, 860-869.	0.5	3
1476	Impact of strategic use of antiretroviral therapy intervention to the HIV continuum of care in 13 cities in Indonesia: an interrupted time series analysis. AIDS Research and Therapy, 2021, 18, 22.	0.7	1
1477	Incidence and impact of low-level viremia among people living with HIV who received protease inhibitor- or dolutegravir-based antiretroviral therapy. International Journal of Infectious Diseases, 2021, 105, 147-151.	1.5	12
1478	Changing Pattern of Chemsex Drug Use Among Newly Diagnosed HIV-Positive Taiwanese from 2015 to 2020 in the Era of Treat-All Policy. AIDS Patient Care and STDs, 2021, 35, 134-143.	1.1	5
1479	Increased targeted HIV testing and reduced undiagnosed HIV infections among gay and bisexual men. HIV Medicine, 2021, 22, 605-616.	1.0	9
1480	Causes of hospitalisation among a cohort of people with HIV from a London centre followed from 2011 to 2018. BMC Infectious Diseases, 2021, 21, 395.	1.3	6
1481	Pregnancy in an Urban Cohort of Adolescents Living with Human Immunodeficiency Virus: Characteristics and Outcomes in Comparison to Adults. AIDS Patient Care and STDs, 2021, 35, 103-109.	1.1	4
1482	HIV testing approaches to reach the first UNAIDS 95% target in sub-Saharan Africa. Lancet HIV, the, 2021, 8, e225-e236.	2.1	29
1483	Financial incentives and deposit contracts to promote HIV retesting in Uganda: A randomized trial. PLoS Medicine, 2021, 18, e1003630.	3.9	12

#	ARTICLE	IF	CITATIONS
1484	Brief Report: Financial Incentives and Real-Time Adherence Monitoring to Promote Daily Adherence to HIV Treatment and Viral Suppression Among People Living With HIV: A Pilot Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 688-692.	0.9	5
1485	Evaluating Point-of-Care Nucleic Acid Tests in Adult Human Immunodeficiency Virus Diagnostic Strategies: A Côte d'Ivoire Modeling Analysis. Open Forum Infectious Diseases, 2021, 8, ofab225.	0.4	0
1486	Changes in Immune Activation During Pregnancy and the Postpartum Period in Treated HIV Infection. Open Forum Infectious Diseases, 2021, 8, ofab245.	0.4	6
1487	HIV detection by an emergency department HIV screening program during a regional outbreak among people who inject drugs. PLoS ONE, 2021, 16, e0251756.	1.1	9
1488	Predictionâ€driven pooled testing methods: Application to HIV treatment monitoring in Rakai, Uganda. Statistics in Medicine, 2021, 40, 4185-4199.	0.8	1
1489	Tolerability of fourâ€drug antiretroviral combination therapy in primary HIVâ€1 infection. HIV Medicine, 2021, 22, 770-774.	1.0	2
1490	Deciphering the association between HIV-specific immunity and immune reconstitution. EBioMedicine, 2021, 67, 103350.	2.7	2
1491	Incidence of diabetes mellitus among people living with and without HIV in British Columbia, Canada between 2001 and 2013: a longitudinal population-based cohort study. BMJ Open, 2021, 11, e048744.	0.8	3
1492	Human Immunotypes Impose Selection on Viral Genotypes Through Viral Epitope Specificity. Journal of Infectious Diseases, 2021, 224, 2053-2063.	1.9	6
1493	Timeliness of antiretroviral therapy initiation in the era before universal treatment. Scientific Reports, 2021, 11, 10508.	1.6	7
1494	The Lived Experiences of Stigmatization in the Process of HIV Status Disclosure among People Living with HIV in Taiwan. International Journal of Environmental Research and Public Health, 2021, 18, 5089.	1.2	6
1495	A Longitudinal Case Study of Concurrent Infection with Syphilis and Human Immunodeficiency Virus During the Early Phase. AIDS Research and Human Retroviruses, 2021, 37, 523-528.	0.5	O
1496	Approaches to Promoting Linkage to and Retention in HIV Care in the United States: a Scoping Review. Current HIV/AIDS Reports, 2021, 18, 339-350.	1.1	6
1497	Long-term virological outcomes in women who started option B+ care during pregnancy for prevention of mother-to-child transmission of HIV in Dar es Salaam, Tanzania: a cohort study. Lancet HIV,the, 2021, 8, e256-e265.	2.1	9
1498	Initiating antiretroviral treatment for newly diagnosed HIV patients in sexual health clinics greatly improves timeliness of viral suppression. Aids, 2021, 35, 1805-1812.	1.0	9
1499	Understanding the Social and Emotional Dimensions of HIV Self-Management: A Qualitative Study of Newly Diagnosed People Living With HIV in Queensland, Australia. Journal of the Association of Nurses in AIDS Care, 2022, 33, 106-117.	0.4	4
1500	How early is too early? Challenges in ART initiation and engaging in HIV care under Treat All in Rwanda—A qualitative study. PLoS ONE, 2021, 16, e0251645.	1.1	12
1501	Changing Knowledge and Attitudes Towards HIV Treatment-as-Prevention and "Undetectable = Untransmittable― A Systematic Review. AIDS and Behavior, 2021, 25, 4209-4224.	1.4	59

#	Article	IF	CITATIONS
1502	Characteristics of newly diagnosed HIV-positive service users using a pan-London e-sexually transmitted infection screening service. International Journal of STD and AIDS, 2021, 32, 1036-1042.	0.5	2
1503	Epigenetic Features of HIV-Induced T-Cell Exhaustion Persist Despite Early Antiretroviral Therapy. Frontiers in Immunology, 2021, 12, 647688.	2.2	19
1504	Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies. Clinical Infectious Diseases, 2022, 74, 865-870.	2.9	30
1505	HIV Infection: Time from Diagnosis to Initiation of Antiretroviral Therapy in Portugal, a Multicentric Study. Healthcare (Switzerland), 2021, 9, 797.	1.0	4
1506	Treated HIV Infection and Progression of Carotid Atherosclerosis in Rural Uganda: A Prospective Observational Cohort Study. Journal of the American Heart Association, 2021, 10, e019994.	1.6	11
1507	HIV Testing by Public Health Centers and Municipalities and New HIV Cases During the COVID-19 Pandemic in Japan. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, e182-e187.	0.9	31
1508	Evaluating fostemsavir as a therapeutic option for patients with HIV. Expert Opinion on Pharmacotherapy, 2021, 22, 1539-1545.	0.9	1
1509	A Collaborative Intervention Between Emergency Medicine and Infectious Diseases to Increase Syphilis and HIV Screening in the Emergency Department. Sexually Transmitted Diseases, 2022, 49, 50-54.	0.8	5
1510	HIV viral exposure and mortality in a multicenter ambulatory HIV adult cohort, United States, 1995–2016. Medicine (United States), 2021, 100, e26285.	0.4	2
1511	Factors Associated with Never Testing for HIV: Directions for Targeted Testing Interventions Among Men Who Have Sex with Men. AIDS Patient Care and STDs, 2021, 35, 204-210.	1.1	2
1512	COVIDâ€19 and beyond: Lessons learned from emergency department HIV screening for populationâ€based screening in healthcare settings. Journal of the American College of Emergency Physicians Open, 2021, 2, e12468.	0.4	1
1513	ART initiation among women newly diagnosed with HIV in a contraceptive trial in sub-Saharan Africa. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 478-485.	0.6	3
1514	Attitudes and Perceptions About Disclosing HIV and Syphilis Results Using Smarttest, a Smartphone App Dedicated to Self- and Partner Testing. AIDS Education and Prevention, 2021, 33, 234-248.	0.6	3
1515	Depression and HIV viral nonsuppression among people engaged in HIV care in an urban clinic, 2014–2019. Aids, 2021, 35, 2017-2024.	1.0	12
1516	Phylogenetic analysis of HIV-1 shows frequent cross-country transmission and local population expansions. Virus Evolution, 2021, 7, veab055.	2.2	5
1517	A systematic review of the effectiveness of non- health facility based care delivery of antiretroviral therapy for people living with HIV in sub-Saharan Africa measured by viral suppression, mortality and retention on ART. BMC Public Health, 2021, 21, 1110.	1.2	12
1518	Trends in HIV pre-exposure prophylaxis use in eight Canadian provinces, 2014–2018. Canada Communicable Disease Report, 2021, 47, 251-258.	0.6	9
1519	Immunological and virological response to initial antiretroviral therapy among older people living with HIV in the Canadian Observational Cohort (CANOC). HIV Medicine, 2021, 22, 759-769.	1.0	0

#	ARTICLE	IF	CITATIONS
1520	Role of Brain Arterial Remodeling in HIV-Associated Cerebrovascular Outcomes. Frontiers in Neurology, 2021, 12, 593605.	1.1	3
1521	Cascade of care in people living with HIV in Iran in 2019; how far to reach UNAIDS/WHO targets. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 590-596.	0.6	13
1522	Box–Behnken design aided optimization and validation of developed reverse phase HPLC analytical method for simultaneous quantification of dolutegravir sodium and lamivudine coâ€loaded in nanoâ€liposomes. Journal of Separation Science, 2021, 44, 2917-2931.	1.3	16
1523	Estimated time from HIV infection to diagnosis and diagnosis to first viral suppression during 2014–2018. Aids, 2021, 35, 2181-2190.	1.0	11
1524	Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection SPARTAC cohort. Aids, 2021, Publish Ahead of Print, 2073-2084.	1.0	0
1525	Same Week: Feasibility of Rapid Antiretroviral Initiation in Brazil. Re:GEN Open, 2021, 1, 68-74.	0.7	0
1526	Evaluation of kidney function tests in HIVâ€positive patients receiving combined antiretroviral therapy. International Journal of Clinical Practice, 2021, 75, e14542.	0.8	1
1527	Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. BMC Infectious Diseases, 2021, 21, 557.	1.3	4
1528	Risk for Non–AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy. Annals of Internal Medicine, 2021, 174, 768-776.	2.0	14
1529	Investigation of post-trial access views among study participants and stakeholders using photovoice and semistructured interviews. Journal of Medical Ethics, 2022, 48, 712-717.	1.0	4
1530	Reflections on 40 Years of AIDS. Emerging Infectious Diseases, 2021, 27, 1553-1560.	2.0	49
1531	Gender, Mental Health, and Entry Into Care with Advanced HIV Among People Living with HIV in Cameroon Under a National †Treat All' Policy. AIDS and Behavior, 2021, 25, 4018-4028.	1.4	7
1532	Longitudinal Changes in Epigenetic Age Acceleration in Aviremic Human Immunodeficiency Virusâé"Infected Recipients of Long-term Antiretroviral Treatment. Journal of Infectious Diseases, 2022, 225, 287-294.	1.9	10
1533	HIVâ€MSS: A userâ€friendly management support system for better planning of HIV care services. International Journal of Health Planning and Management, 2021, 36, 1847-1860.	0.7	0
1534	Decrease in late presentation for HIV care in Kinshasa, DRC, 2006–2020. AIDS Research and Therapy, 2021, 18, 41.	0.7	4
1535	Different Trends of Distinct Time Points of AIDS Events Following HIV Diagnosis in Various At-risk Populations: A Retrospective Nationwide Cohort Study in Taiwan. Infectious Diseases and Therapy, 2021, 10, 1715-1732.	1.8	2
1536	Persons living with HIV in sero-discordant partnerships experience improved HIV care engagement compared with persons living with HIV in sero-concordant partnerships: a cross-sectional analysis of four African countries. AIDS Research and Therapy, 2021, 18, 43.	0.7	3
1537	Short-term mortality from HIV-infected persons diagnosed from 2012 to 2016. Medicine (United States), 2021, 100, e26507.	0.4	8

#	Article	IF	CITATIONS
1538	Interrogating the impact of combination antiretroviral therapies on HIVâ€essociated neurocognitive disorders. HIV Medicine, 2021, 22, 783-790.	1.0	14
1539	Various structural factors influenced early antiretroviral therapy initiation amongst HIV infected prisoners: a qualitative exploration in South Ethiopia. BMC Public Health, 2021, 21, 1463.	1.2	7
1540	Proportion of patients eligible for statin therapy substantially varies between different cardiovascular disease risk calculators and guidelines used. International Journal of STD and AIDS, 2021, 32, 095646242110293.	0.5	1
1541	Partner-delivered HIV self-test kits with and without financial incentives in antenatal care and index patients with HIV in Malawi: a three-arm, cluster-randomised controlled trial. The Lancet Global Health, 2021, 9, e977-e988.	2.9	35
1542	Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008–2018 in Italy. Journal of Clinical Medicine, 2021, 10, 3391.	1.0	3
1543	Infectious Diseases Learning Unit: Understanding Advances in the Treatment of Latent Tuberculosis Infection Among People With Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2021, 8, ofab319.	0.4	2
1544	A 34-Year-Old Man With HIV/AIDS and a Cavitary Pulmonary Lesion. Chest, 2021, 160, e35-e38.	0.4	2
1545	The benefits of tenofovir discontinuation with or without bisphosphonate therapy in osteoporotic people living with HIV. HIV Medicine, 2021, 22, 816-823.	1.0	4
1546	Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study. Journal of Antimicrobial Chemotherapy, 2021, 76, 2394-2399.	1.3	6
1547	Individual health behaviours to combat the COVIDâ€19 pandemic: lessons from HIV socioâ€behavioural science. Journal of the International AIDS Society, 2021, 24, e25771.	1.2	9
1548	Factors associated with testing for HIV and hepatitis C among behaviorally vulnerable men in Germany: a cross-sectional analysis upon enrollment into an observational cohort. AIDS Research and Therapy, 2021, 18, 52.	0.7	4
1549	Experiences and Lessons Learnt from the HIV Treat All Pilot Phase Implementation in Zimbabwe. HIV/AIDS - Research and Palliative Care, 2021, Volume 13, 823-828.	0.4	1
1550	Rapid antiretroviral therapy initiation and its effect on treatment response in MSM in West Africa. Aids, 2021, 35, 2201-2210.	1.0	13
1551	Effect on growth of exposure to maternal antiretroviral therapy in breastmilk versus extended infant nevirapine prophylaxis among HIV-exposed perinatally uninfected infants in the PROMISE randomized trial. PLoS ONE, 2021, 16, e0255250.	1.1	2
1552	Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial. Lancet HIV,the, 2021, 8, e474-e485.	2.1	190
1553	Successful second outpatient autologous hematopoietic cell transplant for relapsed POEMS syndrome in a patient with coexisting HIV, HBV and syphilis infections during the COVID-19 pandemic. Transplant Immunology, 2021, 67, 101412.	0.6	2
1554	Nationwide surveillance of AIDS-defining illnesses among HIV patients in Japan from 1995 to 2017. PLoS ONE, 2021, 16, e0256452.	1.1	6
1555	Missed Testing Opportunities Among HIV-Positive Adults in a Community Emergency Department. AIDS Research and Human Retroviruses, 2021, , .	0.5	0

#	Article	IF	CITATIONS
1556	Next-Generation Human Cerebral Organoids as Powerful Tools To Advance NeuroHIV Research. MBio, 2021, 12, e0068021.	1.8	10
1557	Alzheimer's-Like Pathology at the Crossroads of HIV-Associated Neurological Disorders. Vaccines, 2021, 9, 930.	2.1	10
1558	Virologic suppression and associated factors in HIV infected Ugandan female sex workers: a cross-sectional study. African Health Sciences, 2021, 21, 603-613.	0.3	2
1559	Effect of Text Messaging Plus Peer Navigation on Viral Suppression Among Youth With HIV in the iCARE Nigeria Pilot Study. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, 1086-1092.	0.9	11
1560	Tuberculosis incidence and mortality in people living with human immunodeficiency virus: a Danish nationwide cohort study. Clinical Microbiology and Infection, 2022, 28, 570-579.	2.8	4
1561	Trends in HIV Care Outcomes Among Adults and Adolescents—33 Jurisdictions, United States, 2014–2018. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 333-339.	0.9	4
1562	Virologic outcomes of people living with human immunodeficiency virus who started antiretroviral treatment on the same-day of diagnosis in Ethiopia: A multicenter observational study. PLoS ONE, 2021, 16, e0257059.	1.1	3
1563	A Qualitative Study of the Experience of Immediate Antiretroviral Therapy Among Urban Persons With Newly Diagnosed Human Immunodeficiency Virus. Open Forum Infectious Diseases, 2021, 8, ofab469.	0.4	3
1564	Evolution of Antibodies to Native Trimeric Envelope and Their Fc-Dependent Functions in Untreated and Treated Primary HIV Infection. Journal of Virology, 2021, 95, e0162521.	1.5	1
1565	Characterization of the Population Affected by the 6-Month Recertification Criterion of the Ryan White HIV/AIDS Program's AIDS Drug Assistance Program in Washington State, 2017–2019. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 27-33.	0.9	1
1566	HIV diagnosis period influences ART initiation: findings from a prospective cohort study in China. AIDS Research and Therapy, 2021, 18, 59.	0.7	2
1567	Machine Learning Algorithms Using Routinely Collected Data Do Not Adequately Predict Viremia to Inform Targeted Services in Postpartum Women Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 439-447.	0.9	4
1568	Hematologic cancers in individuals infected by HIV. Blood, 2022, 139, 995-1012.	0.6	35
1569	HIV continuum of care: expanding scope beyond a cross-sectional view to include time analysis: a systematic review. BMC Public Health, 2021, 21, 1699.	1.2	4
1570	Ethically designing research to inform multidimensional, rapidly evolving policy decisions: Lessons learned from the PROMISE HIV Perinatal Prevention Trial. Clinical Trials, 2021, 18, 174077452110457.	0.7	1
1571	Acceptability of Nurse-Driven HIV Screening for Key Populations in Emergency Departments. Nursing Research, 2021, 70, 354-365.	0.8	4
1572	Sameâ€day antiretroviral therapy initiation for people living with HIV who have tuberculosis symptoms: a systematic review. HIV Medicine, 2021, , .	1.0	8
1573	Linear and non-linear analysis of heart rate variability in HIV-positive patients on two different antiretroviral therapy regimens. BMC Infectious Diseases, 2021, 21, 1022.	1.3	3

#	Article	IF	Citations
1574	Test, treat, and maintain: rapid initiation of antiretroviral therapy. Aids, 2021, 35, 1867-1869.	1.0	2
1575	Natural Occurring Polymorphisms in HIV-1 Integrase and RNase H Regulate Viral Release and Autoprocessing. Journal of Virology, 2021, 95, e0132321.	1.5	7
1576	NanoHIV: A Bioinformatics Pipeline for Producing Accurate, Near Full-Length HIV Proviral Genomes Sequenced Using the Oxford Nanopore Technology. Cells, 2021, 10, 2577.	1.8	7
1577	Time trends in cancer incidence in Australian people living with HIV between 1982 and 2012. HIV Medicine, 2022, 23, 134-145.	1.0	9
1578	HIV Infection and the Risk of World Health Organization–Defined Sudden Cardiac Death. Journal of the American Heart Association, 2021, 10, e021268.	1.6	9
1579	Antiretroviral therapy use in selected countries in Latin America during 2013–2017: results from the Latin American Workshop in HIV Study Group. International Journal of Infectious Diseases, 2021, 113, 288-296.	1.5	0
1580	Barriers to Culturally Competent Human Immunodeficiency Virus Care Among the Black, Indigenous, and People of Color Community. Journal for Nurse Practitioners, 2022, 18, 54-57.	0.4	1
1581	Managing cardiovascular risk in people living with HIV inÂAsia – where are we now?. HIV Medicine, 2022, 23, 111-120.	1.0	2
1582	Anti-HIV serological test algorithms to reduce false-positive and inconclusive results for low HIV prevalence and resource-limited areas. International Journal of STD and AIDS, 2021, , 095646242110443.	0.5	1
1583	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021, 100, S1-S276.	2.6	782
1584	Starting HIV therapy in patients with mitochondrial disease. Aids, 2021, 35, 2063-2065.	1.0	0
1585	Bioinspired membrane-based nanomodulators for immunotherapy of autoimmune and infectious diseases. Acta Pharmaceutica Sinica B, 2022, 12, 1126-1147.	5.7	12
1586	Carbon ink-based electrodes modified with nanocomposite as a platform for electrochemical detection of HIV RNA. Microchemical Journal, 2021, 170, 106739.	2.3	5
1587	Distinct transcriptomic profiles of na \tilde{A} -ve CD4+ T cells distinguish HIV-1 infected patients initiating antiretroviral therapy at acute or chronic phase of infection. Genomics, 2021, 113, 3487-3500.	1.3	6
1588	Motivating people living with HIV to initiate antiretroviral treatment outside national guidelines in three clinics in the HPTN 071 (PopART) trial, South Africa. African Journal of AIDS Research, 2021, 20, 32-41.	0.3	0
1589	Immune Dysregulation in Myocardial Fibrosis, Steatosis, and Heart Failure: Current Insights from HIV and the General Population. Current HIV/AIDS Reports, 2021, 18, 63-72.	1.1	6
1590	An expanded HIV care cascade: ART uptake, viral load suppression and comorbidity monitoring among adults living with HIV in Asia. Antiviral Therapy, 2021, 25, 275-285.	0.6	2
1591	CD32+CD4+ memory T cells are enriched for total HIV-1 DNA in tissues from humanized mice. IScience, 2021, 24, 101881.	1.9	10

#	ARTICLE	IF	CITATIONS
1592	Neuropathology of HIV-1 Disease., 2017,, 143-208.		2
1593	The Clinical Spectrum of Human Immunodeficiency Virus Infection. , 2020, , 295-317.		1
1594	HIV Infection. , 2017, , 69-100.		3
1595	Review on the Biological Mechanisms Associated with Depo-Provera and HIV-1 Risk Acquisition in Women. Cell Biochemistry and Biophysics, 2018, 76, 73-82.	0.9	1
1596	Epidemiology, pathophysiology, and prevention of heart failure in people with HIV. Progress in Cardiovascular Diseases, 2020, 63, 134-141.	1.6	22
1599	Aiming for 90–90–90 – the importance of understanding the risk factors for HIV exposure and advanced HIV infection in migrant populations and other groups who do not report male-to-male sex. Sexual Health, 2018, 15, 441.	0.4	5
1600	Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy Initiation. Clinical Infectious Diseases, 2021, 73, e643-e651.	2.9	5
1601	Decreased Time From Human Immunodeficiency Virus Diagnosis to Care, Antiretroviral Therapy Initiation, and Virologic Suppression during the Citywide RAPID Initiative in San Francisco. Clinical Infectious Diseases, 2021, 73, e122-e128.	2.9	24
1602	Recognizing Laboratory Medicine's Collaborative Role in Identifying and Eliminating Health Disparities. journal of applied laboratory medicine, The, 2021, 6, 274-284.	0.6	5
1603	CD4+ cell count recovery following initiation of HIV antiretroviral therapy in older childhood and adolescence. Aids, 2018, 32, 1977-1982.	1.0	13
1604	Progressive phasing out of baseline CD4+ cell count testing for people living with HIV in Kinshasa, Democratic Republic of the Congo. Aids, 2021, 35, 841-843.	1.0	5
1605	New initiatives to develop self-testing for HIV. Current Opinion in Infectious Diseases, 2017, 30, 50-57.	1.3	24
1608	Transmitted HIVâ€1 drug resistance in a large international cohort using nextâ€generation sequencing: results from the Strategic Timing of Antiretroviral Treatment (START) study. HIV Medicine, 2021, 22, 360-371.	1.0	12
1609	Mass cytometry identifies distinct CD4+ T cell clusters distinguishing HIV-1–infected patients according to antiretroviral therapy initiation. JCI Insight, 2019, 4, .	2.3	15
1610	Adoptive lymphocyte transfer to an HIV-infected progressor from an elite controller. JCI Insight, 2019, 4, .	2.3	6
1611	Increased incidence of glaucoma medication usage in middle-aged Australian males taking antiretroviral medication $\hat{a}\in\hat{a}$ a population-based study. Journal of Ophthalmic Inflammation and Infection, 2020, 10, 30.	1.2	2
1612	Impact of Heterogeneity in Sexual Behavior on Effectiveness in Reducing HIV Transmission with Test-and-Treat Strategy. PLoS Computational Biology, 2016, 12, e1005012.	1.5	20
1613	Uptake of Home-Based HIV Testing, Linkage to Care, and Community Attitudes about ART in Rural KwaZulu-Natal, South Africa: Descriptive Results from the First Phase of the ANRS 12249 TasP Cluster-Randomised Trial. PLoS Medicine, 2016, 13, e1002107.	3.9	135

#	Article	IF	CITATIONS
1614	Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial. PLoS Medicine, 2017, 14, e1002357.	3.9	194
1615	HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries. PLoS Medicine, 2018, 15, e1002534.	3.9	38
1616	A clinical score for identifying active tuberculosis while awaiting microbiological results: Development and validation of a multivariable prediction model in sub-Saharan Africa. PLoS Medicine, 2020, 17, e1003420.	3.9	13
1617	CD4/CD8 Ratio and KT Ratio Predict Yellow Fever Vaccine Immunogenicity in HIV-Infected Patients. PLoS Neglected Tropical Diseases, 2016, 10, e0005219.	1.3	50
1618	Willingness to Act upon Beliefs about †Treatment as Prevention' among Australian Gay and Bisexual Men. PLoS ONE, 2016, 11, e0145847.	1.1	23
1619	Views of Medical Doctors Regarding the 2013 WHO Adult HIV Treatment Guidelines Indicate Variable Applicability for Routine Patient Monitoring, for Their Family Members and for Themselves, in South-Africa. PLoS ONE, 2016, 11, e0145911.	1.1	2
1620	Opt-Out Panel Testing for HIV, Hepatitis B and Hepatitis C in an Urban Emergency Department: A Pilot Study. PLoS ONE, 2016, 11, e0150546.	1.1	39
1621	D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events. PLoS ONE, 2016, 11, e0152588.	1.1	50
1622	Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria. PLoS ONE, 2016, 11, e0152910.	1.1	30
1623	Time to HAART Initiation after Diagnosis and Treatment of Opportunistic Infections in Patients with AIDS in Latin America. PLoS ONE, 2016, 11, e0153921.	1.1	24
1624	Drug-Based Lead Discovery: The Novel Ablative Antiretroviral Profile of Deferiprone in HIV-1-Infected Cells and in HIV-Infected Treatment-Naive Subjects of a Double-Blind, Placebo-Controlled, Randomized Exploratory Trial. PLoS ONE, 2016, 11, e0154842.	1.1	27
1625	The Sensitivity and Specificity of Loop-Mediated Isothermal Amplification (LAMP) Assay for Tuberculosis Diagnosis in Adults with Chronic Cough in Malawi. PLoS ONE, 2016, 11, e0155101.	1.1	42
1626	Impact and Cost of Scaling Up Voluntary Medical Male Circumcision for HIV Prevention in the Context of the New 90-90-90 HIV Treatment Targets. PLoS ONE, 2016, 11, e0155734.	1.1	10
1627	Factors Associated with Early Mortality in HIV-Positive Men and Women Investigated for Tuberculosis at Ethiopian Health Centers. PLoS ONE, 2016, 11, e0156602.	1.1	10
1628	Immediate Blood Draw for CD4+ Cell Count Is Associated with Linkage to Care in Durban, South Africa: Findings from Pathways to Engagement in HIV Care. PLoS ONE, 2016, 11, e0162085.	1.1	13
1629	Poor Linkage to Care Despite Significant Improvement in Access to Early cART in Central Poland – Data from Test and Keep in Care (TAK) Project. PLoS ONE, 2016, 11, e0162739.	1.1	10
1630	Detection of Acute and Early HIV-1 Infections in an HIV Hyper-Endemic Area with Limited Resources. PLoS ONE, 2016, 11, e0164943.	1.1	20
1631	Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS ONE, 2016, 11, e0165614.	1.1	20

#	Article	IF	CITATIONS
1632	Comparing longitudinal CD4 responses to cART among non-perinatally HIV-infected youth versus adults: Results from the HIVRN Cohort. PLoS ONE, 2017, 12, e0171125.	1.1	2
1633	ART attrition and risk factors among Option B+ patients in Haiti: A retrospective cohort study. PLoS ONE, 2017, 12, e0173123.	1.1	22
1634	The performance of BD FACSPrestoâ,,¢ for CD4 T-cell count, CD4% and hemoglobin concentration test in Ethiopia. PLoS ONE, 2017, 12, e0176323.	1.1	7
1635	Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical modeling study. PLoS ONE, 2017, 12, e0178249.	1.1	20
1636	High rates of loss to follow-up during the first year of pre-antiretroviral therapy for HIV patients at sites providing pre-ART care in Nigeria, 2004–2012. PLoS ONE, 2017, 12, e0183823.	1.1	15
1637	Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. PLoS ONE, 2017, 12, e0184441.	1.1	19
1638	Missed opportunities for HIV testing among newly diagnosed HIV-infected adults in Abidjan, CÃ te d'Ivoire. PLoS ONE, 2017, 12, e0185117.	1.1	13
1639	Late presentation of HIV infection in the country of Georgia: 2012-2015. PLoS ONE, 2017, 12, e0186835.	1.1	18
1640	Proportion and factors associated with recent HIV infection in a cohort of patients seen for care in Italy over 1996-2014: Data from the ICONA Foundation Study cohort. PLoS ONE, 2017, 12, e0189045.	1.1	4
1641	Factors associated with urinary tract infections among HIV-1 infected patients. PLoS ONE, 2018, 13, e0190564.	1.1	14
1642	Test but not treat: Community members' experiences with barriers and facilitators to universal antiretroviral therapy uptake in rural KwaZulu-Natal, South Africa. PLoS ONE, 2020, 15, e0239513.	1.1	9
1643	Effectiveness of four antiretroviral regimens for treating people living with HIV. PLoS ONE, 2020, 15, e0239527.	1.1	1
1644	Infection and depletion of CD4+ group-1 innate lymphoid cells by HIV-1 via type-I interferon pathway. PLoS Pathogens, 2018, 14, e1006819.	2.1	19
1645	Evidence for optimal HIV screening and testing intervals in HIV-negative individuals from various risk groups: A systematic review. Canada Communicable Disease Report, 2018, 44, 340-350.	0.6	1
1646	Lower Levels of Antiretroviral Therapy Enrollment Among Men with HIV Compared with Women — 12 Countries, 2002–2013. Morbidity and Mortality Weekly Report, 2015, 64, 1281-1286.	9.0	41
1647	Scale-up of HIV Viral Load Monitoring — Seven Sub-Saharan African Countries. Morbidity and Mortality Weekly Report, 2015, 64, 1287-1290.	9.0	105
1648	Health Care Use and HIV Testing of Males Aged 15–39 Years in Physicians' Offices — United States, 2009–2012. Morbidity and Mortality Weekly Report, 2016, 65, 619-622.	9.0	10
1649	Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment — 10 Countries, 2004–2015. Morbidity and Mortality Weekly Report, 2017, 66, 558-563.	9.0	34

#	Article	IF	CITATIONS
1650	Recommendations for HIV Screening of Gay, Bisexual, and Other Men Who Have Sex with Men — United States, 2017. Morbidity and Mortality Weekly Report, 2017, 66, 830-832.	9.0	180
1651	HIV Testing, Linkage to HIV Medical Care, and Interviews for Partner Services Among Black Men Who Have Sex with Men — Non–Health Care Facilities, 20 Southern U.S. Jurisdictions, 2016. Morbidity and Mortality Weekly Report, 2018, 67, 778-781.	9.0	14
1652	Implementation of the Treat All Policy Among Persons with HIV Infection Enrolled in Care But Not on Antiretroviral Therapy — India, May 2017–June 2018. Morbidity and Mortality Weekly Report, 2018, 67, 1305-1309.	9.0	6
1653	Global Mortality and Morbidity of HIV/AIDS. , 2017, , 29-44.		13
1654	HIV Care Continuum in Adults and Children: Cost-Effectiveness Considerations., 2017,, 67-90.		1
1655	Effectiveness and Cost-Effectiveness of Treatment as Prevention for HIV., 2017,, 91-111.		4
1656	Consensus statement on the assessment of comorbidities in people living with HIV in Romania. Germs, 2019, 9, 198-210.	0.5	13
1657	Temporal Trends in the Epidemiology of HIV in Turkey. Current HIV Research, 2020, 18, 258-266.	0.2	20
1658	CD4 Lymphocyte Enumeration and Hemoglobin Assessment Aid for Priority Decisions: A Multisite Evaluation of the BD FACSPrestoâ,,¢ System. Open AIDS Journal, 2017, 11, 76-90.	0.1	7
1659	mHealth Interventions To Support Self-Management In HIV: A Systematic Review. Open AIDS Journal, 2017, 11, 119-132.	0.1	113
1660	Using Digital Communication Technology to Increase HIV Testing Among Men Who Have Sex With Men and Transgender Women: Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2020, 22, e14230.	2.1	18
1661	mHealth Interventions to Promote Anti-Retroviral Adherence in HIV: Narrative Review. JMIR MHealth and UHealth, 2020, 8, e14739.	1.8	23
1662	Web-Based Module for the Collection of Electronic Patient-Reported Outcomes in People Living With HIV in Nouvelle Aquitaine, France: Usability Evaluation. JMIR Formative Research, 2019, 3, e15013.	0.7	2
1663	Exploring People's Candidacy for Mobile Health–Supported HIV Testing and Care Services in Rural KwaZulu-Natal, South Africa: Qualitative Study. Journal of Medical Internet Research, 2019, 21, e15681.	2.1	40
1664	Attitudes to and Understanding of Risk of Acquisition of HIV Over Time: Design and Methods for an Internet-based Prospective Cohort Study Among UK Men Who Have Sex With Men (the AURAH2 Study). JMIR Research Protocols, 2016, 5, e128.	0.5	7
1665	The importance of assessing self-reported HIV status in bio-behavioural surveys. Bulletin of the World Health Organization, 2016, 94, 605-612.	1.5	21
1666	Addressing tuberculosis in differentiated care provision for people living with HIV. Bulletin of the World Health Organization, 2017, 95, 3-3.	1.5	15
1667	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Eurosurveillance, 2015, 20, .	3.9	70

#	Article	IF	CITATIONS
1668	Estimating HIV incidence and number of undiagnosed individuals living with HIV in the European Union/European Economic Area, 2015. Eurosurveillance, 2016, 21, .	3.9	30
1669	Reduction in undiagnosed HIV infection in the European Union/European Economic Area, 2012 to 2016. Eurosurveillance, 2017, 22, .	3.9	12
1670	Integrating hepatitis B, hepatitis C and HIV screening into tuberculosis entry screening for migrants in the Netherlands, 2013 to 2015. Eurosurveillance, 2018, 23, .	3.9	18
1671	Persistent disparities in antiretroviral treatment (ART) coverage and virological suppression across Europe, 2004 to 2015. Eurosurveillance, 2018, 23, .	3.9	12
1672	Prescription of antimicrobials in primary health care as a marker to identify people living with undiagnosed HIV infection, Denmark, 1998 to 2016. Eurosurveillance, 2019, 24, .	3.9	4
1673	AMMI Canada position statement: The use of early antiretroviral therapy in HIV-infected persons. Jammi, 2017, 1, 1-11.	0.3	2
1674	The Protease Inhibitor Monotherapy Versus Ongoing Triple Therapy (PIVOT) trial: a randomised controlled trial of a protease inhibitor monotherapy strategy for long-term management of human immunodeficiency virus infection. Health Technology Assessment, 2016, 20, 1-158.	1.3	11
1675	Southern African HIV Clinicians Society adult antiretroviral therapy guidelines: Update on when to initiate antiretroviral therapy. Southern African Journal of HIV Medicine, 2015, 16, 428.	0.3	14
1676	When will sub-Saharan Africa adopt HIV treatment for all?. Southern African Journal of HIV Medicine, 2016, 17, 459.	0.3	20
1677	When to start antiretroviral treatment? A history and analysis of a scientific controversy. Southern African Journal of HIV Medicine, 2017, 18, .	0.3	3
1678	Adult antiretroviral therapy guidelines 2017. Southern African Journal of HIV Medicine, 2017, 18, 776.	0.3	155
1679	Palliative care guidelines for the management of HIV-infected people in South Africa. Southern African Journal of HIV Medicine, 2019, 20, 1013.	0.3	3
1680	Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults: 2020 update. Southern African Journal of HIV Medicine, 2020, 21, 1115.	0.3	29
1681	HIV prevention & treatment strategies - Current challenges & future prospects. Indian Journal of Medical Research, 2018, 148, 671.	0.4	10
1682	Cardiovascular disease in human immunodeficiency virus infected patients: A true or perceived risk?. World Journal of Cardiology, 2015, 7, 633.	0.5	39
1683	Scaling up HIV viral load monitoring in Manicaland, Zimbabwe: challenges and opportunities from the field. Public Health Action, 2019, 9, 177-181.	0.4	7
1684	Impact of a decade of successful antiretroviral therapy initiated at HIV-1 seroconversion on blood and rectal reservoirs. ELife, 2015, 4, e09115.	2.8	34
1685	A stepped-wedge randomised trial on the impact of early ART initiation on HIV-patients' economic outcomes in Eswatini. ELife, 2020, 9, .	2.8	6

#	Article	IF	CITATIONS
1686	Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against SARS-CoV-2 in People Living with HIV (PLWH) Receiving Antiretroviral Therapy (ART) According with Current CD4 T-Lymphocyte Count. SSRN Electronic Journal, 0, , .	0.4	5
1687	Immune recovery after antiretroviral therapy initiation: a challenge for people living with HIV in Brazil. Cadernos De Saude Publica, 2021, 37, e00143520.	0.4	1
1688	Comparative incidence of adverse drug reaction during the first and subsequent year of antiretroviral therapy in a Nigerian HIV infected cohort. African Health Sciences, 2021, 21, 1027-1039.	0.3	3
1689	Routine HIV Testing and Outcomes: A Population-Based Cohort Study in Taiwan. American Journal of Preventive Medicine, 2022, 62, 234-242.	1.6	9
1690	Alcohol Use Disorder and Recent Alcohol Use and HIV Viral Non-Suppression Among People Engaged in HIV Care in an Urban Clinic, 2014–2018. AIDS and Behavior, 2022, 26, 1299-1307.	1.4	4
1691	Randomized, Blinded, Placebo-Controlled Trial of De Simone Formulation Probiotic During HIV-Associated Suboptimal CD4+ T Cell Recovery. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 89, 199-207.	0.9	3
1692	Irreversible depletion of intestinal CD4+ T cells is associated with T cell activation during chronic HIV infection. JCI Insight, $2021, 6, .$	2.3	11
1694	Acute HIV infection syndrome mimicking COVID-19 vaccination side effects: a case report. AIDS Research and Therapy, 2021, 18, 78.	0.7	2
1695	Mortality among clients in the New York City HIV Care Coordination Program (CCP): Incidence and Associated Clinical Factors. Annals of Epidemiology, 2021, 64, 161-166.	0.9	0
1696	Seroepidemiology of the human herpesvirus 8 infection among people living with HIV in Taiwan, 2014–2018. Journal of Microbiology, Immunology and Infection, 2021, 54, 934-943.	1.5	1
1697	High residual inflammation despite HIV viral suppression: Lessons learned from realâ€time adherence monitoring among people with HIV in Africa. HIV Medicine, 2022, 23, 465-473.	1.0	7
1698	HIV Care Coordination promotes care re-engagement and viral suppression among people who have been out of HIV medical care: an observational effectiveness study using a surveillance-based contemporaneous comparison group. AIDS Research and Therapy, 2021, 18, 70.	0.7	3
1699	Mapping geographic clusters of new HIV diagnoses to inform granular-level interventions for HIV epidemic control in western Kenya. BMC Public Health, 2021, 21, 1926.	1.2	7
1701	Antiretroviral Therapy: When to Start. , 2015, , 1-8.		0
1703	Antiretroviral naive and treated patients: Discrepancies of B cell subsets during the natural course of human immunodeficiency virus type 1 infection. World Journal of Virology, 2016, 5, 155.	1.3	1
1704	Bone Biomarkers in HIV. Exposure and Health, 2016, , 1-27.	2.8	0
1706	HIV Associated Non-AIDS Conditions in Patients Aging with HIV. , 2016, , 19-52.		1
1707	Longâ€term effectiveness of initiating nonâ€nucleoside reverse transcriptase inhibitor†versus ritonavirâ€boosted protease inhibitorâ€based antiretroviral therapy: implications for firstâ€line therapy choice in resourceâ€limited settings. Journal of the International AIDS Society, 2016, 19, 20978.	1.2	0

#	Article	IF	CITATIONS
1708	Twenty Years of Improved Perinatal Outcomes for Pregnancies Affected by HIV Infection. Obstetrics $\&$ Gynecology International Journal, 2016, 4, .	0.0	0
1711	Pharmaceutical Equivalence of Distributed Generic Antiretroviral (ARV) in Asian Settings: The Cross-Sectional Surveillance Study – PEDA Study. PLoS ONE, 2016, 11, e0157039.	1.1	0
1712	Croatian Recommendations for Dialysis of HIV-Positive Patients. BANTAO Journal, 2016, 14, 1-7.	0.1	0
1713	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS ONE, 2016, 11, e0156360.	1.1	0
1714	Canadian and international recommendations on the frequency of HIV screening and testing: A systematic review. Canada Communicable Disease Report, 2016, 42, 161-168.	0.6	1
1715	Antiretroviral Medications, Adult Care, and Treatment. , 2017, , 1-16.		0
1716	Bone Biomarkers in HIV. Biomarkers in Disease, 2017, , 755-781.	0.0	0
1717	From Bench to Bedside: Lessons from HIVÂNatural History Cohort Studies. , 2017, , 137-152.		0
1718	The Odyssey of Linking to and Staying in HIV Care among Male Sex Workers in Peru. Journal of HIV and AIDS, $2017, 3, .$	0.1	4
1719	Evidence for optimal HIV testing intervals in HIV-negative individuals from various risk groups: a systematic review protocol. Canada Communicable Disease Report, 2017, 43, 38-48.	0.6	1
1720	Trends in HIV/AIDS Epidemics in Merauke-Papua, Indonesia, from 1992-2017. Asian Journal of Epidemiology, 2017, 10, 76-82.	0.5	1
1721	A simple model of HIV epidemic in Italy: The role of the antiretroviral treatment. Mathematical Biosciences and Engineering, 2017, 15, 181-207.	1.0	5
1723	Phased implementation of spaced clinic visits for stable HIV-positive patients in Rwanda to support Treat All. Journal of the International AIDS Society, 2017, 20, .	1.2	1
1724	Delay in the Provision of Antiretroviral Therapy to HIV-infected TB Patients in Nigeria. Universal Journal of Public Health, 2017, 5, 248-255.	0.0	0
1728	Chapter 35: Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome., 2017,,.		0
1729	Autoimmune hepatitis in human immunodeficiency virus infection: Case report and literature review. World Journal of Clinical Infectious Diseases, 2017, 7, 50-57.	0.5	2
1731	Antiretroviral Therapy: When to Start., 2018,, 106-113.		0
1732	Antiretroviral Medications, Adult Care, and Treatment. , 2018, , 72-87.		O

#	Article	IF	CITATIONS
1733	Diagnostik und Behandlung HIV-assoziierter Erkrankungen. , 2018, , 275-284.		0
1734	HIV-Behandlung., 2018,, 265-274.		0
1735	Understanding Social Structural Barriers and Facilitators to Behavioral Change: The Case of Cisgender Women Diagnosed with HIV. Nebraska Symposium on Motivation, 2018, , 127-165.	0.9	1
1736	Care of HIV Patients., 2018,, 97-116.		0
1737	TREND OF CD4 CELL COUNT AT INITIATION OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART) IN KLINIK KESIHATAN SEREMBAN (KKS). International Journal of Advancement in Life Sciences Research, 2018, 1, 1-7.	0.1	0
1738	Characteristics of men who have sex with men and transgender women in Myanmar who test frequently for HIV. Journal of Global Health Reports, 0, 2, .	1.0	0
1739	Strategies for Progress., 2019,, 3-43.		0
1740	CLINICAL AND DIAGNOSTIC VALUE OF ASSESSMENT OF SYSTEMIC INFLAMMATION IN PATIENTS WITH HIV INFECTION. HIV Infection and Immunosuppressive Disorders, 2018, 10, 64-71.	0.1	1
1741	Chronic Meningitis. CONTINUUM Lifelong Learning in Neurology, 2018, 24, 1298-1326.	0.4	10
1742	Randomized Trials. , 2019, , 79-111.		0
1743	Therapy of Cancer and Retroviral Diseases. , 2019, , 65-158.		1
1744	Occurrence of hypocortisolism in HIV patients: Is the picture changing?. Ghana Medical Journal, 2018, 52, 147-152.	0.1	2
1745	Cardiovascular disease and antiretroviral therapy. Journal of Global Infectious Diseases, 2019, 11, 91.	0.2	8
1746	HIV-Infektion – PrÃ v alenz, Bedeutung und Implikationen fýr die PrÃ v ention und Gesundheitsförderung. The Springer Reference Pflegerapie, Gesundheit, 2019, , 1-6.	0.2	0
1747	Early initiation of antiretroviral therapy (ART): from point-of-care test to ART at a peer-led community-based testing site in Sydney. Sexual Health, 2019, 16, 94.	0.4	0
1748	Pharmacists' Interventions in Outpatient Care for HIV Infection Assessed by Patients. Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences), 2019, 45, 44-53.	0.0	0
1749	HIV Infection as a Model of Accelerated Immunosenescence., 2019,, 1961-1989.		1
1750	Lessons from Research Innovations in Depression and HIV in Low- and Middle-Income Countries. , 2019, , 1-22.		0

#	Article	IF	CITATIONS
1751	HIV-related disease., 2019,, 681-691.		0
1752	HIV and Injection Drug Use: New Approaches to HIV Prevention. , 2019, , 423-436.		0
1758	The Revolution of HIV Testing. , 2020, , 251-268.		2
1759	Ethics of theÂHIV/AIDS Response. , 2020, , 375-391.		0
1763	Sex and Gender Differences in Rilpivirine based ART - Data from the HIVCENTER Frankfurt. Current HIV Research, 2019, 17, 368-374.	0.2	1
1766	Human Immunodeficiency Virus and Acquired Immunodeficiency Syndrome., 2020,, 271-296.		0
1768	Past HIV-1 Medications and the Current Status of Combined Antiretroviral Therapy Options for HIV-1 Patients. Pharmaceutics, 2021, 13, 1798.	2.0	17
1770	Individual and healthcare supply-related barriers to treatment initiation in HIV-positive patients enrolled in the Cameroonian antiretroviral treatment access programme. Health Policy and Planning, 2021, 36, 137-148.	1.0	3
1771	Effects of the implementation of the HIV Treat All guidelines on key ART treatment outcomes in Namibia. PLoS ONE, 2020, 15, e0243749.	1.1	4
1772	Sexual Behavior and Sexually Transmitted Infection Outcomes Among Men Who Have Sex With Men and Transgender Women Participating in a Study of the Timing of Antiretroviral Therapy in Lima, Peru. Sexually Transmitted Diseases, 2020, 47, 825-831.	0.8	2
1773	Assessing antiretroviral therapy success in HIV/AIDS morbidity and mortality trends in Brazil, 1990–2017: an interrupted time series study. International Journal of STD and AIDS, 2021, 32, 127-134.	0.5	1
1774	Fighting microbial pathogens by integrating host ecosystem interactions and evolution. BioEssays, 2021, 43, 2000272.	1.2	5
1775	DNA methylation is associated with airflow obstruction in patients living with HIV. Thorax, 2021, 76, 448-455.	2.7	12
1776	Plasma Inflammatory Biomarkers Predict CD4+ T-cell Recovery and Viral Rebound in HIV-1 Infected Africans on Suppressive Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 224, 673-678.	1.9	4
1777	The association of human leukocyte antigen alleles with clinical disease progression in HIV-positive cohorts with varied treatment strategies. Aids, 2021, 35, 783-789.	1.0	2
1778	Lessons from Research Innovations in Depression and HIV in Low- and Middle-Income Countries. , 2020, , $1\text{-}22$.		0
1779	CD4 ⁺ :CD8 ⁺ T-cell Ratio Changes in People with HIV Receiving Antiretroviral Treatment. Antiviral Therapy, 2020, 25, 91-100.	0.6	5
1780	Acquired Immunodeficiency Syndrome. , 2020, , 145-159.		0

#	Article	IF	Citations
1782	Antiviral Therapies: A Critical Reappraisal. , 2020, , 297-316.		0
1783	HIV Diagnosis, Management and Prognosis. , 2020, , 127-155.		0
1784	Providing Universal Access While Avoiding Antiretroviral Resistance: Ethical Tensions in HIV Treatment. Public Health Ethics Analysis, 2020, , 37-54.	0.1	2
1785	Infektiologie. , 2020, , 287-313.		0
1787	Importance of HIV Care Continuum. Advances in Medical Diagnosis, Treatment, and Care, 2020, , 50-67.	0.1	0
1788	High viral suppression and low attrition in healthy HIV-infected patients initiated on ART with CD4 above 500 cells/1 ¹ / ₄ L in a program setting in Uganda. African Health Sciences, 2020, 20, 132-141.	0.3	7
1789	Alarming tuberculosis rate among people who inject drugs in Vietnam. Open Forum Infectious Diseases, 2022, 9, ofab548.	0.4	4
1790	A retrospective descriptive investigation of adult patients receiving third-line antiretroviral therapy in the North West province, South Africa. African Health Sciences, 2020, 20, 549-559.	0.3	0
1792	Caring for patients in a new pandemic: the necessity and challenges of observational research. Journal of Clinical Investigation, 2020, 130, 6225-6227.	3.9	5
1793	Incidence and risk factors for medical care interruption in people living with HIV in a French provincial city. PLoS ONE, 2020, 15, e0240417.	1.1	3
1794	The evolution and adoption of World Health Organization policy guidelines on antiretroviral therapy initiation in sub-Saharan Africa: A scoping review. Southern African Journal of HIV Medicine, 2020, 21, 1103.	0.3	1
1797	Early antiretroviral therapy for HIV-infected patients admitted to an intensive care unit (EARTH-ICU): A randomized clinical trial. PLoS ONE, 2020, 15, e0239452.	1.1	4
1798	Go Where the Virus Is: An HIV Micro-epidemic Control Approach to Stop HIV Transmission. Global Health, Science and Practice, 2020, 8, 614-625.	0.6	1
1799	HIV Neuropathy–Associated Foot Drop, a Presenting Sign of HIV Infection, Resolving After Initiation of Antiretroviral Therapy. American Journal of Physical Medicine and Rehabilitation, 2021, 100, e94-e97.	0.7	1
1800	Repeat HIV Testing and Incident Rates among Individuals Attending Voluntary Counseling and Testing Clinics in Wuxi, China: A Retrospective Study. Biomedical and Environmental Sciences, 2018, 31, 37-47.	0.2	9
1801	Higher risks of mother-to-child HIV transmission in countries with lower HIV prevalence: UNAIDS 2013 results for 32 countries with generalised epidemics. Journal of Virus Eradication, 2015, 1, 257-63.	0.3	6
1802	IAS Towards an HIV Cure Symposium: people focused, science driven: 18-19 July 2015, Vancouver, Canada. Journal of Virus Eradication, 2015, 1, 276-81.	0.3	2
1803	Alemtuzumab-induced elimination of HIV-1-infected immune cells. Journal of Virus Eradication, 2016, 2, 12-8.	0.3	7

#	Article	IF	CITATIONS
1804	Treatment outcomes of first-line antiretroviral therapy in HIV-1-positive patients in Serbia. Journal of Virus Eradication, 2016, 2, 32-5.	0.3	0
1805	HIV/AIDS in the South-East Asia region: progress and challenges. Journal of Virus Eradication, 2016, 2, 1-6.	0.3	33
1806	Highlights of the International Congress on Drug Therapy in HIV Infection, 23-26 October 2016, Glasgow, UK. Journal of Virus Eradication, 2017, 3, 97-100.	0.3	1
1807	Towards an ideal antiretroviral regimen for the global HIV epidemic. Journal of Virus Eradication, 2017, 3, 111-116.	0.3	1
1808	Pursuing ethical coherence in the prevention of vertical transmission of HIV: justice and injustice in Option B. Journal of Virus Eradication, 2017, 3, 163-166.	0.3	1
1809	NOVEL MECHANISMS AND ANTI-INFLAMMATORY STRATEGIES TO REDUCE CARDIOVASCULAR RISK IN HUMAN IMMUNODEFICIENCY VIRUS. Transactions of the American Clinical and Climatological Association, 2018, 129, 140-154.	0.9	8
1810	HIV-Related Cardiovascular Disease, Statins, and the REPRIEVE Trial. Topics in Antiviral Medicine, 2015, 23, 146-9.	0.1	70
1811	Antiretroviral Therapy for HIV Infection: When to Initiate Therapy, Which Regimen to Use, and How to Monitor Patients on Therapy. Topics in Antiviral Medicine, 2016, 23, 161-7.	0.1	6
1812	Treating all people living with HIV in sub-Saharan Africa: a new era calling for new approaches. Journal of Virus Eradication, 2018, 4, 1-4.	0.3	26
1813	HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. Journal of Virus Eradication, 2018, 4, 55-58.	0.3	12
1814	Mental health and HIV: research priorities related to the implementation and scale up of 'treat all' in sub-Saharan Africa. Journal of Virus Eradication, 2018, 4, 16-25.	0.3	20
1815	The contribution of observational studies in supporting the WHO 'treat all' recommendation for HIV/AIDS. Journal of Virus Eradication, 2018, 4, 5-8.	0.3	13
1816	Mathematical modelling to inform 'treat all' implementation in sub-Saharan Africa: a scoping review. Journal of Virus Eradication, 2018, 4, 47-54.	0.3	6
1817	Treatment Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents: An Update. Federal Practitioner: for the Health Care Professionals of the VA, DoD, and PHS, 2016, 33, 31S-36S.	0.6	5
1818	Adverse reactions to antiretroviral therapy: a prevalent concern. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2017, 41, e84.	0.6	1
1819	Health Workers' Perspectives on the Outcomes, Enablers, and Barriers to the Implementation of HIV "Test and Treat" Guidelines in Abuja, Nigeria., 2019, 1, 33-45.		O
1820	Management of TB/HIV co-infection: the state of the evidence. Ghana Medical Journal, 2020, 54, 186-196.	0.1	1
1821	A Descriptive Study of HIV Patients Highly Adherent to Antiretroviral. AMIA Annual Symposium proceedings, 2020, 2020, 1295-1304.	0.2	O

#	Article	IF	CITATIONS
1822	Prevention of Mother-to-Child Human Immunodeficiency Virus Transmission in Resource-Limited Countries. Pediatric Clinics of North America, 2022, 69, 1-18.	0.9	2
1823	Delayed antiretroviral therapy in HIV-infected individuals leads to irreversible depletion of skin- and mucosa-resident memory TAcells. Immunity, 2021, 54, 2842-2858.e5.	6.6	22
1824	Drug Resistance, Rather than Low Tenofovir Levels in Blood or Urine, Is Associated with Tenofovir, Emtricitabine, and Efavirenz Failure in Resource-Limited Settings. AIDS Research and Human Retroviruses, 2022, 38, 455-462.	0.5	13
1825	Epidemiology of Kaposi's Sarcoma. Cancers, 2021, 13, 5692.	1.7	20
1826	Principles of HIV Treatment. , 2022, , 391-413.		0
1827	Humoral response to two doses of BNT162b2 vaccination in people with HIV. Journal of Internal Medicine, 2022, 291, 513-518.	2.7	33
1828	Sliding Dynamics and Bifurcations of a Filippov System with Nonlinear Threshold Control. International Journal of Bifurcation and Chaos in Applied Sciences and Engineering, 2021, 31, .	0.7	3
1829	Changes in the profile of newly HIV-diagnosed men who have sex with men, Madrid, 2014 to 2019. Eurosurveillance, 2021, 26, .	3.9	4
1830	HIV continuum of care: bridging cross-sectional and longitudinal analyses. Aids, 2022, 36, 583-591.	1.0	3
1831	CD4 Trends with Evolving Treatment Initiation Policies among Children Living with HIV in Zambézia Province, Mozambique, 2012-2018. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, Publish Ahead of Print, .	0.9	1
1832	A Combination of M50I and V151I Polymorphic Mutations in HIV-1 Subtype B Integrase Results in Defects in Autoprocessing. Viruses, 2021, 13, 2331.	1.5	3
1833	Cohort profile: the Netherlands Cohort Study on Acute HIV infection (NOVA), a prospective cohort study of people with acute or early HIV infection who immediately initiate HIV treatment. BMJ Open, 2021, 11, e048582.	0.8	6
1834	Global estimates of viral suppression in children and adolescents and adults on antiretroviral therapy adjusted for missing viral load measurements: a multiregional, retrospective cohort study in 31 countries. Lancet HIV,the, 2021, 8, e766-e775.	2.1	38
1836	Optimizing switching strategies to simplify antiretroviral therapy: the future of second-line from a public health perspective. Aids, 2021, 35, \$153-\$163.	1.0	1
1837	Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model. Journal of Clinical Investigation, 2022, 132, .	3.9	9
1838	Information Avoidance and Celebrity Exposure: The Effect of "Magic" Johnson on AIDS Diagnoses and Mortality in the U.S SSRN Electronic Journal, 0, , .	0.4	0
1839	Evidence Synthesis Evaluating Body Weight Gain Among People Treating HIV with Antiretroviral Therapy - a Systematic Literature Review and Network Meta-Analysis. SSRN Electronic Journal, 0, , .	0.4	0
1840	Lessons from Research Innovations in Depression and HIV in Low- and Middle-Income Countries. , 2021, , 169-190.		0

#	Article	IF	CITATIONS
1841	Five-Year Mortality for Adults Entering Human Immunodeficiency Virus Care Under Universal Early Treatment Compared With the General US Population. Clinical Infectious Diseases, 2022, 75, 867-874.	2.9	10
1842	HIV-Infektion. , 2015, , 1-15.		O
1843	Management of TB/HIV co-infection: the state of the evidence. Ghana Medical Journal, 2020, 54, 186-196.	0.1	9
1844	THE RELATIONSHIP OF BASIC CLINICAL STATUS WITH THE QUALITY OF LIFE OF HIV AND AIDS PATIENTS. Jurnal Berkala Epidemiologi, 2020, 8, 246.	0.0	O
1845	Medical and Islamic Perspectives on Human Immunodeficiency Virus Infection and its Prevention. IIUM Medical Journal Malaysia, $2019,18,.$	0.1	0
1846	Machine learning classification of false-positive human immunodeficiency virus screening results. Journal of Pathology Informatics, 2021, 12, 46.	0.8	2
1847	Oncologic Treatment of HIV-Associated Kaposi Sarcoma 40 Years on. Journal of Clinical Oncology, 2022, 40, 294-306.	0.8	17
1848	Immunological factors, but not clinical features, predict visceral leishmaniasis relapse in patients co-infected with HIV. Cell Reports Medicine, 2022, 3, 100487.	3.3	14
1850	Progression of cardiac structure and function in people with human immunodeficiency virus. Echocardiography, 2022, 39, 268-277.	0.3	2
1851	COVID-19 â€~asymptomatic' patients: an old wives' tale. Expert Review of Respiratory Medicine, 2022, , 1	-91.0	13
1852	Effect of universal HIV testing and treatment on socioeconomic wellbeing in rural Kenya and Uganda: a cluster-randomised controlled trial. The Lancet Global Health, 2022, 10, e96-e104.	2.9	4
1853	Incidence and clearance of anal high-risk Human Papillomavirus infection and their risk factors in men who have sex with men living with HIV. Scientific Reports, 2022, 12, 184.	1.6	8
1854	Knowledge and Prior Use of HIV Self-Testing in Madrid and Barcelona among Men Who Have Sex with Men More than One Year after Its Legal Authorization in Spain. International Journal of Environmental Research and Public Health, 2022, 19, 1096.	1.2	1
1855	Periods of Homelessness Linked to Higher VACS Index Among HIV-Positive People Who Use Drugs. AIDS and Behavior, 2022, 26, 1739-1749.	1.4	3
1856	Antiretroviral Refill Histories as a Predictor of Future Human Immunodeficiency Virus Viremia. Open Forum Infectious Diseases, 2022, 9, ofac024.	0.4	2
1857	\hat{a} €œWe in this fight together \hat{a} \hat{a} HIV treatment and prevention among couples of HIV-discordant Black and Latino men who have sex with men. Journal of Prevention and Health Promotion, 0, , 263207702210749.	0.4	O
1858	Early Remdesivir to Prevent Progression to Severe Covid-19 in Outpatients. New England Journal of Medicine, 2022, 386, 305-315.	13.9	813
1859	Association of cellular HIV-1 DNA and virological success of antiretroviral treatment in HIV-infected sub-Saharan African adults. BMC Infectious Diseases, 2022, 22, 100.	1.3	1

#	Article	IF	CITATIONS
1860	Cost-Effectiveness of Long-Acting Injectable HIV Preexposure Prophylaxis in the United States. Annals of Internal Medicine, 2022, 175, 479-489.	2.0	37
1861	AIDS at 40 th : The progress of HIV treatment in Japan. Global Health & Medicine, 2022, 4, 1-8.	0.6	1
1862	Virologic failure in people living with HIV in 1st line ART: A 10-year Mexican population-based study. International Journal of STD and AIDS, 2022, , 095646242110670.	0.5	1
1863	Recent trends in adult and pediatric antiretroviral therapy monitoring and failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	0.9	0
1864	Risk-Based Screening Tools to Optimise HIV Testing Services: a Systematic Review. Current HIV/AIDS Reports, 2022, 19, 154-165.	1.1	10
1865	Epidemiologic and Economic Analysis of Rapid Antiretroviral Therapy Initiation with Bictegravir/Emtricitabine/Tenofovir Alafenamide in Spain. PharmacoEconomics - Open, 2022, 6, 415-424.	0.9	4
1866	COVID-19 and the HIV continuum in people living with HIV enrolled in Collaborating Consortium of Cohorts Producing NIDA Opportunities (C3PNO) cohorts. Drug and Alcohol Dependence, 2022, 241, 109355.	1.6	9
1867	A highly virulent variant of HIV-1 circulating in the Netherlands. Science, 2022, 375, 540-545.	6.0	39
1868	The human immunodeficiency virus infection 40 years later. Medicina ClÃnica (English Edition), 2022, 158, 218-218.	0.1	0
1869	Changes in proportionate cardiovascular mortality in patients with chronic infectious and inflammatory conditions in the United States, 1999–2018. Scientific Reports, 2021, 11, 23985.	1.6	7
1870	Human immunodeficiency virus and acquired immunodeficiency syndrome: recent developments and their implications for pediatric surgeons. Seminars in Pediatric Surgery, 1995, 4, 252-61.	0.5	0
1871	Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Human Immunodeficiency Virus-Associated Lymphoma Administered Highly Active Antiretroviral Therapy: Central and Western China Aids Lymphoma League 001 Study (cw-CALL 001). SSRN Electronic Journal, 0, , .	0.4	0
1872	Effectiveness of integrase strand transfer inhibitors in HIVâ€infected treatmentâ€experienced individuals across Europe. HIV Medicine, 2022, , .	1.0	5
1873	Psychological Distress Increases 30-Fold Among People with HIV in the First Year on ART in Nigeria—a Call for Integrated Mental Health Services. International Journal of Behavioral Medicine, 2023, 30, 38-48.	0.8	3
1874	Cardiovascular Implications of Immune Disorders in Women. Circulation Research, 2022, 130, 593-610.	2.0	13
1875	Early HIV treatment and survival over six years of observation in the ANRS 12249 Treatment as Prevention Trial. HIV Medicine, 2022, , .	1.0	2
1876	Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy. Npj Vaccines, 2022, 7, 28.	2.9	64
1878	Ageing with HIV: Challenges and biomarkers. EBioMedicine, 2022, 77, 103896.	2.7	29

#	Article	IF	CITATIONS
1879	HIV-associated talaromycosis: Does timing of antiretroviral therapy matter?. Journal of Infection, 2022, 84, 410-417.	1.7	10
1880	Efficacy of an electronic reminder for HIV screening in primary healthcare based on indicator conditions in Catalonia (Spain). HIV Medicine, 2022, , .	1.0	2
1881	A systematic review and meta-analysis to estimate the time from HIV infection to diagnosis for people with HIV. AIDS Reviews, $2022, 24, \ldots$	0.5	7
1883	Testing and healthcare seeking behavior preceding HIV diagnosis among migrant and non-migrant individuals living in the Netherlands: Directions for early-case finding. PLoS ONE, 2022, 17, e0264435.	1.1	3
1884	â€Î need time to start antiretroviral therapy': understanding reasons for delayed ART initiation among people diagnosed with HIV in Lusaka, Zambia'. Annals of Medicine, 2022, 54, 830-836.	1.5	7
1885	Essential elements of and challenges to rapid ART implementation: a qualitative study of three programs in the United States. BMC Infectious Diseases, 2022, 22, 316.	1.3	5
1886	Retention in care and predictors of attrition among HIV-infected patients who started antiretroviral therapy in Kinshasa, DRC, before and after the implementation of the †treat-all†strategy. PLOS Global Public Health, 2022, 2, e0000259.	0.5	6
1887	HIV-1-Mediated Acceleration of Oncovirus-Related Non-AIDS-Defining Cancers. Biomedicines, 2022, 10, 768.	1.4	4
1890	Initiation of antiretroviral therapy in treatment-naive adults with HIV infection at the first specialist appointment. Journal of Antimicrobial Chemotherapy, 2022, 77, 1741-1747.	1.3	3
1891	Comparison of HIV DNA decay and immune recovery between early and chronic HIVâ€infected individuals 96 weeks after ART. HIV Medicine, 2022, 23, 6-13.	1.0	1
1892	CD4+ cell count recovery after initiation of antiretroviral therapy in HIV-infected Ethiopian adults. PLoS ONE, 2022, 17, e0265740.	1.1	6
1893	La infecci \tilde{A}^3 n por el virus de la inmunodeficiencia humana 40 a $\tilde{A}\pm$ os despu \tilde{A} ©s. Medicina Cl \tilde{A} nica, 2022, 158, 218-220.	0.3	2
1894	Immune activation in primary HIV: influence of duration of infection, treatment, and substance use. Open Forum Infectious Diseases, 0, , .	0.4	1
1895	Humoral and Cellular Immune Response Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral Therapy Based on Current CD4 T-Lymphocyte Count. Clinical Infectious Diseases, 2022, 75, e552-e563.	2.9	79
1896	Incidence of active tuberculosis among people living with HIV receiving longâ€term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy. Journal of the International AIDS Society, 2022, 25, e25900.	1.2	5
1897	Individual and healthcare supply-related HIV transmission factors in HIV-positive patients enrolled in the antiretroviral treatment access program in the Centre and Littoral regions in Cameroon (ANRS-12288 EVOLCam survey). PLoS ONE, 2022, 17, e0266451.	1.1	2
1898	Sameâ€day antiretroviral therapy initiation hub model at the Thai Red Cross Anonymous Clinic in Bangkok, Thailand: an observational cohort study. Journal of the International AIDS Society, 2021, 24, e25869.	1.2	7
1899	A 10-year economic analysis of HIV management in Greece: evidence of efficient resource allocation. Current Medical Research and Opinion, 2022, 38, 265-271.	0.9	1

#	Article	IF	CITATIONS
1900	British HIV Association guidelines for the management of HIVâ€2 2021. HIV Medicine, 2021, 22, 1-29.	1.0	5
1901	Same-sex behavior disclosure to health care providers associated with greater awareness of pre-exposure prophylaxis. BMC Public Health, 2021, 21, 2243.	1.2	2
1903	The role of pharmacogenetics in Efficacy and safety of protease inhibitor based therapy in human immunodeficiency virus type (HIV) infection Acta Biomedica Scientifica, 2021, 6, 113-124.	0.1	1
1904	Ethical considerations for HIV remission clinical research involving participants diagnosed during acute HIV infection. BMC Medical Ethics, 2021, 22, 169.	1.0	2
1905	Persistent low-Level viremia in persons living with HIV undertreatment: An unresolved status. Virulence, 2021, 12, 2919-2931.	1.8	21
1906	Tuberculosis incidence in country of origin is a key determinant of the risk of active tuberculosis in people living with HIV: Data from a 30â€year observational cohort study. HIV Medicine, 2021, , .	1.0	4
1907	Household Contact Tracing With Intensified Tuberculosis and Human Immunodeficiency Virus Screening in South Africa: A Cluster-Randomized Trial. Clinical Infectious Diseases, 2022, 75, 849-856.	2.9	9
1908	HIV incidence, viremia, and the national response in Eswatini: Two sequential population-based surveys. PLoS ONE, 2021, 16, e0260892.	1.1	9
1909	Chapter 35: Human Immunodeficiency Virus and the Acquired Immune Deficiency Syndrome., 2022,,.		0
1910	Antiretroviral Initiation at ≥800 CD4+ Cells/mm3 Associated With Lower Human Immunodeficiency Virus Reservoir Size. Clinical Infectious Diseases, 2022, 75, 1781-1791.	2.9	4
1911	<scp>HIV</scp> : the changing paradigm. Internal Medicine Journal, 2022, 52, 542-549.	0.5	2
1912	Cytomegalovirus viremia and risk of disease progression and death in HIV-positive patients starting antiretroviral therapy. Aids, 2022, Publish Ahead of Print, .	1.0	7
1913	A comprehensive analysis of excess depressive disorder in women and men living with HIV in FranceÂcompared to the general population. Scientific Reports, 2022, 12, 6364.	1.6	4
1914	Longitudinal Improvements in Viral Suppression for Persons with New HIV Diagnosis Receiving Care in the Ryan White Program: A 10-year experience in New Haven, CT (2009-2018). Open Forum Infectious Diseases, 0, , .	0.4	0
1915	HIV Testing Program Activities and Challenges in Four U.S. Urban Areas. AIDS Education and Prevention, 2022, 34, 99-115.	0.6	1
1916	Impaired CD4+ T cell differentiation in HIV-1 infected patients receiving early anti-retroviral therapy. Genomics, 2022, 114, 110367.	1.3	2
1917	Characteristics of men who have sex with men and transgender women in Myanmar who test frequently for HIV. Journal of Global Health Reports, 0, , .	1.0	0
1930	Determinants of retention in HIV antiretroviral treatment (ART) in the Cameroon International epidemiology Database to Evaluate AIDS (leDEA) study clinics: the context of the HIV treat all strategy in Cameroon. Pan African Medical Journal, 2021, 40, 129.	0.3	1

#	Article	IF	CITATIONS
1933	Primary Care of the Person Living with HIV. Pathogens, 2022, 11, 380.	1.2	0
1935	Prognoses of the HIV Infection Under Long-Time Arv Therapy: The Role of Timely Treatment Initiation and the Drugs' Effectiveness. SSRN Electronic Journal, 0, , .	0.4	0
1936	Prevalence of and factors associated with late diagnosis of HIV in Malawi, Zambia, and Zimbabwe: Results from population-based nationally representative surveys. PLOS Global Public Health, 2022, 2, e0000080.	0.5	7
1937	Suboptimal HIV suppression is associated with progression of coronary artery stenosis: The Multicenter AIDS Cohort Study (MACS) longitudinal coronary CT angiography study. Atherosclerosis, 2022, 353, 33-40.	0.4	6
1938	Correlates of antiretroviral therapy (ART) initiation among HIV-positive men who have sex with men (MSM) in China. Journal of Global Health Reports, $0, 6, .$	1.0	1
1939	Targeted Implementation of HIV Self-Testing Increases Testing Uptake Among Partners of Index Persons Known to Have HIV in Kenya. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 90, 524-529.	0.9	4
1940	Evaluation of CCR5-Δ32 mutation and HIV-1 surveillance drug-resistance mutations in peripheral blood mononuclear cells of long-term nonÂprogressors of HIV-1-infected individuals. Future Virology, 0, , .	0.9	1
1941	Serial Analysis of the T-Cell Receptor \hat{l}^2 -Chain Repertoire in People Living With HIV Reveals Incomplete Recovery After Long-Term Antiretroviral Therapy. Frontiers in Immunology, 2022, 13, 879190.	2.2	5
1942	Profiles and Persistence of Initial Antiretroviral Therapy among HIV Infected Patients in Taiwan: A Nationwide Population-Based Cross-Sectional Study from 2011 to 2017. Journal of Microbiology, Immunology and Infection, 2022, , .	1.5	0
1943	HIV Compartmentalization in the CNS and Its Impact in Treatment Outcomes and Cure Strategies. Current HIV/AIDS Reports, 2022, 19, 207-216.	1.1	6
1944	Motivations and Barriers to Routine HIV Testing Among Men Who Have Sex with Men in New York City. AIDS and Behavior, 2022, 26, 3563-3575.	1.4	5
1945	Elimination of HIV transmission in Japanese MSM with combination interventions. The Lancet Regional Health - Western Pacific, 2022, 23, 100467.	1.3	5
1946	Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis. EClinicalMedicine, 2022, 48, 101412.	3.2	29
1947	Immune correlates of cardiovascular co-morbidity in HIV infected participants from South India. BMC Immunology, 2022, 23, 24.	0.9	0
1948	Factors associated with low-level viraemia in people with HIV starting antiretroviral therapy: A Swedish observational study. PLoS ONE, 2022, 17, e0268540.	1.1	5
1949	Delayed HIV treatment, barriers in access to care and mortality in tuberculosis/HIV co-infected patients in Cali, Colombia Colombia Medica, 2021, 52, e2024875.	0.7	0
1950	Development of New Analytical method for the Estimation of Raltegravir in Rabbit plasma. Research Journal of Pharmacy and Technology, 2022, , 1800-1804.	0.2	0
1951	High incidence of subclinical peripheral artery disease in people with HIV. Aids, 2022, 36, 1355-1362.	1.0	4

#	Article	IF	CITATIONS
1952	Antiretroviral Therapy-Induced Dysregulation of Gene Expression and Lipid Metabolism in HIV+ Patients: Beneficial Role of Antioxidant Phytochemicals. International Journal of Molecular Sciences, 2022, 23, 5592.	1.8	1
1953	Distinct forms of migration and mobility are differentially associated with HIV treatment adherence. Aids, 2022, 36, 1021-1030.	1.0	10
1954	Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/HBV Coinfection. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, 91, 79-84.	0.9	2
1957	Benefits and Risks of Rapid Initiation of Antiretroviral Therapy: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 0, 13, .	1.6	6
1959	Frailty and Aging in HIV– Status Post 13 Years of National Awareness. Journal of Frailty & Early &	0.8	0
1960	Awareness and Use of HIV Self-Testing Among Men Who Have Sex With Men Remains Low in Spain 2 Years After Its Authorization. Frontiers in Public Health, 0, 10, .	1.3	1
1961	People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses. Journal of Infectious Diseases, 2023, 227, 838-849.	1.9	31
1962	Nationwide population-based incidence of cancer among patients with HIV/AIDS in South Korea. Scientific Reports, 2022, 12, .	1.6	5
1963	Difference in the neurocognitive functions of WLWH and MLWH in an Italian cohort of people living with HIV. Journal of NeuroVirology, 2022, 28, 422-429.	1.0	1
1964	Factors associated with testing for HIV and other sexually transmitted infections in men who have sex with men and transgender women in Bangkok, Thailand. AIDS Research and Therapy, 2022, 19, .	0.7	2
1965	HIV Health literacy beyond the biomedical model: an innovative visual learning tool to highlight the psychosocial complexities of care. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2022, 34, 1489-1498.	0.6	3
1966	Comparison of Targeted and Routine Adolescent HIV Screening in a Pediatric Emergency Department. Pediatric Emergency Care, 2022, 38, e1613-e1619.	0.5	2
1967	Drug use stigma, antiretroviral therapy use, and HIV viral suppression in a community-based sample of people with HIV who inject drugs. Aids, 0, Publish Ahead of Print, .	1.0	1
1969	Prevention and Initial Management of HIV Infection. Annals of Internal Medicine, 2022, 175, ITC81-ITC96.	2.0	4
1970	Diagnostic accuracy of the rapid Xpert HIV-1 Viral Load XC, Xpert HIV-1 Viral Load & mp; m-PIMA HIV-1/2 Viral Load in South African clinics. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	0.9	1
1971	Hepatitis B virus, hepatitis C virus and human immunodeficiency virus infection in Expatriate workers and Libyan people in Darna. Brilliance, 2022, 2, 31-37.	0.3	0
1972	Finding and treating early-stage HIV infections: A cost-effectiveness analysis of the Sabes study in Lima, Peru. The Lancet Regional Health Americas, 2022, 12, 100281.	1.5	0
1973	Clinical decision support systems to guide healthcare providers on HIV testing. Aids, 2022, 36, 1083-1093.	1.0	2

#	Article	IF	Citations
1974	Estimating the minimum antiretroviral adherence required for plasma HIV-1 RNA viral load suppression among people living with HIV who use unregulated drugs. Aids, 2022, 36, 1233-1243.	1.0	4
1975	Progress in the quality of care for newly diagnosed people with HIV in Spain (2004–2019). Antiviral Therapy, 2022, 27, 135965352211127.	0.6	1
1976	Virological outcomes and risk factors for non-suppression for routine and repeat viral load testing after enhanced adherence counselling during viral load testing scale-up in Zimbabwe: analytic cross-sectional study using laboratory data from 2014 to 2018. AIDS Research and Therapy, 2022, 19, .	0.7	5
1977	Conditional Economic Incentives for HIV Treatment Adherence: Aligning Adolescent Developmental Hallmarks with Behavioral Economic Theory to Improve HIV Treatment Adherence. AIDS Patient Care and STDs, 2022, 36, 272-277.	1.1	0
1979	Neuropathogenesis of HIV and emerging therapeutic targets. Expert Opinion on Therapeutic Targets, 2022, 26, 603-615.	1.5	3
1980	Risk factors for late linkage to care and delayed antiretroviral therapy initiation among adults with HIV in sub-Saharan Africa: a systematic review and meta-analyses. International Journal of Infectious Diseases, 2022, 122, 885-904.	1.5	7
1981	HIV drug resistance in a communityâ€randomized trial of universal testing and treatment: HPTN 071 (PopART). Journal of the International AIDS Society, 2022, 25, .	1.2	3
1982	Recent Advances in the Discovery and Development of Anti-HIV Natural Products. The American Journal of Chinese Medicine, 0, , 1-24.	1.5	1
1983	Evaluation of CD4 count response in HIV subjects with antiretroviral treatment protocol. IP Indian Journal of Immunology and Respiratory Medicine, 2022, 7, 69-72.	0.1	0
1984	Factors associated with the risk of upper respiratory tract bacterial infections among HIV-positive patients. PLoS ONE, 2022, 17, e0270770.	1.1	1
1985	Epidemiological investigation and proteomic profiling of typical TCM syndrome in HIV/AIDS immunological nonresponders. Anatomical Record, 0, , .	0.8	2
1986	Immediate ART and clinical outcomes in New York City among patients newly diagnosed with HIV. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 0, , 1-10.	0.6	0
1987	The Potential of Spirulina platensis to Ameliorate the Adverse Effects of Highly Active Antiretroviral Therapy (HAART). Nutrients, 2022, 14, 3076.	1.7	5
1988	Maternal and infant renal safety following tenofovir disoproxil fumarate exposure during pregnancy in a randomized control trial. BMC Infectious Diseases, 2022, 22, .	1.3	4
1989	HIV and Bone Health., 2021,, 463-473.		0
1990	Scientific Basis of Antiretroviral Therapy. , 2021, , 173-188.		0
1991	Prescribing Antiretroviral Therapy. , 2021, , 189-198.		0
1992	Length of stay in Denmark before HIV diagnosis and linkage to care: a population-based study of migrants living with HIV, Denmark, 1995 to 2020. Eurosurveillance, 2022, 27, .	3.9	3

#	Article	IF	CITATIONS
1993	ANALYSIS OF THE METABOLIC SYNDROME AND ITS ASSOCIATION WITH CART IN HIV POSITIVE INDIVIDUALS RECEIVING VARIOUS CART REGIMENS WITH REVIEW OF LITERATURE, 2022, , 27-30.		0
1994	Longitudinal HIV care outcomes by gender identity in the United States. Aids, 0, Publish Ahead of Print,	1.0	2
1995	Adults Aged ≥50 Years Reached by the Centers for Disease Control and Prevention's HIV Testing Programs in the United States and US Dependent Areas, 2019. Public Health Reports, 0, , 003335492211202.	1.3	1
1997	Preoperative Management of Medications for Rheumatologic and HIV Diseases: Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clinic Proceedings, 2022, 97, 1551-1571.	1.4	3
1998	Analysis of Multiple Sexual Partners among 2665 Male College Students Who Have Sexual Behaviour in Zhejiang Province, China. BioMed Research International, 2022, 2022, 1-8.	0.9	3
2000	Biomarkers in Anal Cancer: Current Status in Diagnosis, Disease Progression and Therapeutic Strategies. Biomedicines, 2022, 10, 2029.	1.4	3
2001	Impact of Age and Gender Disparity on CD4+ Cell Counts to Control Disease Progression Using Specific HAART in HIV-1 Positive Patients: A Case-Control Study. Reviews on Recent Clinical Trials, 2022, 17, 195-207.	0.4	0
2002	First Demonstration Project of Long-Acting Injectable Antiretroviral Therapy for Persons With and Without Detectable Human Immunodeficiency Virus (HIV) Viremia in an Urban HIV Clinic. Clinical Infectious Diseases, 2023, 76, e645-e651.	2.9	32
2003	Antiretroviral therapy initiation and outcomes of hospitalized HIV-infected patients in Ugandaâ€"An evaluation of the HIV test and treat strategy. PLoS ONE, 2022, 17, e0268122.	1.1	3
2004	Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development. Frontiers in Microbiology, 0, 13 , .	1.5	12
2005	SARS-CoV-2 immunity and vaccine strategies in people with HIV. Oxford Open Immunology, 2022, 3, .	1.2	12
2006	The relationship between the epigenetic aging biomarker "grimage―and lung function in both the airway and blood of people living with HIV: An observational cohort study. EBioMedicine, 2022, 83, 104206.	2.7	7
2007	Determinants of long-term survival in late HIV presenters: The prospective PISCIS cohort study. EClinicalMedicine, 2022, 52, 101600.	3.2	10
2008	Clinical characteristics and outcomes of newly diagnosed patients with ⟨scp⟩HIV⟨ scp⟩â€associated aggressive Bâ€cell ⟨scp⟩NHL⟨ scp⟩ in China. Journal of Cellular and Molecular Medicine, 2022, 26, 5067-5077.	1.6	7
2009	The differential impacts of early detection and accelerated antiretroviral therapy on the epidemiologic trend of sexually acquired HIV infection in Hong Kong. PLoS ONE, 2022, 17, e0274498.	1.1	1
2010	Adherence to Antiretroviral Therapy and Its Predictive Factors Among People Living with HIV in China: A Behavioral Theory-Based Prospective Cohort Study. International Journal of Behavioral Medicine, 0,	0.8	1
2011	Evaluating the time of HIV infection, diagnosis and treatment delays based on HIV notification data in Northwest China, 2008–19. Sexual Health, 2022, 19, 556-565.	0.4	1
2013	An exploratory study to characterize the HIV testing-to-care continuum to improve outcomes for Black and Latinx residents of South Los Angeles. PLoS ONE, 2022, 17, e0268374.	1.1	1

#	Article	IF	CITATIONS
2014	Factors associated with poor outcomes among people living with HIV started on anti-retroviral therapy before and after implementation of "test and treat―program in Coastal Kenya. PLoS ONE, 2022, 17, e0270653.	1.1	1
2015	Failure to seroconvert after three doses of inactivated COVID-19 vaccines in a patient co-infected with HBV and HIV: A case report. Human Vaccines and Immunotherapeutics, 2022, 18, .	1.4	2
2016	Increased Self-Reported Mental Health Problems Among Asian-Americans During the COVID-19 Pandemic in the United States: Evidence from a Nationally Representative Database. Journal of Racial and Ethnic Health Disparities, 2023, 10, 2344-2353.	1.8	1
2017	Lymphomas in People Living with HIV. Hemato, 2022, 3, 527-542.	0.2	1
2018	Same-Day Antiretroviral Therapy Initiation as a Predictor of Loss to Follow-up and Viral Suppression Among People With Human Immunodeficiency Virus in Sub-Saharan Africa. Clinical Infectious Diseases, 2023, 76, 39-47.	2.9	8
2019	Recent Stressful Life Events, Lifetime Traumatic Events, Missed Visits, and Antiretroviral Adherence Among Black Women With HIV in the Southeastern United States: A Cross-sectional Study. Journal of the Association of Nurses in AIDS Care, 2022, Publish Ahead of Print, .	0.4	1
2020	A comparison of self-reported pain measures between sensory phenotypes in HIV-associated sensory neuropathy Journal of Pain, 2022, , .	0.7	0
2022	Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiology Spectrum, 2022, 10, .	1.2	20
2023	Single-cell sequencing resolves the landscape of immune cells and regulatory mechanisms in HIV-infected immune non-responders. Cell Death and Disease, 2022, 13, .	2.7	7
2024	Trends in Use of Combination Antiretroviral Therapy and Treatment Response from 2000 to 2016 in the Canadian Observational Cohort (CANOC): A Longitudinal Cohort Study. Canadian Journal of Hospital Pharmacy, 2022, 75, 309-316.	0.1	0
2025	Improving indicator-condition guided testing for HIV in the hospital setting (PROTEST 2·0): A multicenter, interrupted time-series analysis. Lancet Regional Health - Europe, The, 2022, 23, 100515.	3.0	5
2026	At-home infectious disease testing: An idea whose time has come. Antimicrobial Stewardship & Healthcare Epidemiology, 2022, 2, .	0.2	2
2027	Management and treatment of human immunodeficiency virus., 2022,, 1585-1610.		0
2028	Challenges of antiretroviral therapy among children in Free State Province, South Africa. Scripta Medica, 2022, 53, 229-234.	0.0	0
2029	Human Immunodeficiency Virus (HIV) Infection and AIDS. , 2022, , 251-262.		0
2030	Global strategy in the treatment of HIV infection in 2022. Revista Espanola De Quimioterapia, 2022, 35, 34-36.	0.5	2
2031	Tuberculosis prevalence, incidence and prevention in a south african cohort of children living with HIV. Journal of Tropical Pediatrics, 2022, 68, .	0.7	1
2032	Six-Months Retention on Treatment and Attrition Risk Factors among People Living with HIV in Kibera Informal Settlement, Nairobi, Kenya. International Journal of Environmental Research and Public Health, 2022, 19, 12657.	1.2	1

#	Article	IF	CITATIONS
2033	Medicaid Spending on Antiretrovirals from 2007-2019. Clinical Infectious Diseases, 0, , .	2.9	0
2034	<scp>Sameâ€day</scp> and rapid initiation of antiretroviral therapy in people living with <scp>HIV</scp> in Asia. How far have we come?. HIV Medicine, 2022, 23, 3-14.	1.0	5
2035	Viral suppression and self-reported ART adherence after 3 years of universal testing and treatment in the HPTN 071 (PopART) community-randomised trial in Zambia and South Africa: a cross-sectional analysis. Lancet HIV,the, 2022, 9, e751-e759.	2.1	2
2036	Re-evaluating the health impact and cost-effectiveness of tuberculosis preventive treatment for modern HIV cohorts on antiretroviral therapy: a modelling analysis using data from Tanzania. The Lancet Global Health, 2022, 10, e1646-e1654.	2.9	7
2039	Human Immunodeficiency Virus Treatment and Prevention for Pregnant and Postpartum Women in Global Settings. Obstetrics and Gynecology Clinics of North America, 2022, 49, 693-712.	0.7	1
2040	Antiretroviral therapy. , 2023, , 263-283.		0
2041	Epidemiology, comorbidities at diagnosis and outcomes associated with <scp>HIV</scp> late diagnosis from 2010 to 2019 in a Belgian reference centre: A retrospective study. HIV Medicine, 2022, 23, 1184-1194.	1.0	3
2042	Developing an app-based self-management program for people living with HIV: a randomized controlled pilot study during the COVID-19 pandemic. Scientific Reports, 2022, 12, .	1.6	2
2043	The Health Gym: synthetic health-related datasets for the development of reinforcement learning algorithms. Scientific Data, 2022, 9, .	2.4	16
2044	Late diagnosis of <scp>HIV</scp> in 2022: Why so little change?. HIV Medicine, 2022, 23, 1118-1126.	1.0	5
2045	Management of HIV Infection. , 2023, , 700-707.e2.		0
2046	Determinants of Antiretroviral Treatment Success and Adherence in People With Human Immunodeficiency Virus Treated for Tuberculosis. Open Forum Infectious Diseases, 2022, 9, .	0.4	2
2047	Real-world weight changes in people with HIV-1 at risk of weight gain (female, Black or Hispanic) switching from integrase strand transfer inhibitors. Journal of Comparative Effectiveness Research, 2023, 12, .	0.6	0
2048	A randomized prospective study to compare early versus delayed access to antiretroviral therapy over clinical and immunological sequel in HIV-positive adults. Journal of Family Medicine and Primary Care, 2022, 11, 6959.	0.3	0
2049	Acute HIV infection in a 39-year-old man. Cmaj, 2022, 194, E1541-E1541.	0.9	0
2050	Uptake and effect of universal test-and-treat on twelve months retention and initial virologic suppression in routine HIV program in Kenya. PLoS ONE, 2022, 17, e0277675.	1.1	10
2051	Reasons for, and factors associated with, positive HIV retesting: a cross-sectional study in Eswatini. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2023, 35, 1346-1353.	0.6	0
2053	Impact of pre-antiretroviral treatment HIV-RNA on time to successful virological suppression and subsequent virological failure – two nationwide, population-based cohort studies. Aids, 2023, 37, 279-286.	1.0	1

#	Article	IF	CITATIONS
2054	The experienced positive and negative influence of HIV on quality of life of people with HIV and vulnerable to HIV in the Netherlands. Scientific Reports, 2022 , 12 , .	1.6	0
2055	Association between ten-eleven methylcytosine dioxygenase 2 genetic variation and viral load in people with HIV. Aids, 2023, 37, 379-387.	1.0	1
2056	Pregnancy rates and clinical outcomes among women living with HIV enrolled in HPTN 052. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2023, 35, 824-832.	0.6	1
2057	Persistent High Burden and Mortality Associated With Advanced HIV Disease in Rural Tanzania Despite Uptake of World Health Organization "Test and Treat―Guidelines. Open Forum Infectious Diseases, 2022, 9, .	0.4	2
2058	Recurrent visceral leishmaniasis relapses in HIV co-infected patients are characterized by less efficient immune responses and higher parasite load. IScience, 2023, 26, 105867.	1.9	2
2059	Facilitating <scp>HIV</scp> testing in colposcopy clinics to improve identification of <scp>HIV</scp> in a hidden population. The Obstetrician and Gynaecologist, 0, , .	0.2	0
2060	Relationships Among Trajectories of Sleep Disturbance, Depression, and Antiretroviral Therapy in Persons Newly Diagnosed with HIV: A One-and-a-Half-Year Observational Longitudinal Study. Nature and Science of Sleep, 0, Volume 14, 2133-2142.	1.4	0
2061	The effect of HAART on metabolic and haemostatic parameters in HIV infection: A comparative study. African Journal for Physical Activity and Health Sciences, 2022, 28, 338-354.	0.0	1
2062	Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial. Medicine (United States), 2022, 101, e31982.	0.4	1
2063	Faster lung function decline in people living with HIV despite adequate treatment: a longitudinal matched cohort study. Thorax, 2023, 78, 535-542.	2.7	10
2064	CD4+ T lymphocyte recovery in the modern antiretroviral therapy era: Toward a new threshold for defining immunological non-responders. Frontiers in Virology, 0, 2, .	0.7	2
2065	Deep-sequencing of viral genomes from a large and diverse cohort of treatment-naive HIV-infected persons shows associations between intrahost genetic diversity and viral load. PLoS Computational Biology, 2023, 19, e1010756.	1.5	1
2066	Cardiovascular disease and risk assessment in people living with HIV: Current practices and novel perspectives. Hellenic Journal of Cardiology, 2023, 71, 42-54.	0.4	4
2067	Investigation of Causal Effects of Protein Biomarkers on Cardiovascular Disease in Persons With HIV. Journal of Infectious Diseases, 2023, 227, 951-960.	1.9	0
2068	Roadmap for Achieving Universal Antiretroviral Treatment. Annual Review of Pharmacology and Toxicology, 2023, 63, 99-117.	4.2	2
2069	Same-day initiation of bictegravir/emtricitabine/tenofovir alafenamide: Week 48 results of the FAST studyâ€"IMEA 055. Journal of Antimicrobial Chemotherapy, 2023, 78, 769-778.	1.3	5
2070	Long-Term Survivors in a Cohort of People Living with HIV Diagnosed between 1985 and 1994: Predictive Factors Associated with More Than 25 Years of Survival. Infectious Disease Reports, 2023, 15, 70-83.	1.5	1
2071	HIV Infection Indicator Disease-Based Active Case Finding in a University Hospital: Results from the SHOT Project. Infectious Disease Reports, 2023, 15, 94-101.	1.5	3

#	Article	IF	CITATIONS
2072	Implementation and effectiveness of a linkage to HIV care intervention in rural South Africa (ANRS) Tj ETQq0 0 0	rgBT /Ove	erlo <u>c</u> k 10 Tf 5
2074	Temporal Trends of Clinical Characteristics and Treatments in People Living with HIV at the Initiation of Antiretroviral Therapy — Beijing Municipality, China, 2010–2020. China CDC Weekly, 2023, 5, 131-136.	1.0	1
2075	Predict the Effects of Dolutegravir (DTG) Plus Lamivudine (3TC) on Immunological Responses in People Living with HIV (PLWHIV). Journal of Clinical Medicine, 2023, 12, 1176.	1.0	0
2076	The Impact of Asymptomatic Human Immunodeficiency Virus-Positive Disease Status on Inpatient Complications Following Spine Surgery: A Propensity Score-Matched Analysis. Journal of Clinical Medicine, 2023, 12, 1458.	1.0	1
2077	25-Year-Old Man With Fever, Diarrhea, and Weight Loss. Mayo Clinic Proceedings, 2023, 98, 342-347.	1.4	0
2078	Evaluation of the Revised Versus Original Ryan White Part A HIV Care Coordination Program in a Cluster-Randomized, Stepped-Wedge Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2023, 92, 325-333.	0.9	0
2079	Characteristics and short- and long-term direct medical costs among adults with timely and delayed presentation for HIV care in the Netherlands. PLoS ONE, 2023, 18, e0280877.	1.1	3
2080	Non-AIDS-Defining Events in Human Immunodeficiency Virus Controllers Versus Antiretroviral Therapy–Controlled Patients: A Cohort Collaboration From the French National Agency for Research on AIDS CO21 (CODEX) and CO06 (PRIMO) Cohorts. Open Forum Infectious Diseases, 2023, 10, .	0.4	0
2081	Residual Central Nervous System Immune Activation Is Not Prevented by Antiretroviral Therapy Initiated During Early Chronic HIV Infection. Open Forum Infectious Diseases, 2023, 10, .	0.4	1
2082	Acute retroviral syndrome is associated with lower CD4+ T cell nadir and delayed viral suppression, which are blunted by immediate antiretroviral therapy initiation. Aids, 2023, 37, 1103-1108.	1.0	3
2083	Does the rapid initiation of antiretroviral therapy at HIV diagnosis impact virological response in a real-life setting? A single-centre experience in Northern Italy. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2023, 35, 1938-1947.	0.6	1
2084	Association Between Time to Antiretroviral Therapy and Loss to Care Among Newly Diagnosed Rwandan People Living with Human Immunodeficiency Virus. AIDS Research and Human Retroviruses, 2023, 39, 253-261.	0.5	1
2085	Infection aiguë à VIH chez un homme de 39 ans. Cmaj, 2023, 195, E288-E288.	0.9	0
2086	Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection. , 2023, 2, .		3
2087	Evaluation of the Effectiveness of Remdesivir in the Treatment of COVID-19 Outpatients: A retrospective cohort study. Current Drug Therapy, 2023, 18, .	0.2	0
2088	Scientific Inference Does Not Rest on Statistical Testing. , 2023, 2, .		0
2089	Determinants of Successful Human Immunodeficiency Virus Treatment Outcomes: A Linkage of National Data Sources in Malaysia. The Malaysian Journal of Medical Sciences, 2023, 30, 172-184.	0.3	0
2090	Characterization of Rare Spontaneous Human Immunodeficiency Virus Viral Controllers Attending a National United Kingdom Clinical Service Using a Combination of Serology and Molecular Diagnostic Assays. Open Forum Infectious Diseases, 2023, 10, .	0.4	0

#	ARTICLE	IF	CITATIONS
2091	Sensitivity and specificity of two investigational Point of care tests for Syphilis and HIV (PoSH Study) for the diagnosis and treatment of infectious syphilis in Canada: a cross-sectional study. Clinical Microbiology and Infection, 2023, 29, 940.e1-940.e7.	2.8	1
2092	Outcomes of human immunodeficiency virusâ€associated Burkitt lymphoma and diffuse large Bâ€eell lymphoma treated in Australia: A report from the Australasian Lymphoma Alliance. British Journal of Haematology, 2023, 201, 865-873.	1.2	3
2093	Immune Reconstitution Inflammatory Syndrome in People Living with HIV Who Presented with Interstitial Pneumonitis: an Emerging Challenge in the Era of Rapid Initiation of Antiretroviral Therapy. Microbiology Spectrum, 2023, 11 , .	1.2	0
2094	Factors associated with rapid linkage to HIV medical care among persons newly diagnosed with HIV infection in the United States, 2019-2020. Sexually Transmitted Diseases, 0, Publish Ahead of Print, .	0.8	0
2095	Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study. Viruses, 2023, 15, 720.	1.5	5
2096	Outcomes in critically Ill HIV-infected patients between 1997 and 2020: analysis of the OUTCOMEREA multicenter cohort. Critical Care, 2023, 27, .	2.5	5
2097	Optimizing Treatment for Human Immunodeficiency Virus to Improve Clinical Outcomes Using Precision Medicine. American Journal of Epidemiology, 0, , .	1.6	0
2098	Impact of age, antiretroviral therapy, and cancer on epigenetic aging in people living with <scp>HIV</scp> . Cancer Medicine, 2023, 12, 11010-11019.	1.3	3
2099	Pneumoproteins and biomarkers of inflammation and coagulation do not predict rapid lung function decline in people living with HIV. Scientific Reports, 2023, 13, .	1.6	1
2100	<scp>AIDS</scp> in the era of antiretroviral therapy: Changes in incidence rates and predictors of <scp>AIDS</scp> among people living with <scp>HIV</scp> under clinical care in Germany, a cohort study 1999â€"2018. HIV Medicine, 2023, 24, 794-806.	1.0	1
2101	Metabolic syndrome among people living with HIV in Ethiopia: a systematic review and meta-analysis. Diabetology and Metabolic Syndrome, 2023, 15 , .	1.2	2
2102	Contribution of low CD4 cell counts and high HIV viral load to the efficacy of preferred first-line antiretroviral regimens for treating HIV infection: A systematic review and meta-analysis. Clinical Infectious Diseases, 0, , .	2.9	2
2103	Low pre-ART CD4 count is associated with increased risk of clinical progression or death even after reaching 500 CD4 cells/ \hat{l}_4 L on ART. PLoS ONE, 2023, 18, e0283648.	1.1	0
2104	Real-world effectiveness of WHO recommended first-line antiretroviral therapies: a cohort study from a middle-income country. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2023, 35, 1891-1903.	0.6	0
2105	Effect of characteristics on the clinical course at the initiation of treatment for human immunodeficiency virus infection using dimensionality reduction. Scientific Reports, 2023, 13, .	1.6	1
2106	Associations of functional HLA class I groups with HIV viral load in a heterogeneous cohort. Aids, 0, Publish Ahead of Print, .	1.0	1
2107	Human Immunodeficiency Virus in Pregnancy. Obstetrics and Gynecology Clinics of North America, 2023, , .	0.7	0
2108	Efficacy, Convenience, Safety and Durability of DTG-Based Antiretroviral Therapies: Evidence from a Prospective Study by the Italian MaSTER Cohort. Viruses, 2023, 15, 924.	1.5	1

#	Article	IF	CITATIONS
2109	Plasma Cytokine Expression and Immune Reconstitution in Early and Delayed Anti-HIV 96-Weeks Treatment: A Retrospective Study. AIDS Research and Human Retroviruses, 2024, 40, 101-109.	0.5	0
2110	Strategies to increase HIV testing among men who have sex with men and transgender women: an integrative review. BMC Infectious Diseases, 2023, 23, .	1.3	1
2111	Sensitivity and specificity of CRP and symptom screening as tuberculosis screening tools among HIV-positive and negative outpatients at a primary healthcare facility in Lusaka, Zambia: a prospective cross-sectional study. BMJ Open, 2023, 13, e061907.	0.8	2
2112	Consistent Effects of Early Remdesivir on Symptoms and Disease Progression Across At-Risk Outpatient Subgroups: Treatment Effect Heterogeneity in PINETREE Study. Infectious Diseases and Therapy, 2023, 12, 1189-1203.	1.8	6
2113	Access to a novel first-line single-tablet HIV antiretroviral regimen in Affordable Care Act Marketplace plans, 2018–2020. Journal of Pharmaceutical Policy and Practice, 2023, 16, .	1.1	0
2114	Review of HIV Self Testing Technologies and Promising Approaches for the Next Generation. Biosensors, 2023, 13, 298.	2.3	4
2119	Persons With Human Immunodeficiency Virus. , 2024, , 383-390.e2.		0
2152	Clinical Features and Management of HIV/AIDS in Adults. , 2024, , 110-133.		0
2220	Central nervous system complications of human immunodeficiency virus infection., 2024,, 23-43.		0